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EXECUTIVE SUMMARY 
As costs associated with medical care continue to increase, and populations continue to age, 
member states of the EU are increasingly concerned about their long-term public spending 
budgets. Generic drugs have been targeted by EU policy makers as replacements to high 
cost pharmaceutical drugs so as to bring healthcare costs down. The EU has taken several 
measures in the recent past to increase competition in the generic drugs industry within the 
EU marketplace.  
As competition increases in the EU generics market over the coming years, firms within the 
pharmaceuticals drug industry in the region must explore new strategies so as to thrive and 
prosper in the long term. Decisions on making the best use of available resources must be 
made and strategies must be reformulated to determine actions going into the future. 
These long-term strategies will help companies determine their current and future 
positions, and ultimately, the relevant steps that they need take presently to maintain their 
market positions.  
This report seeks to analyze the current EU macro-environment and provide possible future 
(twenty year timeframe) scenarios to which players within the generic drugs market can 
prepare themselves for so as to attain a competitive position in the long-term.  The 
scenarios that were crafted after a thorough macro environmental analysis are: the positive 
scenario  ? ?dŽĚŽ ĞƐ ƵĞŶŽ ? ?), the negative scenario ( ?EĞŝŶ ? ŶŝĐŚƚ ŐƵƚ ? ?) and the mixed 
scenario ( ?ĞƵǆhŶŝŽŶƵƌŽƉĞĞŶŶĞ ? ?). After the scenario crafting phase, opportunities and 
threats were identified for the possible future scenario, and thereafter, versatile strategic 
recommendations were made. 
Based on the scenarios, the report proposes strategies and recommendations by combining 
ƚŚĞŝŵƉůŝĐĂƚŝŽŶŽĨƚŚĞƐĐĞŶĂƌŝŽƐ ? opportunities and threats. The report advices 7 strategies 
that producers can use to add value to their internal strategies and/or further examine the 
implication of the recommendations presented.  
The report argues against traditional strategic polar thinking (cost leadership or 
differentiation) and proposes players to use mixed strategies. It suggests producers to 
identify the key ingredient that differentiated themselves from competitors. It promotes 
investing on research to soften the blow of sudden technology changes, identify new 
technologies to improve business processes, and research to develop new formulation 
patents. It also suggests producers to invest in stakeholder management, focus on green 
technologies, proposes investigating the advantages of strategic manufacturing location (i.e. 
Turkey), and finally, suggests formulating strategic alliances to organizational learning. 
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1 INTRODUCTION  
 
The European pharmaceutical generic drugs sector has been an area of continued attention 
for many years. On a national level, rising expenditures on drugs are posing a threat to the 
accessibility and financing of health care. With a growth rate faster than GDP and the health 
care sector as the whole, the pharmaceutical generic drugs industry has been subjected to 
increased competition and numerous national cost containment strategies.  
Primarily healthcare policy is a national concern (reimbursement and pricing) in the 
European Union (EU), however there is increasing involvement from EU policymakers. The 
EU not only wants to ensure the delivery of satisfactory public health, but also wants to 
encourage competitiveness and innovation because this industry contributes not only 
towards levels of employment but also towards EU trade balances which are of high 
strategic importance for the union. However, subsequent reports such as the suggest that 
Europe in competitiveness in comparison to the United States of America, European 
countries from the Eastern region. Several indicators such as Research and Development 
(R&D), Data monitors, etc. highlight that the EU pharmaceutical generic drug sector has 
been at a disadvantage against its competitors. Furthermore, current EU regulations and 
policy governed under European law are exerting influence. This includes the European 
competition law, the EU Social chapter and the Four Freedom (goods, workers, capital and 
services). The result is expanding regulations, for example anti-trust laws, an increasingly 
harmonized marketing authorization procedure and significant influence on the way 
member states organize their health systems under the European Court of Justice ruling. 
The EU ideology of a Single European Market has yet been restrictive in attempts to 
increase competition within the marketplace. Member states are unwilling to give up their 
national regulatory authority because  Wdepending on their specific policy goals W the 
predominant fear is that it will have a negative impact on their domestic industries (e.g. job 
loss) and their health care systems (e.g. higher prices for pharmaceuticals). This fear holds 
back national support of a Single European Market and often the policy emerges in the use 
of the subsidiary principle.  
Additionally the rise of pharmaceutical generic drugs (which are drugs with expired patents 
or no patents) in the global market, particularly in the EU, has led to the entry of new 
players into what was once the domain of large multinational pharmaceutical corporations. 
With the decline of new patented drugs into the market, generic drug manufacturers are 
increasingly posing a threat as they offer cheaper alternatives for many European 
governments who are struggling to manage healthcare costs (Loftgren, 2002). Hence as a 
result, European governments have worked to create a more favorable environment for 
generic drugs manufacturers to prosper, making it a challenge for multinational 
pharmaceutical companies to maintain their market positions. 
LoĨŐƌĞŶ ?  ? ? ? ? ? ? Ɖ ? ? ? ƐƚĂƚĞƐ ?  “ƚŚĞ ŚŝŐŚĞƐƚ ŵĂƌŬĞƚ ƐŚĂƌĞĨŽƌ ŐĞŶĞƌŝĐƐ ŝƐ ĨŽƵŶĚ ŝŶ ĐŽƵŶƚƌŝĞƐ
where the industry historically had the greatest pricing freedom, including Germany, the 
EĞƚŚĞƌůĂŶĚƐ ĂŶĚ ƚŚĞ h< ? ? /Ŷ ƚĞƌŵƐ ŽĨ ŐƌŽǁƚŚ ƉŽƚĞŶƚŝĂů ? ƚŚĞ ƐƐŽĐŝĂƚŝŽŶ ŽĨ ƚŚĞ ritish 
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WŚĂƌŵĂĐĞƵƚŝĐĂů/ŶĚƵƐƚƌǇ ? ? ? ? ? ?ƐƚĂƚĞƐƚŚĂƚƚŚĞh ?ƐŐĞŶĞƌŝĐƐĚƌƵŐŵĂƌŬĞƚŝƐǁŽƌƚŚ ? ?ďŝůůŝŽŶ ?
with an annual growth rate of 10 - 15% as compared to the annual growth rate of around 7 - 
9% for the pharmaceutical sector overall. This rapid growth rate highlights the fact that the 
continued rapid expansion of the global generics sector is undeniable, making it worthwhile 
for multinational pharmaceutical companies to examine the prospect of establishing their 
presence in this increasingly competitive market. It is therefore important for industry 
players to consider various environmental scenarios in preparation of new opportunities 
and challenges that lay ahead. 
This report seeks to investigate the future business environment of pharmaceutical generic 
drugs industry within the EU. What are the key macro-environmental factors that affect the 
business environment of the pharmaceutical generics drugs industry in the EU? What are 
realistic and plausible scenarios for the future course of the macro business environment of 
pharmaceutical generic drugs industry within the EU? What strategies are recommended to 
the pharmaceutical generic drugs industry players within the proposed scenarios? 
 
1.1 OBJECTIVES 
The main objective of this report is to conduct a macro environmental scan of the 
pharmaceutical generic drugs industry and project possible future business environments in 
the form of plausible scenarios. A thorough EU macro-environmental analysis will be 
conducted to identify the key factors that could shape the future business environment for 
generic drugs players, followed by strategic recommendations for internal decision-making.  
 
1.2 SCOPE OF THE REPORT  
This report focuses specifically on the EU and the scenarios are 20 year projections from the 
period of 2010-2030. The report is restricted to the macro-environmental analysis and will 
not detail industry analysis, market/competitors analysis, and internal analysis. Additionally, 
the analysis will be conducted with the consideration that the customer base is 
predominantly government and insurance funds (i.e. institutional purchases).  
 
1.3 PROJECT PROCESS FLOW  
To achieving the aforementioned objectives, the project was divided into three phases:  
1. Phase 1  W Research: this is the stage where the scope is defined, research is 
conducted and data is collated.  
2. Phase 2  W Scenario Building: this is the stage where the data will be analyzed and the 
scenarios will be crafted.  
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3. Phase 3  W Recommendations: the final stage where strategic and commercial 
recommendations will be proposed. 
Detailed description of the project process flow has been discussed in Part II: Project 
Process & Research. 
 
1.4 REPORT STRUCTURE  
 
The layout of the report is as follows: 
1.4.1 PART I: LITERATURE REVIEW & RESEARCH METHODOLOGY. 
Tasks: 
 Literature Review: A comprehensive literature review is provided in this section and the 
following topics are discussed: 
 The Probable and the possible: This section details the academic perspective of 
forecasts and scenarios, the characteristics and elements that make an effective 
scenario are explored. 
 Understanding Scenario Planning, Scenario aspects and challenges: These 
sections introduce the concepts and objectives of scenario planning (scenario 
thinking). Italso critically reviews scenario planning vis-à-vis approaches and 
methods. It also highlights the challenges organizations face during scenario 
planning.  
 Scenario planning techniques, Strengths & Weaknesses: This section critically 
reviews scenario planning vis-à-vis approaches and methods. It also highlights a 
case study and discusses the challenges organizations face during scenario 
planning.  
 Research Methodology:  This section details the research methods used to achieve the 
objectives of this report and the following topics are discussed: 
 Qualitative & Quantitative Research: These sections review qualitative & 
quantitative research methodologies and define the approaches used to conduct 
primary and secondary research. 
 Research Tools, Sampling & Administration: These section reviews the various 
tools used to conduct the research and identifies the specific administrative tools 
used. 
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1.4.2 PART II: PROJECT PROCESS, RESEARCH & ANALYSIS. 
Tasks: 
 Project Process: This section details the processes that were subscribed to the project 
and the following sections are discussed: 
 Project Thematic Diagram: This section is a graphical representation of the 
project process flow. 
 Project Process Flow: This section details the various stages of the project. 
 Research and Analysis: This section details the research findings and the following 
sections are discussed: 
 Stakeholders: This is a graphical representation of the various stakeholders in the 
European pharmaceuticals market. Their functions, policy and objectives are 
represented systematically. 
 PESTLE Factors: This section is a detailed environmental analysis of the various 
PESTLE factors identified under the scope of the project. 
 PESTLE Factors Tabulated: This is a tabular representation of the various PESTLE 
macro-environmental factors identified under the PESTLE factors section. This 
table also highlights a grading system to show relevance to scenario planning. 
 Policy Governance Trends: This section graphically represents the predicted 
policy trends based on the findings of the quantitative research conducted as 
part of the project methodology. 
1.4.3 PART III: SCENARIOS & STRATEGIC RECOMMENDATIONS. 
Tasks: 
 Scenarios: This section describes the scenarios crafted from the analysis conducted 
under the research and analysis stage in Part II. Scenarios crafted are listed under the 
following sections: 
 TodoesBueno!: Anoptimistic scenario of the macro-environmental factors is 
represented. 
 Nein, nicht gut!: A pessimistic scenario of the macro-environmental factors is 
represented. 
 Duex Union Européenne!: A duality of the macro-environmental factors is 
represented. 
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 Scenario Evaluation & Implication: This section evaluates the economic environment 
described in the scenarios. Based on the macro findings, it hypothesizes the EU generic 
drugs industry and identifies possible opportunities and threats. 
 Strategic Recommendations: This section combines the opportunities and threats 
identified in the scenario evaluation and implications stages and lists strategies and 
recommendations specific to generic drugs players. 
1.4.4 APPENDIX 1 
Appendix 1 includes the following: 
 PESTLE Factors: This section is a detailed environmental analysis of the various PESTLE 
factors identified under the scope of the project. 40 PESTLE factors are researched and 
evaluated.  
1.4.5 APPENDIX 2 
Appendix 2 includes the following: 
 Qualitative research questionnaire: This section contains the snapshot of the qualitative 
questionnaire used as part of the project research.  
 Quantitative research questionnaire: This section contains the snapshot of the 
quantitative questionnaire used as part of the project research. 
1.4.6 APPENDIX 3 
Appendix 3 includes the following: 
 Responses and key points from interviews conducted: The section transcribes the 
interviewees and highlights key elements that were used to supplement the project 
research. 
1.4.7 APPENDIX 4 
Appendix 4 includes the following: 
 Presentation Slides: This section contains a presentation that summarized the details of 
the report on a collection of slides.  
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2 LITERATURE REVIEW AND SCENARIO PLANNING THEORY  
 
2.1 OUTLINE OF LITERATURE REVIEW  
The review identifies three main areas where the literature on scenario planning is defined. 
The first part describes the scenario and scenario planning origins, concepts and definitions. 
A considerable body of extant is revealed in the following sections, drawing on literatures, 
assumptions behind the practices and theoretical frameworks.  
Later subsections describe scenario planning topology and processes. Various literatures are 
reviewed on the methodologies used to govern the scenario planning process. These will 
describe elements, characteristics and models, and critically evaluate the findings. 
The third part will evaluate a case study that holds relevance to the project scope. In this 
section we will also review the strengths and weaknesses of scenario planning.  
The section following the literature review will define the methodology formulated specific 
to the project requirements.  
 
2.2 INTRODUCTION TO LITERATURE  
The business environment is highly dynamic and it compels enterprises and organizations to 
constantly develop and adapt to new concepts, technologies, products and realities. The 
ability to identify and adapt to future market changes has now become a determinant to the 
competitiveness of orŐĂŶŝǌĂƚŝŽŶƐ ?  “dŽ ĂĚĚ ? ƚŚĞ ĐĂƉĂĐŝƚǇ ŽĨ ƚŚĞ ĨŝƌŵƐ ƚŽ ĚĞĂů ǁŝƚŚ ƚŚĞ
uncertainties and to adapt quickly to major changes has become a crucial factor to success 
ĂŶĚĂŵĂũŽƌĐŚĂůůĞŶŐĞĨŽƌŵĂŶĂŐĞƌƐ ? ?sĂƌƵŵ & Melo, 2010). 
Traditional planning is often based upon the acceptance that the application of professional 
expertise to achieve well-defined goals will ensure efficient and effective management. 
However such plans often fail to consider the variety of local conditions or the propensity 
for novel situations to create extraordinary surprises (Scott, 1998).  This uncertainty can 
lease to costly failures and thus scenario planning, a technique for decision-making in the 
ĨĂĐĞ ŽĨƵŶĐŽŶƚƌŽůůĂďůĞ ƵŶĐĞƌƚĂŝŶƚŝĞƐ ? ŽĨĨĞƌƐ ƚŚĞ  “ĐŽŶƐĞƌǀĂƚŝŽŶŝƐƚƐ Ă ŵĞƚŚŽĚ ĨŽƌ ĚĞǀĞůŽƉŝŶŐ
more reƐŝůŝĞŶƚĐŽŶƐĞƌǀĂƚŝŽŶƉŽůŝĐŝĞƐ ? ?,ŽůůŝŶŐ & Meffe, 1996). 
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2.3 THE PROBABLE AND THE POSSIBLE  
 
2.3.1 THE PROBABLE  W PREDICTIONS, FORECASTS, AND PROJECTIONS 
Predictions are different things to different technical disciplines and to different people 
(Sarewitz et al., 2000). An acceptable definition of an ecological prediction can be the 
probability distribution of the specified variable over a specified time in the future, 
conditional on current conditions, specified assumptions about the rivers, measured 
probability distributions of model parameters, and the measures probability that the model 
itself is correct (Clark et al., 2001). Prediction is the best possible estimate of the future 
conditions. Lesser the sensitivity of predictions to the drivers, better the result 
(MacCracken, 2001).  
In contrast to predictions, forecasts are best estimated from a particular method, model, or 
individual. They are widely understood by decision makers as forecasts that may or may not 
be true (MacCracken, 2001). They are more objective in contrast to predictions that are 
subjective and do not rely heavily upon assumptions over drivers that may have unknown, 
imprecise or unspecified probabilities.  
Predictions have three fundamental and interacting problems: uncertainty, contingency, 
and reflexivity (Carpenter, 2002). In many cases, predictions are not rigorously evaluated; 
particularly the model of uncertainty is ignored even though statistical methods are 
available to address these issues (Clark et al, 2001). If uncertainty is evaluated by model 
forecasting, it can be found that the forecast inherits uncertainty. In addition drivers that 
are reflective of human behavior constrain the possibility of predictions (Funtowicz & 
Ravetz, 1993). 
hŶĐĞƌƚĂŝŶƚǇ ĐĂŶ ďĞ ĐŽŶĨƵƐŝŶŐ ĂŶĚ ĚĞŵŽƌĂůŝǌŝŶŐ ĂŶĚ ĐĂŶ ůĞĂĚ ƚŽ ŝŶĂĐƚŝŽŶ Žƌ  “ƉĂƌĂůǇƐŝƐ ďǇ
ĂŶĂůǇƐŝƐ ?ƌĂƚŚĞƌƚŚĂŶĚĞĐŝƐŝǀĞĂĐƚŝŽŶ ?,ŽǁĞǀĞƌ ?ƵŶĐĞƌƚĂŝŶƚǇĐĂŶďĞǀŝĞǁĞĚĂƐĂŶŽƉƉŽƌƚƵŶŝƚǇ
 ?EĞǇ ?dŚŽŵƉƐŽŶ ? ? ? ? ? ? ?/ƚĐĂŶůĞĂĚƚŽƚŚĞ “ĂĐŬŶŽǁůĞĚŐĞŵĞŶƚŽĨŚƵŵŝůŝƚǇ ?ĂƐparticipants 
are ignorant of what the future brings (Peterson et al., 2002). Uncertainty can inspire action 
because the future is not already determined but rather created by the plan and actions of 
people.  
Scenario planning is closely similar to adaptive management (Walters, 1986), and is a 
management approach to comprehend uncertainties into accounts and to supplement 
decision making. 
2.3.2 THE POSSIBLE  W SCENARIOS 
Before understanding and defining scenario planning, it is necessary to understand the 
definition of scenarios. Lynch (2003) describes scenarios as detailed and plausible views of 
how the business environment of an organization might develop in the future based on 
groupings of key environmental influences and drivers to change about which there is a high 
ůĞǀĞůŽĨƵŶĐĞƌƚĂŝŶƚǇ ?^ĐĞŶĂƌŝŽƐĂƌĞĂůƐŽďĞĚĞĨŝŶĞĚĂƐ “QĂŶŝŶƚĞƌŶĂůůǇĐŽŶƐŝƐƚĞŶƚǀŝĞǁŽĨǁŚĂƚ
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the future might turn out to be  W ŶŽƚĂĨŽƌĞĐĂƐƚ ?ďƵƚŽŶĞƉŽƐƐŝďůĞĨƵƚƵƌĞŽƵƚĐŽŵĞ ? ?WŽƌƚĞ  ?
1985). These definitions highlight the difference between scenarios and forecasts: single 
point forecasts developed from an analysis of present day trends can be placed within a 
wide range of uncertainties in the future, and therefore, there is a high probability of getting 
forecasts wrong (i.e. missing the mark). It is also important to understand that scenarios are 
not projections, predictions or preferences about the future, but rather they are coherent 
and credible alternative stories about the future (Cornelius et. al., 2005).   
To create a better understanding of scenarios, Table 1 below lists the characteristics that 
make a scenario. 
TABLE 1: CHARACTERISTICS OF SCENARIOS 
Characteristics of scenarios. 
i. Internally consistent ii. Time-limited 
iii. Coherent iv. Ordering perceptions 
v. Plausible vi. Based on assumptions 
vii. Interconnected events viii. Different possibilities 
ix. Relevance x. Based on past/present 
xi. Challenging xii. Based on pre-determined events 
xiii. Representative xiv. Trent outcomes 
xv. External xvi. Imagined 
xvii. Narrative xviii. Decision-making tool 
xix. Boundaries/framework xx. Progressive 
Source: Extracted from the definitions of scenarios listed by Bradfield et al. (2005). 
In addition to the characteristics, listed below are various elements of an effective scenario: 
 A good story about changes that may possibly occur in the future within a particular 
environment 
 Can capture a listeners imagination 
 Written in a past or present tense to give the impression that trends and events have 
already occurred (what should we do now?) 
 Helps clarify the causes and effects of developments 
 Makes a listener challenge his/her mental models and assumptions about the future 
 Helps enable strategists define and assess a range of future actions 
 Seen as an important element of strategy development 
 
The key difference between forecasts and scenarios is that, forecasts predict the present 
across a single path into the future. Scenarios on the other hand are multiple possibilities 
that encompass uncertainties into cross dimensional paths. They are multiple projections 
and are representatives of futures. Figure 1 below is a graphical representation that 
highlights the key differences between Forecasts and Scenarios. 
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FIGURE 1: SCENARIOS VS. FORECASTS 
 
Source: (Cornelius et al., 2005) 
2.4 UNDERSTANDING SCENARIO PLANNING  
Scenario planning or scenario thinking originates from the military, however their use in 
organizational decision making were developments from the scenario techniques developed 
by Kahn, at Rand Corporation, and Berger in France post World War 2 (Van der heijden et 
al., 2002). During this period several business scenarios were published. It is however the 
business scenarios developed by Royal Dutch Shell (1970s) that were the first to receive 
worldwide attention. Pierre Wack at Shell led a team of strategists and formulated the 
concept of  “ƌĞƉĞƌĐĞŝǀŝŶŐ ƚŚĞ ĨƵƚƵƌĞ ?  ?dŝďďƐ ?  ? ? ? ? ? ?Scenario planning is not a process of 
ĨŽƌĞĐĂƐƚŝŶŐďƵƚ ĨŽƌĞƐŝŐŚƚ ƚŚĂƚĞǀĂůƵĂƚĞƐŵƵůƚŝƉůĞ ĨƵƚƵƌĞƐŽĨ ƚŚĞďƵƐŝŶĞƐƐĞŶǀŝƌŽŶŵĞŶƚ ?   “/ƚ
ĐŽŶƐŝĚĞƌƐŵƵůƚŝƉůĞĂŶĚĞƋƵĂůůǇƉůĂƵƐŝďůĞĨƵƚƵƌĞƐ ? ?ZŝŶŐůĂŶĚ ? ? ? ? ? ? ? 
dŚĞƉůĂŶŶŝŶŐĐŽŶƐŝƐƚƐŽĨĚĞǀĞůŽƉŝŶŐƉŽƐƐŝďůĞƌĞƉƌĞƐĞŶƚĂƚŝŽŶƐŽĨĂĨŝƌŵ ?ƐƉŽƚĞŶƚŝĂůĨƵƚƵƌĞƚŚĂƚ
makes different assumptions about the driving forces of markets and includes uncertainties 
(Kotler, 2003). Private and public organizations both face business environments which are 
very diverse. To cope with this diversity companies must be prepared.  It is the duty of 
strategists to be able to see the plausible futures and their changes in business 
ĞŶǀŝƌŽŶŵĞŶƚ ?dŚĞǇŵĂǇĐŽŶƐŝĚĞƌĂƋƵĞƐƚŝŽŶƐƵĐŚĂƐ  “tŚĂƚǁŝůůǁĞ ĚŽ ŝĨ ŝƚŚĂƉƉĞŶƐ ? ?ĂŶĚ
accordingly, strategists will observe and adopt one scenario as the most plausible future and 
as time passes regard or disregard such a scenario.  
2.5 SCENARIO ASPECTS AND CHALLENGES  
Scenario planning is one of the many tools that strategists and marketers use to plan. It is 
ŽŶĞŽĨ ƚŚĞ ƚŽŽůƐ ŝŶĂƐƚƌĂƚĞŐŝƐƚƐ ?ĂƌƐĞŶĂů ƚŚĂƚ ŝƐƵƐĞĚƚŽƉƌĞĚŝĐƚŽŶ ƚŚĞĂƐƐƵŵƉƚŝŽŶƐ ƚŚĂƚ ŝĨ
strategists cannot predict the forecast, then they consider a variety of foresights, thus 
strategists might be able to hit the right one (Porter, 1985). They are not forecasts but 
rather plausible future structures of environmental factors and relative uncertain variables 
of influences.  
The Present
The Path
The Future
Forecasts
Current
Realities
(mental maps) MultiplePaths
Alternative
Future Images
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Scenario planning helps improve decision making by allowing more complete considerations 
of outcomes and their implications (Fuller-Love 2006). They are the first step to strategic 
planning. If strategic planning is to succeed, scenarios then must be properly factored into 
ƚŚĞ ŽƌŐĂŶŝǌĂƚŝŽŶ ?Ɛ ƉůĂŶ ? dŚĞ ƉƌŽĐĞƐƐ ĐĂŶ ďĞ ĚŽŶĞ ďǇ ŽďƐĞƌǀŝŶŐ ? ŵŽŶŝƚŽƌŝng and 
understanding the changes and complexities in the business environment. As business 
environments become volatile or undergo rapid changes or both, it may be advisable for 
distinct approaches combining one or more views in order to understand future outcomes.  
Building scenarios has traditionally become an outward looking process designed to extend 
the awareness of potential changes in the external environment (Mason & Herman, 2003). 
By casting strategies as scenarios, companies can benefit from traditional scenario planning 
with accelerated decision making for organizations in highly dynamic environments. Two 
approaches can be practiced by companies; the first is building scenarios from configuration 
factors. This is done by: 
1. Identification of high-impact, high uncertainty factors in the environment 
2. Identification of different possible futures by factors 
3. Building scenarios of plausible configurations of factors 
The second approach is the thematic scenario method (Shaukat & Ringland, 2003). Detailed 
scenario planning techniques are discussed in a later sub-chapter. 
It can be concluded that organizations can create many scenarios. However decision making 
involves organization focusing on the most possible options. Factors such as capital 
investment, etc. need to be considered. This is because of a range of effects scenarios have 
on diverse industrial stakeholders.  
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FIGURE 2: EXPLORING CORPORATE STRATEGY 
 
Source: (Cornelius et al., 2005) 
 
Figure 2above shows the various and different environments as well as the complexities 
associated with these environments due to the many separate issues in the business. 
Changes in lifestyle, consumer behavior and buying patterns are all the additional factors 
that need to be considered when planning scenarios, which complement strategy 
development and decision making. It is an important strategic tool for companies as 
marketers see the choices available through scenario planning and the options are screened 
to match possible scenarios. Scenario planning thus can lead to an emergency plan in order 
to meet the requirements of these possible future scenarios. As a result, it is important that 
scenario planners observe, monitor, and imagine the possible future changes to the 
business environment.  
2.6 OVERVIEW OF SELECTED SCENARIO PLANNING TECHNIQUES IN PRACTICE  
Scenarios, despite their story-like characteristics, follow systematic and recognizable steps. 
It is a highly interactive process with intense and imaginative qualities. There are several 
different approaches to scenario planning and these share common or similar aspects. The 
process usually starts by clarifying the decisions to be made, challenging mental maps that 
ƐŚĂƉĞ ƉĞŽƉůĞ ?Ɛ ƉĞƌĐĞƉƚŝŽŶƐ ? ĂŶĚŚƵŶƚŝŶŐ ĂŶĚ ŐĂƚŚĞƌŝŶŐŝŶĨŽƌŵĂƚŝŽŶ ĨƌŽŵ ǀĂƌŝŽƵƐ sources. 
The next steps are analytical: identify the driving forces, the predetermined elements and 
the uncertainties. Thereafter, two or more thoughtfully composed scenarios are plotted, 
each representing a distinct plausible future. The deeper structure and their underlying logic 
The macro-
environment
Industry 
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ĂƌĞ ĨƵƌƚŚĞƌ  ‘ĨůĞƐŚĞĚ ? ƚŽ ƌĞǀĞĂů ƚŚĞŝƌ ĐƌƵĐŝĂů ĚŝĨĨĞƌĞŶĐĞƐ ? &ŝŶĂůůǇ ? ƚŚĞ ŬĞǇ ĞǀĞŶƚ ĂŶĚ ƚƵƌŶŝŶŐ
points that would channel the future towards one scenario are identified. Phelps et al., 
(1998) suggest that scenarios are built according to four stages: 
 Define scope 
 Database construction 
 Building scenarios 
 Choosing strategic options 
 
Numerous methods are available in literatures, ranging from simple models to highly 
complex, qualitative or quantitative models. It should be realized that there is no one 
method or one specific model to developing scenarios, and some of the methods are briefly 
described in Table 2 towards the end of this sub-section. 
2.6.1 TYPE 1: THE EIGHT-STEP SCENARIO PROCESS BY UTE VON REIBNITZ 
Ute von Reibnitz (1992) argues that the ability to create distinctive future situations allows 
strategic planners to deal with scenarios that fall between two extremes. In her book she 
proposes eight steps.  
1. Task analysis: (goals, strategies) this is the stage where the objectives, goals and 
strategies of addressing the issues are identified. 
2. Influence analysis: (factors/areas, system dynamics) this is the stage where the 
strengths and weaknesses profile is drawn up; following is then a matter of acquiring 
knowledge of the system dynamics/structure of the associated areas. The advantage 
of this scenario technique comes from the ability to account for minority votes. 
3. Projections: this stage is part of the scenario workshop which calls for visionary 
thinking ability. Descriptors are identified from different areas of influence. 
4. Clustering alternatives, consistency analysis: this is the stage where the projections 
are clustered and checked against each other for consistency. It is done using a 
consistency matrix to largely view and collate the views of the descriptors. 
5. Scenario interpretations/developments/visualization: this is the stage where the 
scenarios are interpreted and described in a creative/imaginative way.  
6. Consequence analysis: (opportunities, risks, and actions) this is the stage where 
possible opportunities and risks are identified.  
7. Analysis of disruptive events/wild cards: this is the stage where opportunities and 
risks are utilized and contained. This is also the stage where forecasts and scenarios 
differ by incorporating ƚŚĞƵŶĐĞƌƚĂŝŶ ‘ǁŝůĚĐĂƌĚ ?Ɛ ?ŝŶƚŽĨƵƚƵƌĞƐĐĞŶĂƌŝŽƐ ?
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8.  Scenario transfer: (developing core strategy, monitoring system) this is the final 
stage where the strategies and measures in the previous two stages are evaluated. 
(Schwab et al., 2003) 
2.6.2 TYPE 2: THE EIGHT-STEP SCENARIO APPROACH BY PETER SCHWARTZ 
Peter Schwartz (1996) president of Global Business Network is a pioneer in the field of 
scenario development. He is the well-ŬŶŽǁŶ ĂƵƚŚŽƌ ŽĨ  ‘dŚĞ ƌƚ ŽĨ ƚŚĞ >ŽŶŐ sŝĞǁ ? ? dŚĞ
approach of Schwartz is to look for archetypal plots, which are reoccurrences in human 
history, and fit the driving forces to them.  The procĞƐƐƐƚĂƌƚƐǁŝƚŚƚŚĞĐƌŝƚŝĐĂů ŝƐƐƵĞ P ‘ǁŚĂƚ
ŝŵƉĞŶĚŝŶŐ ĚĞĐŝƐŝŽŶ ŬĞĞƉƐ ǇŽƵ ĂǁĂŬĞ Ăƚ ŶŝŐŚƚ ? ? dŚŝƐ ƚŚĞŶ ůĞĂĚƐ ƚŽ ƋƵĞƐƚŝŽŶŝŶŐ ƚŚĞ ŬĞǇ
ĨĂĐƚŽƌƐ ƚŚĂƚĚĞƚĞƌŵŝŶĞ ƚŚĞ ƐƵĐĐĞƐƐ Žƌ ĨĂŝůƵƌĞƐ ŽĨ ƚŚĞ ŝƐƐƵĞ ?  ‘tŚĂƚ ĂƌĞ ƐŽŵĞ ŽĨ ƚŚĞ ĚƌŝǀŝŶŐ
forces creating changes in the wider wŽƌůĚ ? ?dŚĞ ĚƌŝǀŝŶŐ ĨŽƌĐĞƐĂƌĞ ƌĂŶŬĞĚďǇ ŝŵƉŽƌƚĂŶĐĞ
and uncertainty: most important and most uncertain. Scenario logics are selected and the 
scenario matrix is created. The next step is to flesh the scenarios by referring to the key 
factors, and a selection of plausible events that might create that state has to be 
ŝŶĐŽƌƉŽƌĂƚĞĚ ? ‘,ŽǁĚŽĞƐƚŚĞĚĞĐŝƐŝŽŶůŽŽŬŝŶĞĂĐŚƐĐĞŶĂƌŝŽ ? ?^tKdĂŶĂůǇƐŝƐŝƐƐƵŐŐĞƐƚĞĚ ?
and the final step is to identify leading indicators that are heading towards one or another 
of these scenarios. 
2.6.3 TYPE 3: SCENARIO PLANNING BY MICHEL GODET AND FABRICE ROUBELAT 
Godet and Roubelat (1999) suggest that building scenarios and strategies should be done 
using simple and rational tools to stimulate the imagination. They have elaborated a toolbox 
which classifies problem solving methods as follows: 
1. Asking the right questions and identifying key variables: futures workshops and 
ƐƚƌƵĐƚƵƌĂůĂŶĂůǇƐŝƐƵƐŝŶŐƚŚĞ ‘D/D ?ŵĞƚŚŽĚƐ ? 
2. ŶĂůǇǌŝŶŐƚƌĞŶĚƐĂŶĚĂĐƚŽƌƐƐƚƌĂƚĞŐŝĞƐ PƌĞƚƌŽƐƉĞĐƚŝǀĞƐƚƵĚŝĞƐĂŶĚ ‘DdKZ ?ŵĞƚhod. 
3. Reducing uncertainties to realizable scenarios: morphological analysis using expert 
methods such as Delphi, cross-impacts. 
4. /ĚĞŶƚŝĨǇŝŶŐĂŶĚĂƐƐĞƐƐŝŶŐƐƚƌĂƚĞŐŝĐŽƉƚŝŽŶƐ PĂŵƵůƚŝĐƌŝƚĞƌŝĂĂŶĂůǇƐŝƐĂŶĚ ‘Dh>d/WK> ?
method. 
Broadly, the process comprises of three major stages (1) construction of the basis, (2) 
identification of major issues, and (3) construction of scenarios. (Arcade et al., 1999). 
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TABLE 2: COMPARISON OF VARIOUS APPROACHES OF SCENARIO TECHNIQUE 
Author(s) Definition Aim/ Purpose Types/Categories Concept 
Peter Schwartz 
(1996) 
Scenarios are tools for 
ordering one's perceptions 
about alternative future 
environments in which 
today's decisions might be 
played out. In practice, 
scenarios resemble a set of 
stories, written or spoken, 
built around carefully 
constructed plots. Stories are 
an old way of organizing 
knowledge. When used as a 
strategic tool, they confront 
denial by encouraging in fact, 
requiring the willing 
suspension of disbelief. 
Stories can express multiple 
perspectives on complex 
events and scenarios give 
meaning to these events. 
 To highlight large scale forces that 
push the future in different 
directions.  
 
 It is about making these forces 
visible, so that if they do happen, 
the planner will at least recognize 
them. 
No types or categories identified. Eight steps: 
1. Identification of the focal issues or decisions. 
2. Identification of key forces in the local 
environment. 
3. List of the driving forces (social, economic, 
political, environmental, technological 
forces): "What are the macro-
environmental, and technological forces 
listed in step 2?" 
4. Ranking of key factors and driving forces by 
importance and uncertainty. 
5. Selection of scenario logics, in effect, the 
axes along which the eventual scenarios will 
differ. 
6. Fleshing out the scenario  W the logics give 
the skeleton of the scenarios and returning 
to the key factors and trends listed in step 1 
and 3. 
7. Exploration of the implications. 
8. Selection of leading indicators and signposts. 
Von Reibnitz 
(1988, 1992), 
Schwab, 
Cerutti, von 
Reibnitz (2003) 
A scenario approach that 
involves developing future 
environment situations 
(scenarios) and describing the 
path from any given present 
to these future situations. 
These scenarios cover the 
"edges" of the scenario 
funnel. 
 Create alternatives in case of 
uncertainties and to assemble them 
into highly consistent scenarios. 
 Scenarios are recommended 
whenever the problem is complex, 
uncertain and has long-term effects. 
 Corporate identities should be 
developed and tested in tandem 
with the development of strategies 
on the basis of worked out 
scenarios. 
 Development goals and strategies 
(master and alternative strategies) 
 Re-examining existing goals and 
strategies. 
 Assessing strategic decisions. 
 
Scenario approach suggests to: 
 Include quantitative and qualitative 
information/ data. 
 Use explorative scenarios. 
 Develop three types of scenarios in 
the scenario building process: trend 
extrapolation, best-case and worst-
case scenario. 
Eight steps: 
1. Task analysis (goals, strategies). 
2. Influence analysis (areas/ factors, system 
dynamics). 
3. Projections. 
4. Clustering alternatives, consistency analysis. 
5. Scenario 
interpretation/development/visualization. 
6. Consequence analysis (opportunities, risks, 
actions). 
7. Analysis of disruptive events/ wild cards. 
8. Scenario transfer (developing core strategy, 
monitoring system). 
Page 23 of 143 
 
Author(s) Definition Aim/ Purpose Types/Categories Concept 
Heinecke, 
Schwager 
(1995) 
Scenarios are alternative, 
plausible and consistent 
pictures of the future which 
consist of logically suited 
premises and the description 
of development paths of 
possible futures built on the 
present situation. 
 
They give not a future 
forecast or prognosis of what 
will happen but consistent 
pictures of what could 
possibly happen without 
evaluating the probability of 
becoming reality. 
Scenarios 
 Foster systematic thinking on 
external influencing factors. 
 Reveal basic assumptions. 
 Help to identify strategic gaps, 
structural changes and 
disruptive factors. 
 Lead to a different awareness of 
problems. 
 Make decision-makers more 
sensitive to future potentials. 
 Reduce misjudgments. 
 Help to formulate and evaluate 
visions and strategies. 
Scenario approach suggests to: 
 Include quantitative and qualitative 
information/ data. 
 Link intuitive (deductive) and model 
based (inductive) methods/ tools. 
 Use explorative scenarios (not normative 
or descriptive ones). 
 Build scenarios for managers at the level 
of the corporation and SBUs. 
Eight steps similar to von Reibnitz: 
 Identification of influence areas/ factors. 
 Identifying descriptors, projections. 
 Consistency analysis and/or cross-impact 
analysis. 
 Scenario interpretation. 
 Analysis of disruptive factors/wild cards. 
 Consequence analysis. 
 Elaborating core strategy, scenario transfer 
linking scenario technique with other 
methods/ tools (e.g. creativity techniques, 
Delphi, risk analysis, cluster analysis). 
Michel Godet, 
FabriceRoubelat 
(1997), Godet 
(1987), Godet, 
Roubelat (1996) 
A scenario is a description of a 
future situation and the 
course of events which allows 
one to move forward from 
the original to the future 
situation. 
 Stimulate strategic thought and 
communication within 
companies. 
 Improve internal flexibility of 
responses to environmental 
uncertainties, and provide 
better preparation for possible 
system breakdowns. 
 A distinction is made between possible 
scenarios (everything that can be 
imaged), realizable scenarios (all that is 
possible, taking account of constraints) 
and desirable scenarios (they are possible 
but not all necessarily realizable). 
 According to their probability, these 
scenarios may be termed reference, 
trend based, contrasted or normative. 
 A trend-based scenario whether it is 
possible or not corresponds to the 
extrapolation of trends at all points 
where choices are to be made. 
 It is among the realizable scenario, which 
has a higher than zero probability, that 
we find contrasted (unlikely) scenarios 
and the field of development where the 
most probable scenarios are found. 
 As regards desirable scenarios, these are 
found certain within the possible zone 
and are not all necessarily realizable. 
Three major stages: 
1. Construction of the basis and identification 
of essential variables. 
2. Identification of major issues at stake and 
key questions for the future. 
3. Elaboration of exploratory scenarios. 
Table 2: Comparison of Various Approaches of Scenario Technique. Source: (Mietzner &  Reger, 2004) 
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2.6.4 CASE ANALYSIS: SHELL OIL SCENARIOS  W SUCCESS STORY 
During the early 1970s, Shell Oil used scenario planning to evaluate the organizations long-
term decisions and strategies. Around this period world oil prices were low and expected to 
remain low. However Shell scenario planners considered a possible price rise, contrary to 
expectation. Because by then there was uncertainty involved over how much the prices 
would rise by, traditional forecasting approaches were inappropriate. Strategy planners at 
Shell then used scenario planning and identified a number of tensions, and realized that at 
some point of the oil production, oil was kept better in the round than sold suggesting a 
number of possible changes in the status quo. One of these scenarios envisioned a time 
where countries would form a collation and control oil prices. This scenario was considered 
radical, but still plausible. This exercise lead Shell to adjust the business practices and hedge 
against the potential for high oil prices by increasing the efficiency of its refining and 
shipping operation. These changes, combined with the ability to respond to the oil prices 
allowed Shell to adapt to a world of expensive oil much faster than its competitors.  
2.7 STRENGTHS AND WEAKNESSES OF SCENARIOS  W FUTURE RESEARCH  
^ŚĞůůƐĐĞŶĂƌŝŽƐŝŶƚŚĞ ? ? ? ?ƐƉŽŝŶƚĞĚŽƵƚ “Ăchange in the paradigm of futures research from 
ĨŽƌĞĐĂƐƚŝŶŐ ƚŽǁĂƌĚƐ ĨŽƌĞƐŝŐŚƚ ?  ?DŝĞƚǌŶĞƌ & Reger, 2004). Forecasting is considered as a 
prediction function of what is expected to happen in the future, in relation to a particular 
event. Whereas foresight is the ability to see what ones future needs are likely to be ranging 
from different possibilities. However there has been a shift in scenario planning techniques 
from a more quantitative modeling process to a more qualitative oriented process. These 
techniques have several strengths and weaknesses, and these are discussed below. 
2.7.1 SCENARIO PLANNING STRENGTHS 
1. They are not forecasts but foresight, and the strength of scenarios is that they do not 
describe one future but several realizable or desirable futures placed side by side. 
2. Scenario planning and scenarios incorporate imagination, and challenge long-held 
internal beliefs of organizations. Their use can change corporate cultures, compelling 
managers to rethink radically the hypothesis that has founded their strategy.  
3. ^ĐĞŶĂƌŝŽƐ ĂƌĞ ĂŶ ĂƉƉƌŽƉƌŝĂƚĞ ǁĂǇ ŽĨ ƌĞĐŽŐŶŝǌŝŶŐ  ‘ǁĞĂŬ ƐŝŐŶĂůƐ ? ? ƚĞĐŚŶŽůŽŐŝĐĂů
discontinuous or disruptive events and including them into long-range planning 
results in organizations better handling new situations. 
4. Scenarios and scenario planning can create a common language to deal with 
strategic issues by opening a strategic conversation within the organization.  
5. The process supports organizational learning and decision making is improved as 
participants share the aims, opportunities, risks and, strategies and later support the 
coordination and implementation of action. 
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6. There are a variety of different scenario planning techniques and the process of 
building scenarios are very flexible and can be adjusted to specific tasks/situations. 
2.7.2 SCENARIO PLANNING WEAKNESSES 
1. The scenario planning process is very time-consuming. 
2. It requires a lot more qualitative approaches and in practice this is a difficult task. 
3. It requires extensive in-depth research of all the various factors and this makes 
scenario building even more time consuming. 
4. It could be difficult not to think about extreme scenarios during the building 
processes. 
The practice is fairly practitioner-driven and there is very little academic literature on failed 
scenarios leading to wrong decision-making. However, it is a handy initial tool for strategic 
decision making and does promote managers to re-evaluate their strategies. 
 
3 RESEARCH METHODOLOGY  
 
The following section outlines the research methodologies that were used in achieving the 
objectives of this project. Data-mining has been conducted using both primary and 
secondary resources.  It is important to note at this point that due to time constraints and 
availability of resources the project has focused largely on secondary data. However this 
data has been successfully complemented with information gathered from primary 
resources. 
3.1 QUALITATIVE RESEARCH  
Qualitative research is a method of inquiry appropriated in many different academic 
disciplines, traditionally in the social sciences but also in market research and further 
contexts. Qualitative researchers aim to gather an in-depth understanding of human 
behavior and the reasons that govern such behavior. The qualitative method investigates 
the why and how of decision making, not just what, where, when. Hence, smaller but 
focused samples are more often needed, rather than large samples. 
Qualitative methods produce information only on the particular cases studied, and any 
more general conclusions are only hypotheses (informative guesses). Quantitative methods 
can be used to verify which of such hypotheses are true. 
 
Page 26 of 143 
 
3.2 QUANTITATIVE RESEARCH 
Quantitative research focuses on a systematical empirical investigation of the quantity 
properties, their phenomena and the relationships. Measurement processes are focal to 
quantitative research because they provide the fundamental relationships between the 
empirical observation and the formulated mathematical/statistical expression of the 
quantitative relationship. 
 
3.2.1 RESEARCH TOOL  W STRUCTURED INTERVIEW 
One of the tools used to populate the research in this project was structured interviews. The 
aim of this approach is to ensure that each candidate is presented with exactly the same 
questions in the same order. The candidates are evaluated using a common rating scale, and 
the interviewers are in agreement on acceptable answers. This ensures that answers can be 
reliably aggregated and that comparisons can be made with confidence between sample 
subgroups or between different survey periods. Organizing a structured interview 
questionnaire requires 8 distinctive steps: 
1. Conduct a Job Analysis  
2. Determine the competencies to be assessed by the Interview  
3. Choose the interview format and develop questions  
4. Develop rating scales to evaluate candidates  
5. Create interview probes  
6. Pilot-test the interview questions  
7. Create the interviewers guide  
8. Document the development process  
Two sets of questionnaires were prepared. The first set represented 26 interview questions 
encompassing the most relevant factors identified under Part II Project Process, Research & 
Analysis  W PESTLE Factors Tabulated. These questions provided qualitative information in 
context to the factors defined and supplemented the secondary research. The second 
questionnaire represented 26 policies and required candidates to forecast/project them on 
a Likert scale. This was done with the purpose of quantifying the likelihood of policies on the 
scale below: 
1. Fully national 
2. Predominantly national 
3. 50/50 
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4. Predominantly European 
5. Fully European 
The survey questionnaires have been included in Appendix 2  W Questionnaire for 
informatory purposes. 
3.2.2 RESEARCH TOOL  W FOCUSED (SEMI-STRUCTURED) INTERVIEW 
In addition to structured interviews, semi-structured interviews were also conducted. This 
technique is used to collect qualitative data by setting up a situation that allows the 
candidate time and scope to talk about their opinions on a particular subject. The focus of 
the interview is decided by the researcher as there may be areas the researcher is 
interested in exploring further. The objective is to understand the ƌĞƐƉŽŶĚĞŶƚ ?Ɛ ƉŽŝŶƚ ŽĨ
view rather than make generalizations about behavior. It uses open-ended questions, some 
suggested by the researcher and some that may have arose naturally during the interview. 
The researcher tries to build a rapport with the respondent and the interview is like a 
conversation. Questions are asked when the interviewer feels it is appropriate to ask them. 
They may be prepared questions or questions that occur to the researcher during the 
interview. The wording of questions will not necessarily be the same for all respondents. 
This technique was used to interview candidates, who were not experts in the 
pharmaceutical/generic drugs industry but experts in functional areas (e.g. Strategy, 
Healthcare general, etc.). 
3.2.3 SAMPLING  W QUESTIONNAIRE 
The questionnaire has been administered to selective candidates who match any of the 
criteria mentioned below: 
1. Experts with extensive experience in pharmaceuticals industry. 
2. Experts with extensive experience in industrial economics. 
3. Experts with extensive experience in the EU healthcare sector. 
4. Experts with extensive experience in pharmaceutical/generic drugs industry. 
5. Experts with extensive experience in legal/regulatory policy in the EU. 
6. Experts with expertise in formulating functional strategies. 
For extensive research, 30 candidates were shortlisted based on their credentials. However, 
7 candidates responded positively while the remaining candidates were subjected to 
unavailability. Although this sample was smaller than earlier expectations, it did not deter 
the research as most of the candidates met more than one criterion of selection. 
Additionally, the secondary research conducted produced extensive data to supplement any 
gaps. 
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3.2.4 ADMINISTRATION METHOD  W TELE-CONFERENCE INTERVIEW 
Following the preparation of the interview questionnaire and identification of the sample 
size, administration strategies were formulated. Questionnaires can be administered in 
writing, orally, in person, via telephone interview, by email or by posting. Each method has 
specific advantages and disadvantages. The selection of which method to be followed 
depends on the question content and complexity.  Costs are always a consideration and 
emailing surveys is usually the least expensive option. It can be generalized that if the same 
data can be extracted from different methods with the desired accuracy, then the least 
costly should be considered. Table 3 represents the modes of administration with regards to 
advantages and disadvantages. 
TABLE 3: ADMINISTRATION METHODS 
Type Advantage Disadvantage 
Mail interview ǯ
convenience, 
Privacy from interviewers 
expectations, 
Visual inputs and visual scales. 
Lowest response rate, 
Doubts cannot be clarified, 
Researcher has little control 
over when the survey will be 
returned.  
Self-administered 
questionnaires  
Excellent during pilot phase, 
Balances question clarity and 
answer confidentiality, 
Researcher can monitor 
completion rates, 
Highly consistent instruction. 
 
High costs because researcher 
need to be present, 
Pilot study can be done with 
non-target segment. 
Electronic interviews Lowest Cost, 
Quickest dissemination, 
Quickest results, 
Large population. 
Low confidentiality, 
Internet access. 
 
Personal interviews Small sample/group, 
Most confidential, 
Honest answers, 
Incentive schemes. 
Poorly generalized sample, 
Very expensive. 
Telephone interviews No geographic proximity, 
Personal Interview, 
Longer more complex questions. 
 
Slightly expensive. 
 
The administration method selected was predominantly telephone interviews and personal 
interviews. This is due to the inherit complexity of the questionnaires and their relative 
answers.  
 
Page 29 of 143 
 
PART II PROJECT PROCESS FLOWS, 
RESEARCH & ANALYSIS 
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4 PROJECT PROCESS  
 
4.1 PROJECT THEMATIC DIAGRAM  
 
Figure 3 below is a graphical representation of the project process flow. 
FIGURE 3: THEMATIC DIAGRAM OF PROJECT PROCESS FLOW 
 
Source: Author 
4.2 PROJECT PROCESS FLOW  
This section details the project process flow as represented by the Project Thematic Diagram 
in the previous sections. The project process flow has been divided into three phases:  
1. Phase 1  W Research: this is the stage where the scope is defined, research is 
conducted and data is collated. 
2. Phase 2  W Scenario Building: this is the stage where the data is analyzed and the 
scenarios will be crafted.  
3. Phase 3  W Recommendations: the final stage where strategic and commercial 
recommendations will be proposed.  
Details of the various stages are described in the proposal supplemented with this report. 
1. Scope
 ?EU - Generics Market
 ?Crafting 20 years Scenarios
 ?Customer Base:
 ?Government
 ?Insurance Funds
2. Research
 ?Primary  Wi.e. interviews
 ?Secondary  Wi.e. desk 
research
3. Collation
 ?Data
 ?Quantitative/Qualitative
4. Design
 ?Conceptual Scenarios
 ?Black
 ?White
 ?Grey
 ?Green
5. Analysis
 ?Field analysis
 ?Factor prioritisation
6. Prognostic
 ?Projection of key trends with 
Implications
 ?Positive (+)
 ?Neutral (0)
 ?Negative (-)
 ?Uncertain (/)
7. Scenario Building
 ?Plausibility
 ?Consistency
 ?Comprehensiveness
 ?Surprise
8. Scenario Testing
 ?Consultation
 ?Iterating
9. Final Scenarios
 ?Mutual exclusivity
 ?Commonalities
 ?Key shared themes
 ?Common implication
 ?Action points
Phase 1 - Research Phase 2  WScenario Building Phase 3 -
Recommendations
10. Recommendations
Strategy
Commercial
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5 PROJECT RESEARCH  
 
5.1 STAKEHOLDERS: PHARMACEUTICAL INDUSTRY  
There are several direct/indirect stakeholders involved in the pharmaceutical industry and 
Figure 4 (below) is a diagrammatic representation of the stakeholders and their interactions. 
It is important to understand these interactions in order to govern the scenarios and 
propose relevant strategies. 
FIGURE 4: STAKEHOLDERS IN THE EUROPEAN PHARMACEUTICAL MARKET 
 
Source: Ginneken & Busse (2010). 
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5.2 PESTLE FACTORS  
dŚĞƉƌŽũĞĐƚŚĂƐŝĚĞŶƚŝĨŝĞĚ ? ?W^d>ĨĂĐƚŽƌƐĂŶĚĂƐƐŝŐŶĞĚǁĞŝŐŚƚďĂƐĞĚŽŶƚŚĞƌĞƐĞĂƌĐŚĞƌƐ ?
initial opinion with respect to their relevance to the Pharmaceutical/Generics Industry. 
Table 4 (below) lists the PESTLE factors identified and their assigned weight. 
TABLE 4: TABULATED PESTLE FACTORS & ASSIGNED WEIGHTAGE 
PESTLE Factor Identified Assigned Weight 
Political   Low 1 - 5 High 
1 EU Expansion & Integration 4 
2 EU Regulatory Framework 4 
3 EU Monetary Policy 4 
4 EU Fiscal Policy 4 
5 ȋǯȌ 3 
6 EU Patent Protection 4 
7 EU Price Regulations 3 
8 EU Political Stability 2 
9 EU War & Conflicts 2 
10 EU Market Intervention/s 4 
11 EU Tax Policy 4 
12 EU Trade Barriers and Tariffs 4 
Economics     
1 EU Economic Growth Rate 4 
2 EU Unemployment 2 
3 EU Outsourcing/Offshoring 3 
4 EU Infrastructure Quality 2 
5 EU Business Cycles 3 
6 EU Disposable and Discretionary Income 4 
7 EU Exchange Rates 3 
8 EU Inflation Rates 2 
9 EU Interest Rates 2 
10 EU Financial Markets 2 
11 EU Savings Rate 2 
Social     
1 EU Demographics 4 
2 EU Education 2 
3 EU Entrepreneurial Spirit 2 
4 EU Lifestyle changes 3 
5 EU Social Mobility 3 
Technology     
1 
EU New Products and Research & Development ȋǮƬǯȌ 4 
2 EU Biotechnology 5 
3 EU Incremental & Disruptive technologies 4 
Legal     
1 EU Labor Laws 2 
2 EU Health and safety regulations 2 
3 EU Consumer Protection 4 
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4 EU Benefits System 4 
5 EU Anti-Trust Laws 4 
Environment     
1 EU Environmental legislation, Social Responsibility, 
Sustainability & Global Climate Change 
3 
2 EU Waste Product 3 
3 EU Non-Governmental Organisations (NGOs) 4 
4 EU Packaging 2 
Source: Authors interpretation 
The factors identified are further explored in Appendix 1. 
5.3 POLICY GOVERNANCE TREND 
Our quantitative research projected the following trends in policies that are directly and 
indirectly related to the scope of the project. Table 5 below highlights the opinions of 
experts and specialists over the possible policy trends in the future circa 2030. 
FIGURE 5: POLICY GOVERNANCE PREDICTED MOVEMENTS 
 
Source: Authors research 
 
 
 
1 2 3 4 5
Policy on Price Regulations
Patent Laws
Taxation policy
Govt. interventions in the free market (Protectionism)
Favoured trading partners
Monetary & Fiscal Policy
Prescribing drugs
Dispensing drugs
Reimbursement for drugs
Pharmacovigilance
Packaging/Waste
Trade Restrictions
Tariffs
Outsourcing/off shoring
Inflation Rates
Healthcare Expenditure
Policies on Demographics (eg. Migration)
R&D spending
Labour Laws (e.g. minimum wage, retirement age etc)
Health and safety regulations
Consumer Protection
Benefits System
Anti-Trust Laws
Environmental Legislation
Social Responsibility
Sustainability
Policy governance predicted movements
Current
Projected
1 - Fully National
2 - Predominantly National
3 - 50/50
4 - Predominantly European
5 - Fully European
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6 PROJECT ANALYSIS  
Following the research phase, key trends identified from the researched factors were 
projected 20 years into the future as defined under the factor prognostics stage (see project 
process). The projected trends were clustered under 4 categories based on the project 
ƚĞĂŵ ?ƐĞǀĂůƵĂƚŝŽŶŽĨ ƚŚĞŝƌimpact to the future of the generic drugs market in the EU: (1) 
Positive, (2) Negative, (3) Neutral, and (4) Uncertain. Figure 6 below is a graphical 
representation of the process. 
FIGURE 6: FACTOR PROGNOSTICS 
 
Source: Authors interpretations 
Additionally, these projected trends were graded on a scale of relevance vis-à-vis scenario 
creation. The grading was on a scale of 1-5 with 1 being low relevance and 5 being high 
relevance. It is important to note here that only key trends were projected  W based on the 
second round of relevance rating of the factors done following the PESTLE research phase. 
6.1 FACTOR PROGNOSTICS  
6.1.1 PROJECTION OF KEY MACRO FACTORS (POSITIVE): 
1. EU Expansion and Integration. Relevance 4. 
Croatia, Bosnia and Herzegovina, Serbia, Montenegro, Macedonia, Kosovo, Albania and 
Turkey are now members of the EU. After acceptance of these new members, the EU slows 
down on granting other nations accession into the EU. 
2. EU Regulatory Framework. Relevance 5. 
The EU has a uniform policy on generics  W all member states have to comply with the EU 
policy on generics, and now, the average generic uptake percentage in the EU is at par with 
the uptake percentage in the US. There is a separate body in the EU that specializes in, and 
has the authority to approve generics.   
Factor 
Positive 
Neutral 
Negative 
Uncertain 
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3. EU Monetary Policy. Relevance 4. 
The Eurozone now includes all countries that are part of the EU including the countries that 
recently gained accession. The Euro is the sole currency operating amongst all member 
states. This has reduced transaction costs and exchange rate risks, and has brought about 
stability throughout the EU regional economy. 
4. EU Fiscal Policy. Relevance 4. 
The EU and the ECB are stronger. Austerity measures have strengthened the financial and 
economic stability of a majority of member states. There is strict governance by the EU 
regulators with regard to fiscal deficits and debts.  
5. hWƌĞĨĞƌĞŶƚŝĂůdƌĂĚĞŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? ?ZĞůĞǀĂŶĐĞ ? ? 
Several countries and regional blocks have signed preferential trade agreements with the 
EU. This has increased competition, lowered prices and expanded the market for generic 
drugs in the EU.  
6. EU Outsourcing/Offshoring. Relevance 3. 
Outsourcing and offshoring is strongly encouraged by the EU and the levels of outsourcing 
and offshoring by European corporations have now skyrocketed. Organizations in the EU are 
now extremely competitive globally as the achieve economies of scale and lowered cost 
structures. These activities have made industries within the EU thrive. 
7. EU Pricing Regulations. Relevance 4. 
There is across the board harmonization across the EU on the use and implementation of 
market based measures to reduce prices. Market based interventions (such as internal and 
external reference pricing) are used extensively in all member states across the EU. This has 
reduced drug prices dramatically. In countries with complete health care insurance 
coverage, the EU has imposed market based interventions to reduce prices and the EU has 
also implemented policies to ensure that efficiencies are achieved and bureaucracies are 
reduced within national healthcare systems.  
8. EU Political Stability. Relevance 2. 
The EU is now united and there is strong political will and leadership as member states are 
subscribed under one banner towards achieving long-term objectives. They have recognized 
the importance of unity in an environment of cut-throat global competition. National 
concerns are now at par with European concerns. 
9. EU Market Interventions. Relevance 4. 
The EU is responsible for a collaborative market intervention and there is greater integration 
and harmonization amongst all member states. This collaborative effort is complementing 
free-market trade and competition thus enforcing cost containment strategies particularly 
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with regard to lowering healthcare costs. This is done by direct market demand and supply 
interventions as part of a central policy within the EU. 
10. EU Economic Growth Rate. Relevance 3. 
Austerity measures taken by member states have reduced fiscal deficits and debts. The EU 
now maintains a positive growth rate as a whole and economies of member states are now 
vibrant and stable. Unemployment and inflation is under control and provides a favorable 
economic environment for organizations to grow and develop. The free-trade policy within 
the EU is promoting competition and organizations are more resilient and efficient in foreign 
markets.  
11. EU Unemployment. Relevance 3. 
The overall EU unemployment rate and volatility in unemployment rates in most member 
states is low. Youth unemployment is low and governments are effective in promoting the 
life cycle approach to work. They are encouraging lifelong learning and improving support 
systems for EU citizens to find jobs. There is also strong support for diversity and inclusion in 
the workplace. New industries have come along within the EU and helped diversify the 
ƌĞŐŝŽŶ ?ƐĞĐŽŶŽŵŝĐďĂƐĞ ? 
12. EU Financial Markets. Relevance 3. 
Financial markets are stable, secure and efficient throughout the EU. EU regulators have 
stringent monitory systems to ensure stricter reinforcement and compliance to measures 
and closer integration of efforts.  There is harmonization of standards and regulations and 
this has insured stability within the financial markets throughout the EU. 
13. EU Business Cycles. Relevance 3. 
There is little volatility in business cycles and output. Inflation and interest rates have 
become stable. Economic activity between core and periphery member states is as 
divergent as it was in the past. Less volatility in business cycles across the EU has insured 
stability and positive growth rates across the member states.  
14. EU Exchange Rates. Relevance 2. 
All member states have now joined the Euro zone and have eliminated exchange rates risks, 
reduced transaction costs and created exchange rate stability throughout the region this has 
had a positive impact towards economic growth. 
15. EU Inflation Rates. Relevance 2. 
The EU has achieved stability in inflation rates through sound policy by the ECB and 
disparities in economic conditions between original and new member states have been 
reduced. This has resulted in positive economic growth across the region. 
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16. EU Interest Rates. Relevance 2. 
The ECB has adapted a policy of stabilizing inflation by stringent interest rate control across 
the member states thus promoting economic growth and reducing disparity in inflation 
figures.  
17. EU Trade Barriers and Tariffs. Relevance 3. 
The EU has relaxed non-tariff trade barriers in an effort to increase competition within the 
EU. This policy is lowering prices and enhancing efficiencies across the EU. 
18. EU Savings Rate. Relevance 2. 
The savings rate has increased as industries have picked up in the region, unemployment 
and inflation rates are low. As citizens are living longer, the EU has encouraged more savings 
by all citizens. 
19. EU Education, Entrepreneurial Spirits & Social Mobility. Relevance 2. 
The EU coordinated strategy of improving education amongst the local workforce has 
upgraded the standards of workforces to meet the needs of employers for high-skilled 
workers. Additionally immigration policy has been designed so as to allow only immigrants 
with specialized skills to relocate to the EU and fill the gaps in the skilled workforce as 
required. Member states have realized the need for social mobility and are promoting and 
supporting social mobility across the social hierarchies within their economies. There is an 
added advantage in that immigrants have higher levels of entrepreneurial spirit and this has 
led to increased levels of SME business activity within the EU. 
20. EU Lifestyle Changes. Relevance 4.  
Citizens of the EU are enjoying very high standards of living. Preventive care levels have 
increased, the population is more active and obesity and related diseases levels have 
dropped. This has lead to healthier lifestyles across the EU member states and lessened the 
burden on healthcare systems. Life expectancy levels are highest in the EU as compared to 
other parts/regions of the world.  
21. EU Attitude towards Generics vs. Patented Drugs. Relevance 3 
Generic drugs are now widely accepted in all societies as suitable replacements towards 
patented drugs. The attitudes towards generics drugs are now positive. 
22. EU Counterfeit Drugs. Relevance 3. 
The EU has undertaken successful initiatives to curb the proliferation of counterfeit drugs. 
Policies and regulations have led to the implementation of strict measures to ensure that 
the value chain does not source from counterfeit producers. Prosecution and enforcement 
activities have led to the lowest levels of counterfeit drugs within supply chains. 
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23. EU Advances in Genomics. Relevance 3. 
Rapid and numerous developments in genomics have lead to targeted preventive 
treatments of numerous diseases. Certain diseases have been treated well in advance 
leading to lower hospital patient populations. The EU has collaborated effectively on 
advancing genomic sciences because it has recognized the great potential with regards to 
preventive care.  Additionally genomics sciences have led to more targeted forms of 
treatments and niche drugs. Patients are now being diagnosed for genetically inherited 
diseases and treatments are available well in advance to ensure that patients do not 
contract diseases to which they are genetically prone.  
24. EU Drug Delivery Systems. Relevance 3. 
Drug delivery systems have been improved to a level whereby side effects on patients have 
been curbed. More targeted compounds can now be released to specific parts of the body 
reducing the timeframe of treatments. Additionally nanotechnology enabled drug delivery 
systems have been developed and many small biotech companies have emerged in this field 
across the EU. More advances with regard to nanotechnology are anticipated as the EU is 
now focused on exploring this field of science to improve the overall healthcare of its 
citizens.  
25. EU Biotechnology Systems. Relevance 3. 
Technologies such as pharmacogenomics, stem cells, gene therapy have advanced as 
alternatives to conventional treatment. 50% of new drugs launched into the market are 
derived from the fields of biotechnology. These treatments are now being made available by 
generic drug companies as well as the big-pharma companies.  
26. EU Consumer Protection. Relevance 3. 
EU Consumer protection policy has increased transparency across all industries especially 
healthcare ensuring transparency in manufacturing, sourcing and dealings. This has lead to 
increased consumer confidence levels. Consumer protection regulations are now 
harmonized across all EU member states.   
27. EU Benefits Systems. Relevance 3. 
Significant reforms have occurred throughout the EU with regards to benefits systems. The 
private healthcare sector has developed tremendously throughout the EU to a level where 
an average of 50% of the care for all EU citizens is provided from this sector. The main 
reason this has occurred is because EU member states have tried to reduce public spending, 
fiscal deficits and debt levels. In addition they have incorporated more market forces into 
the healthcare systems to improve efficiencies, reduce bureaucracy and improve the overall 
quality of their healthcare systems.  
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28. EU Anti-Trust Regulation. Relevance 3. 
Numerous anti-trust cases initiated by the EU against players in the industry found to have 
the aim of gaming the system have resulted in a freer and more secure market trading 
environment. EU regulators are now seen as strict enforces of anti-trust laws and this 
scenario has benefited the EU market.  The main goal of the EU has been to promote fair 
competition amongst players and this goal has now been realized.  
29. EU Waste Management. Relevance 2. 
The impact of the pharmaceutical and generic drugs industry on the environment has been 
significantly reduced especially with regard to waste products. Chemicals used in the 
industrial production of drugs are environmentally friendly due in large part to strict 
regulation and enforcement throughout the EU. The carbon footprint of the 
pharmaceuticals industry as a whole has been severely reduced across all member states.  
30. hE'K ?Ɛ ?ZĞůĞǀĂŶĐĞ ? ? 
E'K ?ƐĂƌĞŶŽǁĐŽŶƐŝĚĞƌĞĚŬĞǇƐƚĂŬĞŚŽůĚĞƌƐǁŝƚŚŝŶƚŚĞĞŶƚŝƌĞƉŚĂƌŵĂĐĞƵƚŝĐĂůĂŶĚŐĞŶĞƌŝĐƐ
industry. The effect of this has been an increase in CSR activity, ethical supply chains and 
more sustainability practices.  
31. EU Packaging. Relevance 2. 
Numerous advances have been made in packaging technology. Materials used are more 
sustainable and environmentally friendly. Additionally packaging of drugs are now more 
patient (user) friendly, and better packaging has led to extended life cycles of use for 
numerous drugs.  
 
6.1.2 PROJECTION OF KEY MACRO FACTORS (NEGATIVE): 
1. EU expansion and Integration. Relevance 4. 
The EU has put the brakes on its expansion. Only a few countries have been allowed 
accession over the past several years:  Turkey, Croatia, and Bosnia and Herzegovina.  
2. EU Regulatory Framework. Relevance 5. 
Member states are still fragmented and generics drug uptake is a national policy concern. 
The uptake percentage is high in some EU member states while very low in the remainder. 
3. EU Monetary Policy. Relevance 4. 
The Euro Zone has collapsed.  All member states have reverted to their old currencies and 
economic policy is now a national level concern. 
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4. EU Fiscal Policy. Relevance 4. 
Fiscal policy is now a national level concern and the financial stability of member states is 
precarious due to high fiscal debt levels. Austerity measures have not been exercised in 
numerous member states and EU member states that have not met the requirements of the 
EU with regards to lowering fiscal deficits and debt levels have been exempted from the 
Union. 
5. hWƌĞĨĞƌĞŶƚŝĂůdƌĂĚĞŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? ?ZĞůĞǀĂŶĐĞ ? ? 
EU has now set higher standards of requirements with regard to preferential trade 
agreements. EU has taken a protectionist stance and has raised the standard to trade with 
Non-EU countries by tightening trade policies. This is done by higher quality requirements 
and trade quotas resulting in restricted foreign trade.  
6. EU Outsourcing/Offshoring. Relevance 3. 
Outsourcing and offshoring levels are low in many member states. Member states are now 
in full protectionist mode in accordance to the rising pressures of local populations to lower 
national unemployment levels.  
7. EU Pricing Regulations. Relevance 4. 
There is fragmentation across EU and member states are imposing national price control 
measures. Market based measures are not exercised across the EU and more purely 
administrative measures (such as central price controls) are being imposed in numerous 
member states. These administrative price regulations pose as a hindrance to the entry of 
generics into these countries.  
8.  EU Political Stability. Relevance 2. 
The EU has fragmented with member states further prioritizing national interest over a 
collaborative effort. This fragmentation has weakened the EU. 
9. EU Economic Growth Rate. Relevance 3. 
dŚĞ h ŝƐ ŵĂĚĞ ƵƉ ŽĨ ǁĞĂŬ ĂŶĚ ƐƚƌŽŶŐ ĞĐŽŶŽŵŝĞƐ ? ^ƚƌŽŶŐ  ‘ĐŽƌĞ ? ŵĞŵďĞƌ ƐƚĂƚĞƐ ƐƵĐŚ ĂƐ
Germany, UK, and France have stabilized their economies by national austerity measures 
ǁŚŝůĞ ‘ƉĞƌŝƉŚĞƌǇ ?ŵĞŵďĞƌƐƚĂƚĞƐƐƚŝůůƐƵĨĨĞƌĨƌŽŵƐƚĂŐŶĂŶƚŽƌŶegative GDP growth rates.  
10. EU Unemployment. Relevance 3. 
The average EU unemployment rate is high and there is high volatility numerous labor 
markets.  High levels of unemployment can be found in member states across the EU and 
this has affected social cohesion and economic growth rates. Youth unemployment is high 
and has lead to social tensions. Governments have moved more towards a protectionist 
stance and spending on social benefits has increased while tax revenues have been reduced. 
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11. EU Business Cycles. Relevance 3. 
There is high business cycle volatility throughout the EU because of the persistent 
ĚŝĨĨĞƌĞŶĐĞƐ ŝŶ ĞĐŽŶŽŵŝĐ ĂĐƚŝǀŝƚǇ ďĞƚǁĞĞŶ  ‘ĐŽƌĞ ? ĂŶĚ  ‘ƉĞƌŝƉŚĞƌǇ ? ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ƵƐŝŶĞƐƐ
cycle volatility has led to a negative impact on growth rates of several member states across 
the EU.  
12. EU Exchange Rates. Relevance 2. 
The Euro zone has collapsed and countries have reverted to their original national 
currencies. This has increased transaction costs and created exchange rate instability 
throughout the EU resulting in poor levels of economic activity and low growth rates. 
13. EU Inflation Rates. Relevance 2. 
The volatility of energy and food prices has translated into high rates of inflation especially 
ĂŵŽŶŐƐƚƚŚĞŶĞǁŵĞŵďĞƌƐƚĂƚĞĂŶĚƐƚĂƚĞƐǁŝƚŚŝŶƚŚĞ ‘ƉĞƌŝƉŚĞƌǇ ?ŽĨƚŚĞh ?dŚŝƐŚĂƐĚŝƌĞĐƚůǇ
affected business cycles thereby leading to negative effects to the EU economy as a whole. 
14. EU Interest Rates. Relevance 2. 
/ŶƚĞƌĞƐƚƌĂƚĞƐĂƌĞǀŽůĂƚŝůĞƚŚƌŽƵŐŚŽƵƚƚŚĞhƌĞŐŝŽŶ ?ǁŝƚŚůŽǁƌĂƚĞƐŝŶƚŚĞ ‘ĐŽƌĞ ?ƐƚĂƚĞƐ ?ĂŶĚ
ŚŝŐŚĞƌ ƌĂƚĞƐ ŝŶ ƚŚĞ  ‘ƉĞƌŝƉŚĞƌǇ ? ƐƚĂƚĞƐ ? dŚŝƐ ŚĂƐ ůĞĚ ƚŽ ƐŝŐŶŝĨŝĐĂŶƚ ĚŝƐƉĂƌŝƚŝĞƐ ŝŶ ĞĐŽŶŽŵŝĐ
growth rates across the region. 
15. EU Trade Barriers and Tariffs. Relevance 3. 
The EU has increased the number of non-tariff barriers in an attempt to protect local 
industries from foreign competitors. This protectionist stance had embedded inefficiencies 
amongst EU based firms and has led to increased pressures from non-EU firms to open up 
the EU market. At this time, countries outside the EU have very strong economies, and 
these countries have also adopted protectionist measures in retaliation. This has led to 
shrinking global markets for products manufactured within the EU.  
16. EU Savings Rate. Relevance 2. 
The savings rate is low across the EU. This is partly due to low growth in the economy 
combined with high unemployment. Inflation has risen private healthcare is now a very 
small part of health care systems within the EU. As savings rates are low, member states 
have realized that the only way that most citizens can get healthcare is if it is provided at no 
cost by the government.  
17. EU Demographics. Immigration and Fertility rate. Relevance 3. 
There is no harmonized policy for immigration within the EU and member states, because of 
high employment combined with negative attitudes towards immigrants, have limited 
migration of immigrants into their countries. Because of aging populations and low fertility 
rates, the work force needs of the industry growth are not being met. Additionally workers 
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from new member states do not possess the right skills criterion making it difficult for 
economies to progress. 
18. EU Counterfeit Drugs. Relevance 2. 
Counterfeit drugs have now proliferated the EU marketplace. Member states, due to budget 
constraints have failed to enforce counterfeit drug control measures. Citizens have resorted 
ƚŽďƵǇŝŶŐŵĞĚŝĐĂƚŝŽŶƐ ‘ŽĨĨ-the-ƐƚƌĞĞƚ ?ĂŶĚĂďůĂĐŬŵĂƌŬĞƚĨŽƌŶƵŵĞƌŽƵƐĚƌƵŐƐŚĂƐĞŵĞƌŐĞĚ ?
Drugs are being smuggled across borders, and the illegal trade of medications is thriving. 
19. EU Benefits Systems. Relevance 3. 
No significant reforms have occurred throughout the EU with regards to benefits systems. 
The private healthcare sector has been replaced in many countries by public healthcare 
systems. Private healthcare has developed only to a level where an average of 25% of the 
care is provided from this sector in most member states. This has led to increased public 
spending, larger fiscal deficits and debt levels in many EU member states. Efficiencies are 
low and bureaucracy levels are high.  
 
6.1.3 PROJECTION OF KEY MACRO FACTORS (UNCERTAIN): 
1. EU Monetary Policy. Relevance 4. 
The euro zone is smaller and now consists of only members with strong economies and the 
criterion for membership into the euro zone is much stricter. Member states that have weak 
economies and do not meet the strict criteria of being part of the euro zone are subject to 
exclusion from the euro zone.  
2. EU Fiscal Policy. 4. 
EU still has weak member states that are subjected to weak financial economies. These 
member states are suffering from high levels of fiscal debt and high levels of government 
spending. To stimulate economic activity, EU member states with strong economies are 
supporting weaker member states with bail-outs and injections of investment funds.  
 
6.1.4 PROJECTION OF KEY MACRO FACTORS (NEUTRAL): 
1. EU Intellectual Property Protection. Relevance 2.  
The EU has strong patent protection policies and does not grant patent extensions. There is 
strong commitment to ensure that organizations do not behave opportunistically with 
regards to patent policies and strict measures are exercised otherwise. This factor has been 
regarded neutral because generic drugs are off-patent and are not governed under this 
policy.  
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2. EU Infrastructure Quality. Relevance 2. 
The EU has established the long-term single multi-modal network that integrates land, sea, 
and air transport networks throughout the EU region and has kept pace in further 
developing infrastructure. Because this development has kept pace, it has neither positively 
nor negatively affected industry in the EU. 
3. EU War & Conflict. Relevance 2. 
The EU holds unity to the stated goals of the EU when founded: to act as a force of stability, 
cooperation and understanding in the wider world. It follows the trend of addressing 
conflict through diplomacy rather than explicit military action. The way of the past whereby 
individual member states would engage in military action in parts of the world to serve their 
national interest has been replaced with a more unified EU diplomatic stance.  
4. EU Market Interventions. Relevance 4. 
Market interventions are predominantly national concerns and subjected to several factors 
at a national level.  Several member states are practicing different interventions to control 
ĐŽƐƚƐ ĂƐ ƐŽŵĞ ďĞĂƌ ƉŽƐŝƚŝǀĞ ƌĞƐƵůƚƐ ĂŶĚ ŽƚŚĞƌ ĚŽŶ ?ƚ ?ĞĐĂƵƐĞ ƚŚĞ h ŝƐ ŶŽƚ ǇĞƚ ĨƵůůǇ
integrated at present and member states currently have individualistic policies, it does not 
hold a collaborative effect on industries in the future thus this possible scenario has been 
regarded as neutral with regard to future impact.  
5. EU Tax policy. Relevance 2. 
Tax policy is a national concern and this scenario has not been subjected to much change. 
These is no across the board harmonization in member states tax systems. There is however 
a common consolidated corporate tax base which exists for firms across the EU eliminating 
the need for filing separate accounts in each country and separate accounting practices 
from country to country. 
6. EU Disposable and Discretionary Income. Relevance 2. 
Most countries within the EU have national insurance healthcare systems therefore 
discretionary income does not play a significant role with respect to the future of the 
generic drugs industry in the EU. There are still significant levels of disparity across the EU 
with citizens in urban regions having more disposable incomes compared to those in rural 
regions.  
7. EU Demographics. Immigration and Fertility rate. Relevance 3. 
Over the coming years the EU will have a harmonized policy in immigration. The policy is 
designed in a manner to allow enough migration to offset the effects of aging populations 
and low fertility rates. Additionally because of EU expansion, high youth populations from 
countries that have been allowed membership in the EU (for example: Turkey, etc.) will 
bring in enough workers to meet the needs of the economies. Therefore there will neither 
be a negative or positive impact on industry in the EU. 
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8. EU Labor Laws. Relevance 2. 
Freedom of movement of workers from one member state to another is still the right of any 
EU citizen. This policy has not been subjected to change and therefore remains neutral with 
regard to the future of the EU economy. 
9. EU Health and Safety. Relevance 3. 
As has always been the case, health and safety regulation are stringent and EU policy 
makers are determined to ensure that all drugs meet H&S requirements.  Because this 
policy has not been subjected to much change it remains neutral. 
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6.2 FACTOR PROGNOSTICS TABULATED  
Table 5 below is the tabulated representation of the factor prognostics stage and their respective relevance to EU generic drugs industry. 
TABLE 5: FACTOR PROGNOSTICS 
Factor Prognostics and Relevance to EU Generic Drugs Industry 
Positive Projection 
 
Negative Projection 
 
Neutral Projection 
 
Uncertain Projection 
 EU Regulatory 
Framework 5 
EU Regulatory 
Framework 5 EU Market Interventions 4 EU Monetary Policy 4 
EU Expansion and 
Integration 4 
EU expansion and 
Integration 4 
EU Demographics. 
Immigration and 
Fertility rate 3 EU Fiscal Policy 4 
EU Monetary Policy 4 EU Monetary Policy 4 EU Health and Safety 3     
EU Fiscal Policy 4 EU Fiscal Policy 4 
EU Intellectual Property 
Protection 2     
EU Pricing Regulations 4 EU Pricing Regulations 4 
EU Infrastructure 
Quality 2     
EU Market Interventions 4 
EU Preferential Trade 
ŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? 3 EU War & Conflict 2     
EU Lifestyle standards 4 
EU 
Outsourcing/Offshoring 3 EU Tax policy 2     
EU Preferential Trade 
ŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? 3 
EU Economic Growth 
Rate 3 
EU Disposable and 
Discretionary Income 2     
EU 
Outsourcing/Offshoring 3 EU Unemployment 3 EU Labor Laws 2     
EU Economic Growth 
Rate 3 EU Business Cycles 3         
EU Unemployment 3 
EU Trade Barriers and 
Tariffs 3         
EU Financial Markets 3 EU Demographics 3         
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EU Business Cycles 3 EU Benefits Systems 3         
EU Trade Barriers and 
Tariffs 3 EU Political Stability 2         
EU Attitude towards 
Generics vs. Patented 
Drugs 3 EU Exchange Rates 2         
EU Counterfeit Drugs 3 EU Inflation Rates 2         
EU Advances in 
Genomics 3 EU Interest Rates 2         
EU Drug Delivery 
Systems 3 EU Savings Rate 2         
EU Biotechnology 
Systems 3 EU Counterfeit Drugs 2         
EU Consumer Protection 3             
EU Benefits Systems 3             
EU Anti-Trust Regulation 3             
EU NGO 3             
EU Political Stability 2             
EU Exchange Rates 2             
EU Inflation Rates 2             
EU Interest Rates 2             
EU Savings Rate 2             
EU Education, 
Entrepreneurial Sprits& 
Social Mobility 2             
EU Waste Management 2             
EU Packaging 2             
Source: Authors interpretations 
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Page 49 of 143 
June 30th, 2030:  
Nigel wakes up at 9am with a nudge from Jeeves. As he opens his eyes, Jeeves ? ƐŚŝŶǇ
ĨůƵŽƌĞƐĐĞŶƚĞǇĞƐĂƌĞ ĨůĂƐŚŝŶŐǁŝƚŚ ũŽǇ ?ĂŶĚ ƚŚĞƌĞ ?ƐĂďŝŐ ƐŵŝůĞŽŶŚŝƐ ĨĂĐĞ ?  “'ŽŽĚŵŽƌŶŝŶŐ
:ĞĞǀĞƐ ? ?EŝŐĞůƐĂǇƐĂƐŚĞƌƵďƐƚŚĞƐůĞĞƉĨƌŽŵŚŝƐĞǇĞƐ ? “,ĞůůŽEŝŐĞů ?ŚŽƉĞƚŚĂƚǇŽƵƐůĞƉƚǁĞůů ?
:ĞĞǀĞƐƌĞƉůŝĞƐŝŶĂĨƌŝĞŶĚůǇƚŽŶĞ ?/ƚ ?ƐďĞĞŶĂǇĞĂƌƐŝŶĐĞEŝŐel bought his robotic butler Jeeves 
from the Japanese company with a showroom on Bond St in London. Jeeves is a butler 
ƌŽďŽƚ ? ƉƌŽŐƌĂŵŵĞĚ ƚŽ ƉƌŽǀŝĚĞ ďĂƐŝĐ ƐŽůƵƚŝŽŶƐ ĨŽƌ EŝŐĞů ?Ɛ ĚĂǇ-to-day needs around the 
ŚŽƵƐĞ ?  “EŝŐĞů ?ǁŽƵůĚǇŽƵ ůŝŬĞŵĞƚŽƵƉĚĂƚĞǇŽƵŽŶƚŚĞĂŐĞŶĚĂĨŽƌƚŽĚĂǇ ? ?:ĞĞǀĞƐĂƐŬƐ ?  “/
ŬŶŽǁ ƚŚĂƚ ǇŽƵ ŚĂǀĞ ƚŚĞ ĚĂǇ ŽĨĨ ĨƌŽŵ ǁŽƌŬ ? ďƵƚ ǇŽƵ ?ǀĞŐŽƚ ĂŶ ŝŵƉŽƌƚĂŶƚ ƚĞůĞƉƌĞƐĞŶĐĞ
ŝŶƚĞƌǀŝĞǁĂƉƉŽŝŶƚŵĞŶƚĂƚ ? ?Ăŵ ?:ĞĞǀĞƐƐĂǇƐĂƐŚĞŵĂŐŝĐĂůůǇŐůŝĚĞƐĂĐƌŽƐƐƚŚĞĨůŽŽƌĂŶĚŝŶƚŽ
ƚŚĞ ŬŝƚĐŚĞŶ ?  “ďƐŽůƵƚĞůǇ :ĞĞǀĞƐ ? / ƌĞŵĞŵďĞƌ ? Nigel says as he gets out of bed. Yes, the 
ŝŶƚĞƌǀŝĞǁ ŝƐ ƋƵŝƚĞ ŝŵƉŽƌƚĂŶƚ ? EŝŐĞů ƚŚŝŶŬƐ ƚŽ ŚŝŵƐĞůĨ ? EŝŐĞů ?Ɛ employer, an Indian 
pharmaceutical company based in New Delhi has had him conduct some research on the EU 
macro environment in an effort to craft the ĨŽůůŽǁŝŶŐ ǇĞĂƌ ?Ɛ ƐƚƌĂƚĞŐǇ ĨŽƌ ƚŚĞ ĐŽŵƉĂŶǇ ?Ɛ
European expansion plans. Juan Cervantes is quite an important member of the Spanish 
parliament, and therefore, his views on the current EU environment will be crucial in 
ƐƵƉƉůĞŵĞŶƚŝŶŐ EŝŐĞů ?Ɛ ƌĞƐĞĂƌĐŚ ? Ɛ EŝŐĞů sits on his leather couch, he commands the 
ĐŽŵƉƵƚĞƌ ƐĐƌĞĞŶ ƚŽ ĐŽŵĞ ŽŶ ? dŚĞ ǁĂůů ? ǁŚŝĐŚ ƚƵƌŶƐ ŝŶƚŽ ƚŚĞ ƐĐƌĞĞŶ ? ďůŝŶŬƐ ŽŶ ?  “dŽĚĂǇ ?Ɛ
ŶĞǁƐ ?EŝŐĞůĐŽŵŵĂŶĚƐĂƐŚĞƌĞĐůŝŶĞƐďĂĐŬŝŶƚŽƚŚĞĐŽƵĐŚ ?dŚĞǀŝƌƚƵĂůdsĂŶĐŚŽƌƌĞůĂƚĞƐƚŚĞ
key events of the day around the globe. The big story is regarding the civil unrest in the 
yŝŶũŝĂŶŐƉƌŽǀŝŶĐĞŽĨŚŝŶĂ ?  “,ŽǁĚŽǇŽƵƚŚŝŶŬ ƚŚŝƐǁŝůů ƚƵƌŶŽƵƚ :ĞĞǀĞƐ ? ? EŝŐĞůĂƐŬƐĂƐŚĞ
ƉŽŝŶƚƐƚŽǁĂƌĚƐƚŚĞƐĐƌĞĞŶ ? “tĞůů ?/ƚŚŝŶŬƚŚĂƚƚŚĞŚŝŶĞƐĞŐŽǀĞƌŶŵĞŶƚŝƐŐŽŝŶŐƚŽƋƵĞůůƚŚĞ
violence in XinjŝĂŶŐ ?ďƵƚƉŽĐŬĞƚƐŽĨƵŶƌĞƐƚǁŝůůĐŽŶƚŝŶƵĞƚŽƐƉƌĞĂĚƚŚƌŽƵŐŚŽƵƚƚŚĞĐŽƵŶƚƌǇ ?
:ĞĞǀĞƐ ƌĞƉůŝĞƐ ? ,Ğ ?Ɛ ƌŝŐŚƚ ? EŝŐĞů ƚŚŝŶŬƐ ƚŽ ŚŝŵƐĞůĨ ?  “^Ž :ĞĞǀĞƐ ? ůĞƚ ŵĞ ŚĂǀĞ ŵǇ ŝŶƚĞƌǀŝĞǁ
ƋƵĞƐƚŝŽŶƐ ŽŶ ƚŚĞ ƐĐƌĞĞŶ ? ĂŶĚ ŐĞƚ Ă ŚŽůĚ ŽĨ Dƌ ? ĞƌǀĂŶƚĞƐ ? DĂǇďĞ ŚĞ ?Ɛ ƌĞĂĚǇ ĨŽƌ ŽƵƌ
interviĞǁ ?EŝŐĞůƐĂǇƐ ?dŚĞƐĐƌĞĞŶƐǁŝƚĐŚĞƐŽŶƚŽĂĚŝĨĨĞƌĞŶƚƚĞŵƉůĂƚĞ ?ĂŶĚEŝŐĞů ?ƐƉƌĞ-written 
questions appear. Jeeves goes to the command board next to the screen and transfers in his 
ĐŽŵŵĂŶĚƐƚŚƌŽƵŐŚĂǁŝƌĞůĞƐƐŝŶƚĞƌĨĂĐĞ ? “Dƌ ?ĞƌǀĂŶƚĞƐŝƐĂǀĂŝůĂďůĞEŝŐĞů ?ĂŶĚhe can start 
ƚŚĞŝŶƚĞƌǀŝĞǁŝŶ ?ŵŝŶƵƚĞƐ ?:ĞĞǀĞƐƐĂǇƐ ?EŝŐĞůƚŚĞŶƐƚĞƉƐŝŶƚŽŚŝƐďĞĚƌŽŽŵƚŽƋƵŝĐŬůǇĚƌĞƐƐ
ƵƉ ?ĨƚĞƌƉƵƚƚŝŶŐŽŶĂƐŚŝƌƚĂŶĚƉĂŶƚƐ ?EŝŐĞůƚŚĞŶƐƚĞƉƐďĂĐŬŝŶƚŽƚŚĞůŝǀŝŶŐƌŽŽŵ ? “K<:ĞĞǀĞƐ ?
/ ?ŵ ƌĞĂĚǇ ? ƐĂǇƐ EŝŐĞů ? :ĞĞǀĞƐ ƚŚĞŶ ƐƚĞƉƐ ŝŶƚŽ ƚŚĞ ĂĚũŽŝŶŝŶŐ ƌŽŽŵ ĂƐ Dƌ ? ĞƌǀĂŶƚĞƐ ? ǀŽŝĐĞ
ĐŽŵĞƐ ƚŚƌŽƵŐŚ ŽŶ ƚŚĞ ƐƵƌƌŽƵŶĚ ƐƉĞĂŬĞƌƐ ? dŚĞ ŝŶƚĞƌǀŝĞǁ ŚĂƐ ďĞŐƵŶ ? :ƵĂŶ ĞƌǀĂŶƚĞƐ ?
telepresence ƐŝůŚŽƵĞƚƚĞŵĂŐŝĐĂůůǇĂƉƉĞĂƌƐŝŶƚŽƚŚĞƌŽŽŵĨƌŽŵĂƉƌŽũĞĐƚŽƌŽŶƚŚĞǁĂůů Q 
Nigel: Good Morning Juan!  
Mr. Cervantes: Hola Nigel, how are you doing today?   
Nigel: I am well, how about yourself? 
Mr. Cervantes: Muy bien Nigel. Are you ready to fire away your questions? 
Nigel: Sure! You do know what our interview is about right? Jeeves sent you a draft of our 
questionnaire, and a brief on the purpose of the interview yesterday. Your office did receive 
his file right? 
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Mr. Cervantes: Yes, Jeeves did send the file through. I am quite ready to answer all your 
questions. 
EŝŐĞů PK< ?>Ğƚ ?ƐƐƚĂƌƚƚŚĞŶ ?dŚĞĨŝƌƐƚƋƵĞƐƚŝŽŶŝƐ P,ŽǁĂƌĞƚŚŝŶŐƐŐŽŝŶŐŝn the new EU member 
state economies? 
Mr. Cervantes: Todo es Bueno Nigel. The integration of the new states has been going very 
well. Croatia, Bosnia and Herzegovina, Serbia, Montenegro, Macedonia, Kosovo, Albania and 
Turkey are fully on board, and these countries have done quite well over the past few years 
in meeting the criteria of the EU with regard to getting their economies in order. As you 
ŬŶŽǁ ? ƚŚĞǇ ?ǀĞ ĂůƐŽ Ăůů ũŽŝŶĞĚ ƚŚĞ ĞƵƌŽ ǌŽŶĞ ? ĂŶĚ ƉŽƐŝƚŝǀĞ 'W ŐƌŽǁƚŚ ƌĂƚĞƐ ĂƌĞ ďĞŝŶŐ
forecast for all these economies in the next few years.  
EŝŐĞů P zĞƐ ? ƚŚĂƚ ?Ɛ ďĞĞŶ ŐŽŝŶŐ ƋƵŝƚĞ ǁĞůů ? / ?ŵ ƐŽ ŐůĂĚ ƚŚĂƚ ƚŚĞ ƉŽůŝƚŝĐĂů ůĞĂĚĞƌƐŚŝƉ ƐŝƚƵĂƚŝŽŶ
within the EU has been sorted. The Turkish presidency of the EU has been quite successful, 
and all the efforts of European leaders ovĞƌƚŚĞƉĂƐƚĚĞĐĂĚĞƐĞĞŵƚŽďĞďĞĂƌŝŶŐĨƌƵŝƚ ?/ƚ ?ƐƐŽ
great to have a united Europe! Can you tell me a little more with regard to the rate of 
generics uptake within EU states? 
Mr. Cervantes: Generic uptake levels are now at par with the level in the US thanks to the 
h ?ƐƵŶŝĨŽƌŵ ƉŽůŝĐǇŽŶŐĞŶĞƌŝĐƐ ?dŚĞĐĞŶƚƌĂů hďŽĚǇƚŚĂƚǁĂƐ ƐĞƚƵƉ ƚŽ ƐƉĞĐŝĂůŝǌĞ ŝŶĂŶĚ
approve generics has been quite effective. Additionally, member states have been very 
compliant with policies from Brussels on increasing generics usage. You should pay close 
attention to the new preferential trade agreement that will soon be signed with the Union 
of African States. That could play a big part vis-à-vis market expansion plans for European 
based pharmaceutical and generics companies over the coming years. This will also be quite 
important in the sense that there will be increased competition in this industry from 
pharmaceutical and generics manufacturers in Africa. But then again, they have a long way 
to go before they can match the low prices and excellent quality of medicines being 
produced in India by the big European pharma companies. 
EŝŐĞů PzĞƐ ?/ĂŐƌĞĞ ?dŚĞƵƌŽƉĞĂŶƉŚĂƌŵĂ ?ƐŚĂǀĞďĞĞŶǀĞƌǇƐƵĐĐĞƐƐĨƵůŝŶŽƵƚƐŽƵƌĐŝŶŐĐĞƌƚĂŝŶ
functions to India, and in off shoring their manufacturing there as well. How else have EU 
member states succeeded in getting their medications prices so low?        
Mr. Cervantes: There has been across the board harmonization across the EU on the use 
and implementation of market-based measures to reduce prices. The use of Internal and 
external reference pricing over the past decades has played a big role in reducing prices. In 
countries with national health care insurance like the NHS in the UK, the EU has been 
effective in imposing market-based interventions and also in implementing policies to 
ensure that efficiencies are achieved and bureaucracies reduced.   
Nigel: Can you tell me more on how effective the austerity measures have been over the 
past decades? And how has this benefitted the EU as a whole? 
Mr. Cervantes: Todo es Bueno! The austerity measures were vital! Since they started around 
ƚŚĞ ǇĞĂƌ  ? ? ? ? ? ƚŚĞǇ ?ǀĞ ďĞĞŶ ǀĞƌǇ ĞĨĨĞĐƚŝǀĞ Ăƚ ƌĞĚƵĐŝŶŐ ĨŝƐĐĂů ĚĞĨŝĐŝƚƐ ĂŶĚ ĚĞďƚ ůĞǀĞůƐ ?
Amongst the strong EU member state economies, GDP growth rates are up, and industries 
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are thriving. Unemployment is down, and inflation is under control in most EU countries. 
The austerity measures also helped stabilize the economies throughout the region. Business 
cycle volatility in the EU has been reduced. As I said earlier, the austerity measures were 
vital, and the current stable period of strong growth may not have been possible without 
the austerity measures. 
Nigel: How about the financial markets? 
Mr. Cervantes: Financial markets are stable, secure and efficient throughout the EU. EU 
regulators have stringent monitory systems to ensure stricter reinforcement and 
compliance to measures, and here again, closer integration and collaboration amongst 
member states within the EU has made this possible. There is harmonization of standards 
and regulations as well. So, as I said, TodoesBueno! 
Nigel: What can you tell me about non-tariff trade barriers? 
Mr. Cervantes: Todo es Bueno! The EU has cut back on many of these barriers, and this has 
in fact helped open up many markets for EU companies, as well as increased the flow of 
goods into the EU. 
Nigel: How about lifestyles of EU citizens? 
Mr. Cervantes: Todo es Bueno! Citizens of the EU are enjoying high standards of living. 
Preventive care levels have increased, the population is more active and obesity and related 
disease levels have dropped. People in the EU are living a very healthy lifestyle, and life 
expectancy levels are up.  
Nigel: Has the EU been effective at reducing the amount of counterfeit drugs in the 
marketplace? 
Mr. Cervantes: Todo es Bueno! The EU has undertaken successful initiatives to curb the 
proliferation of counterfeit drugs. Policies and regulations have led to the implementation 
of strict measures to ensure that the supply chains are free of counterfeits. Prosecution and 
enforcement activities have been very effective. 
Nigel: Tell me more about the advances in Genomics. 
Mr. Cervantes: Todo es Bueno! Rapid and numerous developments in genomics over the 
past decade have led to targeted preventive treatments of numerous diseases. Certain 
diseases have been treated and cured well in advance thanks to Genomics, and hospital 
patient populations have been reduced. Patients are now being diagnosed for genetically 
inherited diseases and medications have been developed to treat people well in advance.  
Nigel: What about drug delivery systems? 
Mr. Cervantes: Todo es Bueno! Drug delivery systems have been improved to a level 
whereby side effects on patients have been curbed. More targeted compounds can now be 
released to specific parts of the body reducing the timeframe of treatments. Additionally, 
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nanotechnology enabled drug delivery systems have been developed by many small biotech 
companies. 
Nigel: What about biotechnology? 
Mr. Cervantes: TodoesBueno! Technologies such as pharmacogenomics, stem cells, gene 
therapy have advanced as alternatives to conventional treatments. 50% of new drugs 
launched into the market are derived from the field of biotechnology. These treatments are 
now being developed by both pharmaceutical and generics companies. 
Nigel: Tell me about the benefits systems in the EU member states. 
Mr. Cervantes: Todo es Bueno! Significant reforms have occurred throughout the EU with 
regards to benefits systems. The private healthcare sector has developed tremendously 
throughout the EU to a level where an average of 50% of the care for all EU citizens is 
provided from this sector. The main reason this has occurred is because EU member states 
have tried to reduce public spending, fiscal deficits and debt levels. In addition they have 
incorporated more market forces into the healthcare systems to improve efficiencies, 
reduce bureaucracy and improve the overall quality of their healthcare systems.  
Nigel: How about waste management and packaging of medications. 
Mr. Cervantes: The impact of the pharmaceutical and generic drugs industry on the 
environment has been significantly reduced especially with regard to waste products. 
Chemicals used in the industrial production of drugs are environmentally friendly due in 
large part to strict regulation and enforcement throughout the EU. The carbon footprint of 
the pharmaceuticals industry as a whole has been severely reduced across all member 
states. With regard to packaging, numerous advances have been made in packaging 
technology. Materials used are more sustainable and environmentally friendly. Additionally 
packaging of drugs is now more patient (user) friendly, and better packaging has led to 
extended life cycles of use for numerous drugs.  
Nigel: You have been very helpful Juan! Any final comments? 
Dƌ ?ĞƌǀĂŶƚĞƐ PƐ / ?ǀĞƐĂŝĚŽǀĞƌĂŶĚŽǀĞƌ ?dŽĚŽĞƐƵĞŶŽEŝŐĞů ?tĞ ?ǀĞĐŽŵĞĂ ůŽŶŐǁĂǇ ŝn 
the European journey, and now finally, the hard work of many years and strong political will 
for unity in the Union is paying huge dividends. I see a very bright future for industry in the 
years ahead! 
EŝŐĞů PdŚĂƚ ?Ɛ ũŽůůǇŐŽŽĚ ?ƌĞǇŽƵŐŽŝŶŐƚŽǁĂƚĐŚƚŚĞ World Cup final in Barcelona? Who do 
you think will win? 
Mr. Cervantes: Yes! Nigeria will beat Turkey for sure! The Nigerians have got a solid team, 
and the Turks will have their hands full. 
EŝŐĞů P/ĂŐƌĞĞ ?dŚĂŶŬƐĂŐĂŝŶ:ƵĂŶ ?ĂŶĚ/ ?ůůĐŽŶƚĂĐƚǇŽƵĂŐĂŝŶŝĨ necessary. Good bye for now. 
Mr. Cervantes: Gracias Nigel. Take care. 
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Juan leaves the room in the blink of an eye as Jeeves re-ĞŶƚĞƌƐ ƚŚĞ ƌŽŽŵ ?  “,Žǁ ĚŝĚ ƚŚĞ
ŝŶƚĞƌǀŝĞǁŐŽEŝŐĞů ? ?:ĞĞǀĞƐĂƐŬƐ ?  “sĞƌǇǁĞůů :ĞĞǀĞƐ ? / ƚŚŝŶŬ / ?ůůŐŽƚŽWĂƌŝƐ ĨŽƌŝŶŶĞƌ ?ŽŽŬ
me ĂƚŝĐŬĞƚŽŶƚŚĞďƵůůĞƚƚƌĂŝŶ ?dŚĂƚ ?ůůŐĞƚŵĞƚŚĞƌĞŝŶ ?ŚŽƵƌƐ Q 
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August 19th, 2030:  
Egyptian reporter Heba Aly is on an assignment for Bloomberg News. She left Cairo at 9am, 
and is scheduled to arrive in Frankfurt by 11am via Express Europe flight A410. The airplane 
ƐŚĞ ?ƐŽŶ ?ŵĂŶƵĨĂĐƚƵƌĞĚďǇŚŝŶĂŝƌĐƌĂĨƚDĂŶƵĨĂĐƚƵƌĞƌƐ ?ŝƐĂŶĞǁƐŽůĂƌƉŽǁĞƌĞĚ^ƵƉĞƌ ũĞƚ
capable of a cruise speed of up to 2,000km/h. What a dream ride Heba thinks to herself, as 
the airplane touches down on the tarmac at Frankfurt International. Super-fast, super 
ůƵǆƵƌŝŽƵƐĂŶĚǌĞƌŽĐĂƌďŽŶĞŵŝƐƐŝŽŶƐ ?Ɛ,ĞďĂůĞĂǀĞƐƚŚĞĂŝƌƉŽƌƚ ?ƐŚĞ ?ƐƐƚƌƵĐŬďǇƚŚĞŶƵŵďer 
of tourists from India and China that have congregated outside the airport waiting for their 
tour shuttle to arrive. Over the past decade or so, tourism has been an industry that has 
thrived in Europe. As China and India have shared the second and third spots respectively on 
the rankings of largest world economies (with the US economy still barely clinging on to first 
place), the now affluent citizens of these two nations have been swarming all over Europe 
visiting the many tourist destinations across thĞĐŽŶƚŝŶĞŶƚ ?,ĞďĂŐĞƚƐŽŶ&ƌĂŶŬĨƵƌƚ ?ƐƐƵƉĞƌ
ƵŶĚĞƌŐƌŽƵŶĚ ?ĂŶĚǁŝƚŚŝŶŵŝŶƵƚĞƐ ?ƐŚĞ ?ƐĂƚƚŚĞĚŽŽƌƐƚĞƉŽĨƚŚĞ&ƌĂŶŬĨƵƌƚ'ƌĂŶĚ,ǇĂƚƚ ?,Ğƌ
meeting with Economist Jurgen Deitrich is scheduled for 12noon, and so Heba has some 
time to grab a quick bite at the automated Café in the hotel lobby. She picks her meal from 
the display screen in the Café, a Cappuccino with biscotti, and flashes her mobile phone 
across the pay pad. The pay pad beeps, and a quick look on her mobile phones screen 
ƌĞǀĞĂůƐƚŚĂƚƐŚĞ ?ƐďĞĞŶĐŚĂƌŐĞd 10 Deutsche Marks. As Heba takes a seat in the café, she 
puts on her eyeglasses, which have a computer display on the lenses. She pushes in some 
commands on her mobile phone, and the latest news of the day start flashing across the 
eyeglass lenses. The bŝŐƐƚŽƌŝĞƐŽĨ ƚŚĞĚĂǇ PĂďĂďǇďŽǇ ?ƐďŝƌƚŚŽŶƚŚĞŵŽŽŶŚĂƐ ůĞĚƚŽƚŚĞ
human colony there surpassing the 20,000 mark; a huge celebration is taking place in 
Astoria, Oregon as that city opens its massive water desalination plant that will supply a 
monthly output of 20 million gallons from the Pacific Ocean to all States on the West Coast 
of America, and that Ukraine has finally agreed to become a part of Russia after years of 
negotiations. As Heba sips the last of her Cappuccino, her mobile phone flashes, and she can 
see that Jurgen Deitrich has arrived at the Hyatt hotel for the interview. Heba tidies up her 
ƚĂďůĞ ?ĂŶĚůĞĂǀĞƐĨŽƌƚŚĞĐŽŶĨĞƌĞŶĐĞƌŽŽŵ Q 
Heba: Hello Herr Jurgen! 
Jurgen: Guten Tag Heba. How are you doing today? 
Heba: I am well, how are you? 
Jurgen: / ?ǀĞŚĂĚĂƌŽƵŐŚŵŽƌŶŝŶŐƚŽďĞƋƵŝƚĞĨƌĂŶŬ ?/ƚ ?ƐƐŽŚĂƌĚƚŽŐĞƚĂŶĂŐƌĞĞŵĞŶƚǁŝƚŚƚŚĞ
regulators you know! 
Heba: Yes Herr Jurgen, I totally understand. 
Jurgen: So, I looked through your interview questions last night. Are you ready to start the 
interview? 
Heba: Yes Sir! 
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:ƵƌŐĞŶ P/ƐĞĞƚŚĂƚǇŽƵ ?ƌĞĚŽŝŶŐĂŶĞǁƐƐƚŽƌǇĨŽƌůŽŽŵďĞƌŐEĞǁƐŽŶƚŚĞĐƵƌƌĞŶƚĞĐŽŶŽŵŝĐ
environment in Europe for the Pharmaceuticals industry. I had a chance to do some 
ƌĞƐĞĂƌĐŚ ƚŚĞƐĞ ƉĂƐƚ ĨĞǁ ĚĂǇƐ ? ĂŶĚ / ƚŚŝŶŬ ƚŚĂƚ / ?ŵ ƋƵŝƚĞ ƉƌĞƉĂƌĞĚ ƚŽ ĂŶswer all your 
questions. 
Heba: Thank you so much Herr Jurgen!  
:ƵƌŐĞŶ PKŬ ?ƐŽůĞƚ ?ƐƐƚĂƌƚǁŝƚŚǇŽƵƌĨŝƌƐƚƋƵĞƐƚŝŽŶƚŚĞŶ ? 
Heba: Sure! Please tell me what you know about integration efforts within the EU. Also, tell 
ŵĞĂďŽƵƚƚŚĞh ?ƐĨƵƚƵƌĞĞǆƉĂŶƐŝŽŶƉůĂŶƐ ? 
Jurgen: Heba, in two words, nicht gut! As you know, since 2007, the EU has only granted 
accession to Turkey, Croatia, and Bosnia and Herzegovina. These countries integrated into 
the EU at a very slow pace since gaining accession. There are still numerous disparities 
ďĞƚǁĞĞŶƚŚĞĞĐŽŶŽŵŝĞƐŽĨƚŚĞƐĞƐƚĂƚĞƐĂŶĚƚŚĞ ‘ĐŽƌĞ ?ŵĞŵďĞƌƐƚĂƚĞƐ ?dŚĞhŚĂƐďĞĐŽŵĞ
very wary of expansion, and as of right now, there seems to be very little political will and 
unity in the EU on the issue of granting accession to more states. 
Heba:  What about the re-establishment of euro zone? Are things looking positive on that 
front? 
:ƵƌŐĞŶ PEĞŝŶ ?ŶŝĐŚƚŐƵƚ ?ŐĂŝŶ ?ĂƐǇŽƵ ?ƌĞĂǁĂƌĞ ?ƚŚĞĞƵƌŽǌŽŶĞĐŽůůĂƉƐĞĚŝŶ ? ? ? ? ?ůůŵĞŵďĞƌ
ƐƚĂƚĞƐ ƌĞǀĞƌƚĞĚ ƚŽ ƚŚĞŝƌ ŽůĚ ĐƵƌƌĞŶĐŝĞƐ ? dŚĞ ĨŝƐĐĂů ĐƌŝƐĞƐ ? ŝŶ 'ƌĞece, Spain, Portugal and 
/ƌĞůĂŶĚ ĂďŽƵƚ ƚǁĞŶƚǇ ǇĞĂƌƐ ĂŐŽ ƚŽŽŬ ŵĂŶǇ ǇĞĂƌƐ ƚŽ ƐŽƌƚ ŽƵƚ ? ĂŶĚ ƚŚĞƐĞ ĐƌŝƐĞƐ ? ƉƵƚ Ă
tremendous financial burden on the stronger economies within the EU at the time. Frankly, 
the stronger economies just did not want to continue bailing out the weaker economies. 
Several EU member states were predicted to follow the same path that the aforementioned 
countries had followed. High levels of public spending and high debt levels were forecasted 
ŝŶŵĂŶǇ ‘ƉĞƌŝƉŚĞƌǇ ?ŵĞŵďĞƌƐƚĂƚĞƐ ?ĂŶĚǁĞĂůůpretty much reached a point where national 
interests became far more important.   
Heba: In your opinion, how did the breakdown of the euro zone impact the EU? 
Jurgen:Nicht gut! At the time, it seemed like reverting to old currencies was the right way to 
go, but looking back, the break-up of the euro zone caused tremendous long-term damage 
ƚŽƚŚĞh ?ƐĐŽŵƉĞƚŝƚŝǀĞƉŽƐŝƚŝŽŶŝŶƚŚĞŐůŽďĂůĞĐŽŶŽŵǇ ?dŚĞƌĞŚĂƐďĞĞŶŝŶĐƌĞĂƐĞĚǀŽůĂƚŝůŝƚǇ
in business cycles and unemployment levels across many member states. Additionally, 
transaction costs went up. All these factors resulted in lower levels of economic growth 
across the EU. In hindsight, we should all have remained united at the time, but as I said, 
national governments went into protective stances, and this short-term way of thinking had 
a huge negative impact on the EU as a whole. 
Heba: The austerity measures worked well for the UK economy did they not? 
Jurgen: Yes! That was the smart way to go. The UK economy got its public spending under 
control by 2015. This helped the British economy gain a foothold and become more 
competitive in the years that followed. If only more member states in the EU would have cut 
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back on public spending at the time, and got their fiscal budgets and debt levels under 
control, we would all be in a much better economic condition now.   
Heba: So, protectionism was a bad stance for EU member states to take? 
Jurgen: Protectionism? Nein, nicht gut! The protectionist stance taken by almost all EU 
member states since then has led to low economic growth rates, industries moving out of 
ƚŚĞh ?ĂŶĚŚŝŐŚƵŶĞŵƉůŽǇŵĞŶƚĂŶĚŝŶĨůĂƚŝŽŶƌĂƚĞƐ ?dŚĞƐĞĐŽŶĚŝƚŝŽŶƐŝŵƉĂĐƚĞĚ ‘ƉĞƌŝƉŚĞƌǇ ?
states quite severely, and these states were already dealing with numerous economic 
problems at the time. Additionally, all the preferential trade agreements that had been 
signed previously were affected negatively due to numerous protectionist non-tariff 
barriers. With EU states becoming more protective of their own national economies, 
countries outside the EU retaliated by implementing numerous trade barriers as well.   
Heba:  There have also been several issues with regards to labor strikes in numerous EU 
member states since, correct? 
Jurgen: Nicht gut! The labor unions have gotten stronger in countries like France, Spain and 
Greece. Youth unemployment levels have gone up significantly in many member states and 
this scenario created a vicious cycle whereby public spending for benefits had to go up to 
maintain social cohesion and to curb social unrest. 
Heba: Tell me about inflation rates. 
Jurgen: Nein, nicht gut! High energy and food prices have translated into high inflation rates 
especially within the weaker EU economies. Again, this created a negative vicious cycle 
scenario, and has had a negative impact on economic growth rates in many member states. 
Heba: Tell me about immigration policy in the EU. 
Jurgen: Nein, nicht gut! There has not been a harmonized stance on immigration policy. 
Many member states, due to negative attitudes towards immigrants within their 
populations, severely cut down migration into their countries. This has affected industry 
growth rates as businesses have not been able to find skilled workers. 
Heba: What do you have to say about benefits systems in the EU? 
Jurgen: Nein, nicht gut! Reforms to benefits systems ŝŶƚŚĞhŚĂǀĞďĞĞŶŐŽŝŶŐĂƚĂƐŶĂŝů ?Ɛ
pace for many years. Due to high unemployment, low savings rates and ageing populations, 
governments in many member states have enormous public spending levels. The private 
health care sector has been growing at a very slow rate. Efficiencies are low in national 
health care systems and bureaucracy levels are still quite high.   
Heba: So Jurgen, there has been very little progress over the past two decades on several 
important macro environmental issues throughout the EU right? 
:ƵƌŐĞŶ P zĞƐ ? tĞ ŶŽǁ ƌĞĨĞƌ ƚŽ ƚŚĞ ĚĞĐĂĚĞ ĨƌŽŵ  ? ? ? ? ƚŽ  ? ? ? ? ? ĂƐ  “ƚŚĞ ůŽƐƚ ĚĞĐĂĚĞ ? ? dŚŝƐ
decade was a transition period for the EU as member states were recovering from the global 
financial crisis at the start of the decade. Additionally, many member states were 
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contemplating their futures during this decade. From 2020 to 2030, a lack of unity and 
political will, increased fragmentation on policies, and increased protectionism have all led 
to very slow progress in the EU on many fronts during this decade. So, looking back on how 
things have gone in the EU over the past decade, all I can say is Nicht gut, Heba. Nicht gut!  
Heba: OK. So now, with regard to the pharmaceutical industry in the EU, what is the 
situation? 
Jurgen: Again, Nicht gut! The fragmentation of member states led to increased price 
controls at national levels. Generics were thought to be a smart way to reduce spending 
levels at one time, but now, due to a lack of harmonization, and the existence of different 
prescription policies in many EU states, generic uptake levels across the EU are still not at 
par with the generic uptake level in the US. Additionally, price controls in many countries 
posed as a hindrance to the entry of generics into these countries. Some member states 
have high upƚĂŬĞ ůĞǀĞůƐ ĂŶĚ ƐŽŵĞ Ɛƚŝůů ĚŽŶ ?ƚ ? DĂŶǇ ŽĨ ƚŚĞ ďŝŐ ƉŚĂƌŵĂ ĐŽŵƉĂŶŝĞƐ ŚĂǀĞ
moved their manufacturing bases outside the EU. Additionally, there have been plenty of 
opportunities for these companies in the Asian, Latin American and African markets. 
Heba: Well, thank you so much for your time Jurgen. You have been very helpful.    
Jurgen: Danke Heba. Are you flying back to Cairo immediately? 
,ĞďĂ PEŽ:ƵƌŐĞŶ ?/ŚĂǀĞƚŚĞŶĞǆƚƚǁŽĚĂǇƐŽĨĨ ?/ƚŚŝŶŬ/ ?ůůŚĞĂĚĚŽǁŶƚŽƚŚĞŵĂůĨŝŽĂƐƚĨŽƌĂ
short vacation. I can hop onto the bullet train in Frankfurt and be in Naples by this 
afternoon. The one thing that Europe has made a lot of progress on over the past decades 
ŚĂƐ ďĞĞŶ ƚŚĞ ƚƌĂŶƐƉŽƌƚ ĂŶĚ ŝŶĨƌĂƐƚƌƵĐƚƵƌĞ ƐǇƐƚĞŵ ƚŚƌŽƵŐŚŽƵƚ ƵƌŽƉĞ ? /ƚ ?Ɛ ƐŽ ĞĂƐǇ ƚŽ ŐĞƚ
around these days! 
Jurgen: Yes Heba. You are right. Score one for the EU on that front. Enjoy your time in Italy 
ĂŶĚĂůůƚŚĞďĞƐƚǁŝƚŚǇŽƵƌƐƚŽƌǇĨŽƌůŽŽŵďĞƌŐEĞǁƐ Q 
Heba and Jurgen shake hands and part ways. As Heba is leaving the hotel, she notices again 
the large number of tourists from China and India in the hotel lobby. Thank god there has 
been progress elsewhere in the world; Europe would have been in far more choppy waters 
ŝĨ ŝƚŚĂĚŶ ?ƚďĞĞŶ ĨŽƌĞĐŽŶŽŵŝĞƐĞůƐĞǁŚere in the world getting their act together over the 
ƉĂƐƚĚĞĐĂĚĞ,ĞďĂƚŚŝŶŬƐƚŽŚĞƌƐĞůĨ Q 
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July 20th, 2030:  
Ajay Bhakshi ŚĂƐũƵƐƚĂƌƌŝǀĞĚĂƚƚŚĞŚĂƌůĞƐĚĞ'ĂƵůůĞŝƌƉŽƌƚŝŶWĂƌŝƐ ?ũĂǇ ?ƐƚƌŝƉŚĂƐĂƚǁŽ-
ĨŽůĚ ŵŝƐƐŝŽŶ P ƚŚĞ ĨŝƌƐƚ ŝƐ ƚŽ ŝŶƚĞƌǀŝĞǁ DŽŶƐŝĞƵƌ &ƌĂŶĕŽŝƐ 'ŝƌďĂƵĚ ? ƚŚĞ h ?Ɛ ŶĞǁ ƚƌĂĚĞ
commissioner, and the second is to watch the highly anticipated cricket match between 
England and France. Ajay works for the Indian Pharmaceutical company Vijay 
Pharmaceuticals. The company was formed in 2025, and is in the process of exploring 
market opportunities in the EU. As for the cricket match, the French national cricket team is 
highly favored to beat the English team. The good form of the French team has been quite 
the talk of the cricket world over the past few years. France, a country which long 
considered cricket an English sport, had not been enthusiastic about cricket till 2015. In 
recent years, the French team has become quite dominant, and this showdown with 
England has been the hot-topic in Paris and London for the past few weeks. Ajay is anxious 
to get out of the overcrowded airport. He picks up his bags, and heads towards the taxi stall. 
dŚĞƌĞ ?ƐĂĨůĞĞƚŽĨĞůĞĐƚƌŝĐƉŽǁĞƌĞĚƚĂǆŝƐǁĂŝƚŝŶŐ ?ĂŶĚũĂǇŚŽƉƐŝŶƚŽƚŚĞĨŝƌƐƚŽŶĞŝŶůŝŶĞ ?Ɛ
ŚĞŐĞƚƐŝŶƚŽƚŚĞƚĂǆŝ ?ŚĞƐƉĞĂŬƐŝŶƚŽŚŝƐŐŽŽŐůĞƚƌĂŶƐůĂƚŽƌĚĞǀŝĐĞ P “^ŝƌ ?ƉůĞĂƐĞƚĂŬĞŵĞƚŽƚŚĞ
WĂƌŝƐZŝƚǌ ?,ŽǁŵƵĐŚǁŝůůƚŚĂƚĐŽƐƚ ? ?dŚĞŐŽŽŐůĞtranslator device translates his speech into 
French, and a speaker on the device conveys a fluent French voice to the taxi driver. The taxi 
ĚƌŝǀĞƌ ƌĞƉůŝĞƐ ŝŶ &ƌĞŶĐŚ ? ĂŶĚ ŚŝƐ ŐŽŽŐůĞ ĚĞǀŝĐĞ ƚŚĞŶ ĐŽŶǀĞƌƚƐ ŚŝƐ ƐƉĞĞĐŚ ŝŶ ŶŐůŝƐŚ P  “EŽ
problem sir. The trip will ĐŽƐƚǇŽƵ ? ? ?ƵƌŽƐ ? ?ƐƚŚĞƚĂǆŝ ůĞĂǀĞƐƚŚĞĂŝƌƉŽƌƚ ?ũĂǇƚƵƌŶƐŽŶ
the television screen in the taxi. The news of the day, in French, is on the screen. Ajay 
changes the TV setting to Hindi, and pays close attention to the news. The top global stories 
of the day are: Iran and Israel sign a peace treaty after years of war, and the Chinese Yuan is 
now the official currency in the Union of Asian Nations. The taxi arrives at the Ritz, and Ajay 
ĨůĂƐŚĞƐ ŚŝƐ ĐƌĞĚŝƚ ĐĂƌĚ ŽǀĞƌ ƚŚĞ ƉĂǇ ƉĂĚ ?  “DĞƌĐŝ ŵŽŶƐŝĞƵƌ ? ? ũĂǇ ƚĞůůs the taxi driver, and 
walks into the Ritz hotel lobby with his bags in-tow. As Ajay gets into the hotel lobby, he 
notices Mr. Girbaud sitting in the lounge area. He walks over to him and introduces 
ŚŝŵƐĞůĨ Q 
Ajay: Monsieur Girbaud, how are you sir? 
Monsieur Girbaud: Ajay! I am well, how was your flight from Mumbai? 
Ajay: Excellent. I really like the Ritz hotel, quite swanky eh? 
DŽŶƐŝĞƵƌ'ŝƌďĂƵĚ PŚ ?ǇĞƐ ? /ƚ ŝƐ ŝŶĚĞĞĚĂ ũĞǁĞů ŝŶ ƚŚĞ ĂƌƚŽĨWĂƌŝƐ ? /ƚ ?ƐƐŽŐƌĞĂƚƚŚĂƚƚŚĞ
entire hotel is now 100% green. I mean, the entire building is solar-powered, and there 
ĂƌĞŶ ?ƚĞǀĞŶĂŶǇƐŽůĂƌƉĂŶĞůƐƚŽďĞƐĞĞŶĂŶǇǁŚĞƌĞŽŶƚŚĞĞŶƚŝƌĞďƵŝůĚŝŶŐ ?YƵŝƚĞ ŝŵƉƌĞƐƐŝǀĞ
ŚŽǁƚŚĞǇ ?ƌĞĂďůĞƚŽƉƵůůƚŚĂƚŽĨĨŶŽǁĂĚĂǇƐ ? 
Ajay: Yes, quite remarkable. So, are you ready for the interview? Did you get a chance to 
skim through the questionnaire that I sent you last week? 
DŽŶƐŝĞƵƌ'ŝƌďĂƵĚ PzĞƐ ?/ĂŵƌĞĂĚǇ ?&ŝƌĞĂǁĂǇ Q 
ũĂǇ P^Ž ? ůĞƚ ?Ɛ ƐƚĂƌƚǁŝƚŚ ƚŚŝƐ ŝƐƐƵĞŽĨĞƵǆhŶŝŽŶƵƌŽƉĠĞŶŶĞ ƚŚĂƚ / ?ǀĞďĞĞŶŚĞĂƌŝŶŐĂ ůŽƚ
ĂďŽƵƚůĂƚĞůǇ ?dĞůůŵĞŵŽƌĞ Q 
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Monsieur Girbaud: Oui! Deux Union Européenne. This situation has been evolving for many 
years, and now, we can almost clearly distinguish the presence of two unions. There is no 
ůŽŶŐĞƌĂƵŶŝƚĞĚƵƌŽƉĞĂŶhŶŝŽŶ ?dŚĞƌĞŝƐĂƵŶŝŽŶŽĨƚŚĞƐƚƌŽŶŐ ‘ĐŽƌĞ ?ƐƚĂƚĞƐĂŶĚĂƐĞƉĂƌĂƚĞ 
ƵŶŝŽŶŽĨƚŚĞ ‘ƉĞƌŝƉŚĞƌǇ ?ƐƚĂƚĞƐ ?ĂƐŝĐĂůůǇ ?ƚŚĞ ‘ƉĞƌŝƉŚĞƌǇ ?ƐƚĂƚĞƐĚĞĐŝĚĞĚƚŚĂƚƚŚĞŝƌ ŝŶƚĞƌĞƐƚƐ
ǁĞƌĞŶŽƚĞǀĞƌĂĐŽŶĐĞƌŶŽĨ ƚŚĞ  ‘ĐŽƌĞ ?ƐƚĂƚĞƐ ?dŚĞ  ‘ĐŽƌĞ ?ƐƚĂƚĞƐĂůǁĂǇƐ ůŽŽŬĞĚŽƵƚ ĨŽƌƚŚĞŝƌ
own interests, while the weaker states were always getting a very tiny piece of the pie. So, 
ƚŚĞƐĞ ǁĞĂŬĞƌ  ‘ƉĞƌŝƉŚĞƌǇ ? ƐƚĂƚĞƐ ŚĂǀĞ ŶŽǁ ĨŽƵŶĚ Ă ǁĂǇ ƚŽ ǁŽƌŬ ĂŵŽŶŐƐƚ ƚŚĞŵƐĞůǀĞƐ ƚŽ
realise their own objectives. 
Ajay: So there is no integration basically? 
Monsieur Girbaud: Oui. There was some integration many years ago, but as the global 
marketplace became more and more competitive, the EU policymakers were dominated by 
the strong states, and these states always succeeded in having the policymakers craft 
policies that addressed only their needs. 
Ajay: So, how has this affected the business environment in the EU? 
Monsieur Girbaud: The deux Union Européenne scene has been good only for the states 
ƚŚĂƚ ĂƌĞ ĐƵƌƌĞŶƚůǇƉĂƌƚŽĨ ƚŚĞ ĞƵƌŽ ǌŽŶĞ ?Ɛ ǇŽƵ ŬŶŽǁ ? ďĂĐŬ ŝŶ ƚŚĞ  ? ? ? ? ?Ɛ ? ƚŚĞ ĞƵƌŽ ǌŽŶĞ
started kicking out the member states that had large public spending levels and high debt 
levels. So now, there are only ten states within the euro zone, and these states have the 
ƐƚƌŽŶŐĞƐƚĞĐŽŶŽŵŝĞƐ ?dŚĞƌĞƐƚŚĂǀĞĂůǁĂǇƐďĞĞŶ ?ĂŶĚĐŽŶƚŝ ƵĞƚŽƉůĂǇĐĂƚĐŚƵƉ ?ŶĚƚŚĞǇ ?ǀĞ
been trying to play catch up basically without much support from EU policymakers. 
Ajay: So give me some more specifics with regard to disparities in economic conditions. 
Monsieur Girbaud: Within the stronger states, there is positive GDP growth, low 
unemployment and inflation, and low volatility in the business cycle. And in the weaker 
states, these economic parameters have been, and continue to head into the opposite 
direction.  
Ajay: Tell me about the labor markets and some more on policies such as immigration and 
healthcare. 
Monsieur Girbaud: As I said earlier, unemployment levels are low in the stronger 
economies, and so, income levels are higher in these states. As unemployment levels are 
high in the weaker non euro states, there are stronger labor unions and strikes by workers 
almost every month. The stronger states have been smarter when it comes to immigration 
ƉŽůŝĐǇ ? dŚĞǇ ?ǀĞ ďĞĞŶ ĂďůĞ ƚŽ ĐŽŶƚƌŽů ŵŝŐƌĂƚŝŽŶ ĂŶĚ ƚŚĞǇ ?ǀĞ ďĞĞŶ ĂďůĞ ƚŽ ďring in skilled 
workers from other parts of the world as needed. Workers in the weaker states have very 
high levels of unskilled labor, and because of the lack of jobs, these states have had a closed 
door mentality on immigration policy  W ƚŚĞǇ ?ǀĞƐŚƵƚŽƵƚmigrants from outside the EU. As 
for healthcare, again, there is the deux Union Européenne dynamic. The stronger euro zone 
states have systems that are 50-50 public/private while the weaker states have national 
healthcare systems that are 100% funded by the governments. Therefore, the stronger 
economies have very efficient healthcare systems with excellent quality care and very low 
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hospital populations, while the weaker states systems are very inefficient, with poor quality 
care and extremely high patient populations. 
Ajay: And lifestyle quality is quite poor in the non euro zone states as well right?  
Monsieur Girbaud: Oui. Again, deux Union Européenne. In the weaker states, quality of life 
of citizens is low, with lower life expectancy rates. The citizens of the weaker states have 
more health related problems at earlier ages, and hence, as I said earlier, patient 
populations are high in these states. 
Ajay: So, tell me more about how these dynamics affect the scene with regard to the 
pharmaceuticals and generics drug industry in the EU. 
Monsieur Girbaud: Well, with regard to counterfeit drugs, these have infiltrated the systems 
in the weaker states very significantly. The rate is about 40%. In the stronger states, the 
infiltration percentage of counterfeit drugs stands at about 5%. There is also a very negative 
attitude with regard to generics in the stronger states. There has been a lot of bad PR about 
generics coming into the stronger states, and citizens of these states just do not trust 
pharmaceuticals manƵĨĂĐƚƵƌĞĚ ŽƵƚƐŝĚĞ ƚŚĞ h ? ĚĚŝƚŝŽŶĂůůǇ ? E'K ?Ɛ ĂŶĚ ĐŽŶƐƵŵĞƌ
protection agencies have been very effective in painting a bad picture of generics coming 
into the EU from countries outside the EU. In fact, generics are also looked upon in a very 
negative light in the weaker states because of the high levels of counterfeit drugs and 
numerous fake internet pharmacies. 
Ajay: What about the reputation of pharmaceuticals with regards to impact on the 
environment? 
Monsieur Girbaud: Again, deux Union Européenne. In the stronger EU states, the 
pharmaceuticals companies have 100% green buildings, low levels of waste in 
ŵĂŶƵĨĂĐƚƵƌŝŶŐ ? ĂŶĚ  ‘ŐƌĞĞŶ ? ƉĂĐŬĂŐŝŶŐ ? Ƶƚ ŝŶ ƚŚĞ ǁĞĂŬĞƌƐƚĂƚĞƐ ? ƚŚĞƐĞ ƐĂŵĞ ƉŚĂƌŵĂ
ĐŽŵƉĂŶŝĞƐŚĂǀĞŶŽƚŝŶǀĞƐƚĞĚŝŶ ‘ŐƌĞĞŶ ?ƚĞĐŚŶŽůŽŐŝĞƐĂŶĚƚŚĞǇ ?ǀĞƉůĂĐĞĚǀĞƌy little emphasis 
ŽŶ ƌĞĚƵĐŝŶŐ ǁĂƐƚĞ ĂŶĚƵƚŝůŝǌŝŶŐ  ‘ŐƌĞĞŶ ?ƉĂĐŬĂŐŝŶŐ ŵĂƚĞƌŝĂůƐ ? dŚŝƐ ŝƐ ŵĂŝŶůǇ ďĞĐĂƵƐĞ ŽĨ ƚŚĞ
fact that governments in the weaker states have strict price controls, and the 
ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐŽŵƉĂŶŝĞƐ ŚĂǀĞ ƚŚĞƌĞĨŽƌĞ ůŽǁĞƌ ŝŶǀĞƐƚŵĞŶƚ ůĞǀĞůƐ ŝŶ  ‘ŐƌĞĞŶĞƌ ?
manufacturing processes and materials. 
Ajay: One final question then Monsieur Girbaud, who will win the big cricket match today? 
DŽŶƐŝĞƵƌ'ŝƌďĂƵĚ P,Ă,ĂũĂǇ ?/ŬŶĞǁƚŚĂƚǇŽƵ ?ĚĂƐŬŵĞƚŚĂ ĂƚƐŽŵĞƉŽŝŶƚ ?ůů/ĐĂŶƐĂǇŝƐ P
Vive la France! Ha Ha! 
Ajay: I must say that I am not surprised by your answer. I am going to watch the big match 
ĂƚƚŚĞ^ƚĂĚĞĚĞ&ƌĂŶĐĞƚŚŝƐĂĨƚĞƌŶŽŽŶǇŽƵŬŶŽǁ ?/ ?ŵƌĞĂůůǇůŽŽŬŝŶŐĨŽƌǁĂƌĚƚŽƚŚŝƐƚǁĞŶƚǇ-
twenty match up. 
Monsieur Girbaud: Aaah, enjoy yourself Ajay. All the best, and if you have any more 
questions later, feel free to contact me. 
ũĂǇ PdŚĂŶŬǇŽƵǀĞƌǇŵƵĐŚDŽŶƐŝĞƵƌ'ŝƌďĂƵĚ ?zŽƵŚĂǀĞďĞĞŶŵŽƐƚŚĞůƉĨƵů Q 
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ũĂǇƌĞĂĐŚĞƐŽǀĞƌĂŶĚƐŚĂŬĞƐDŽŶƐŝĞƵƌ'ŝƌďĂƵĚ ?ƐŚĂŶĚǀŝŐŽƌŽƵƐůǇ ?ĂŶĚƚŚĞƚǁŽƉĂƌƚǁĂǇƐ ?
As Ajay leaves the café, he enters the hotel lobby. This is indeed a magnificent hotel Ajay 
thinks to himself as he looks around. He then departs from the hotel front door, and 
outside, the sun is shining. What a beautiful day to watch some cricket Ajay thinks as he 
hails the taxi parkeĚĂƚƚŚĞƚĂǆŝƐƚĂŶĚ Q 
 
7 SCENARIO EVALUATION & IMPLICATION 
To formulate recommendations and strategies, the project will first evaluate the scenarios 
using the three levels of organizational environment. These can be broadly divided into: 
external economic environment, industry environment, and firm level environment with 
their respective frameworks as represented in the Figure 7 below. 
FIGURE 7: 3-LEVEL OPERATIONAL ENVIRONMENT 
 
Source: Authors Interpretation. 
The EU economic environment has already been described in the Scenarios and the PESTLE 
factors prognostics in previous chapters. In order to evaluate the scenarios and their 
implications we have proposed a 4 step approach: 
1. Identify key descriptive phrases that summarize the EU economy circa 2030 
2. Hypothesize the possible EU generics drugs industry circa 2030 
3. Identify firm level opportunities and threats 
4. Summarize possible scenario implications 
The sub-sections below evaluate the scenarios using the 4 step approach as mentioned 
above. 
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7.1 ^EZ/K ? P “dKK ES hEK ? ?s>hd/KE ?IMPLICATION 
Step 1: Possible descriptive phrases of the EU environment circa 2030: 
1. Expanded and expanding EU 
2. Growing Economy 
3. Cooperation  
4. Harmonization 
5. Political leadership 
6. Common currency 
7. Stringent regulatory frameworks 
8. International free market 
9. Business environment stability 
10. Improved lifestyles 
11. Global competition 
12. Revolutionary Technology 
13. Market information 
14. Many choices 
15. New entrants 
16. Environment friendly 
17. Social responsibility 
18. Low public spending 
19. Low unemployment 
20. Aging population 
21. Mature industry 
^ƚĞƉ  ? P /ŶĚƵƐƚƌǇ ĂŶĂůǇƐŝƐ ƵƐŝŶŐ WŽƌƚĞƌ ?Ɛ  ? ĨŽƌĐĞƐ  ? ? ?    ? &ŝŐƵƌĞ8 below represents the 
strengths of the forces involved. 
FIGURE 8ǣǯ ?	 EVALUATING SCENARIO 1 
 
Source: Authors interpretations 
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Step 3: Possible opportunities and threats that are presented to EU generic drugs industry 
players. Table 6 below lists the various possible opportunities and threats. 
TABLE 6: OPPORTUNITIES & THREATS SCENARIO 1 
Opportunities Threats 
Integrated global markets Disruptive technology 
New technologies Intense global competition 
New Products Substitute products 
Affluent society Increased buyers power 
Aging population Increased due diligence and compliance 
standards 
Less bureaucracy Spreading prophylactic approaches 
Harmonized policies Price control 
Expanding EU  
Growing attentions to healthcare  
New therapies and delivery systems  
Increased use of generic drugs  
Positive attitude for soft medication (OTC 
drugs) 
 
Expanded health insurance sector  
New diagnosis and new social diseases  
Quality focus  
Environmental focus  
Differentiation focus  
Source: Authors interpretations 
^ƚĞƉ  ? P ǀĂůƵĂƚŝŶŐ ƚŚĞ ĞĐŽŶŽŵŝĐ ĞŶǀŝƌŽŶŵĞŶƚ  ?W^d> ? ? ŝŶĚƵƐƚƌǇ ĞŶǀŝƌŽŶŵĞŶƚ  ?WŽƌƚĞƌ ?Ɛ  ?
ĨŽƌĐĞƐ ? ? ĂŶĚ Ĩŝƌŵ ůĞǀĞů  ?ŽƉƉŽƌƚƵŶŝƚŝĞƐ ĂŶĚ ƚŚƌĞĂƚƐ ? ǁĞ ŶŽƚŝĐĞ ƚŚĂƚ ƚŚĞ h ŐĞŶĞƌŝĐ ĚƌƵŐ ?Ɛ
industry in 2030 is subjected to near-perfect competition and is not an attractive industry. In 
this scenario we can assume that players in the EU generic drugs industry find it difficult to 
achieve cost leadership because perfect competition dictates marginal costs equal to 
average costs. However; it also implies that the markets are both allocatively and 
productively efficient. Furthermore; we notice that generic drugs industries are using 
differentiation strategies to enhance and extend their product portfolio. 
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7.2 ^EZ/K ? P “E/E ?E/,d'hd ? ? 
Step 1: Possible descriptive phrases of the EU environment circa 2030: 
1. EURO Zone disintegration 
2. Disparity in EU member state economies 
3. Weak global competitive position 
4. Protectionism  
5. Fragmentation 
6. Political instability 
7. Low EU GDP 
8. Slow/Stagnant EU expansion 
9. Volatile Business cycles 
10. High inflation 
11. High transaction costs 
12. Aging population 
13. High unemployment 
14. High public spending 
15. Low morality 
16. Strong labor unions 
17. Less competition 
 
^ƚĞƉ  ? P /ŶĚƵƐƚƌǇ ĂŶĂůǇƐŝƐ ƵƐŝŶŐ WŽƌƚĞƌ ?Ɛ  ? ĨŽƌĐĞƐ  ? ? ?    ? &ŝŐƵƌĞ9 below represents the 
strengths of the forces involved. 
FIGURE 9ǣǯ ?	 EVALUATING SCENARIO 2 
 
Source: Authors interpretations 
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Step 3: Possible opportunities and threats that are presented to EU generic drugs industry 
players. Table 7 below lists the various possible opportunities and threats. 
TABLE 7: OPPORTUNITIES & THREATS SCENARIO 2 
Opportunities Threats 
Long-term contracts Disruptive technology 
Lobbying Intense global competition 
Secure large market share Substitute products 
Aging population Counterfeit drugs  
Market knowledge Increased buyers power 
Hedging Finances Increased due diligence and compliance 
standards 
Multi-strategy Spreading prophylactic approaches 
Growing attention to healthcare Price control 
Government support Parallel import 
Cost leadership Transaction costs 
New therapies and delivery systems  
Increased use of generic drugs  
Positive attitude for soft medication 
(OTC drugs) 
 
New diagnosis and new social diseases  
Source: Authors interpretations 
^ƚĞƉ  ? P ǀĂůƵĂƚŝŶŐ ƚŚĞ ĞĐŽŶŽŵŝĐ ĞŶǀŝƌŽŶŵĞŶƚ  ?W^d> ? ? ŝŶĚƵƐƚƌǇ ĞŶǀŝƌŽŶŵĞŶƚ  ?WŽƌƚĞƌ ?Ɛ  ?
ĨŽƌĐĞƐ ? ? ĂŶĚ Ĩŝƌŵ ůĞǀĞů  ?ŽƉƉŽƌƚƵŶŝƚŝĞƐ ĂŶĚ ƚŚƌĞĂƚƐ ? ǁĞ ŶŽƚŝĐĞ ƚŚĂƚ ƚŚĞ h ŐĞŶĞƌŝĐ ĚƌƵŐ ?Ɛ
industry in 2030 might still be an oligopoly and remains to be an attractive industry. In this 
scenario we can assume that players in the EU generic drugs industry can use multi-
strategies, explicit market knowledge and government support to strengthen the barriers to 
entry from foreign competition. They might also have ability to achieve cost leadership, and 
secure large market share throughout the EU. 
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7.3 ^EZ/K ? P “hyhE/KEhZKWEE ? ?
Step 1: Possible descriptive phrases of the EU environment circa 2030: 
Deux EU 
 EU Zone 
1. Growing Economy 
2. Cooperation  
3. Harmonization 
4. Political stability 
5. Strong EURO 
6. Stringent regulatory frameworks 
7. Consumer protection 
8. International free market 
9. Business environment stability 
10. Improved lifestyles 
11. Revolutionary Technology 
12. Market information 
13. Many choices 
14. Environment friendly 
15. Social responsibility 
16. Low public spending 
17. Efficient healthcare systems 
18. Low unemployment 
19. Aging population 
20. Non Ȃ EU Zone 
21. Weak Economy 
 Non-EU Zone cooperation 
1. Protectionism against international competition 
2. Low GDP 
3. Political instability 
4. Consumer protection 
5. Volatile Business cycles 
6. High inflation 
7. High transaction costs 
8. Weak global competitive position 
9. Aging population 
10. High unemployment 
11. High public spending 
12. Low morality 
13. Poor healthcare systems 
14. Strong labor unions 
15. Less competition 
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^ƚĞƉ  ? P /ŶĚƵƐƚƌǇ ĂŶĂůǇƐŝƐ ƵƐŝŶŐ WŽƌƚĞƌ ?Ɛ  ? ĨŽƌĐĞƐ  ? ? ?   ? ? &ŝŐƵƌĞ10 below represents the 
strengths of the forces involved. 
FIGURE 10: PORTER'S 5 FORCES EVALUATING SCENARIO 3 
 
Source: Authors interpretations 
Step 3: Possible opportunities and threats that are presented to EU generic drugs industry 
players. Table 8 below lists the various possible opportunities and threats. 
TABLE 8: OPPORTUNITIES & THREATS SCENARIO 3 
Opportunities Threats 
Dual markets Disruptive technology 
Multi-strategies Intense global competition 
Multi-positioning Substitute products 
Aging population Counterfeit drugs  
Growing attention to health Increased due diligence and compliance 
standards 
Quality focus Spreading prophylactic approaches 
New therapies and delivery systems Price control 
Increased use of generic drugs Parallel import 
Positive attitude for soft medication (OTC 
drugs) 
Transaction costs 
New diagnosis and new social diseases  
Environmental focus  
Strong barriers to entry  
Secure large market share  
Source: Authors interpretations 
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^ƚĞƉ  ? P ǀĂůƵĂƚŝŶŐ ƚŚĞ ĞĐŽŶŽŵŝĐ ĞŶǀŝƌŽŶŵĞŶƚ  ?W^d> ? ? ŝŶĚƵƐƚƌǇ ĞŶǀŝƌŽŶŵĞŶƚ  ?WŽƌƚĞƌ ?Ɛ  ?
forces), and firm level (opportunities and threats) we notice that the EU ŐĞŶĞƌŝĐ ĚƌƵŐ ?Ɛ
industry in 2030 might still be an oligopoly and remains to be an attractive industry. In this 
scenario we can assume that players in the EU generic drugs industry can use distinct 
ƐƚƌĂƚĞŐŝĞƐƚŽƐƵŝƚƚŚĞƚǁŽĚŝĨĨĞƌĞŶƚh ?ƐǁŝƚŚĂǀĂƌŝĞƚǇŽĨchoices. They might also have the 
ability to achieve cost leadership strategies in the non-EU Zone countries and differentiation 
strategies in the EU Zone, thus securing large market share throughout the EU. 
 
8 STRATEGIES AND RECOMMENDATIONS 
Scenarios are used to challenge implicit and explicit assumptions, stretch strategic thinking 
and foster organizational learning (Tenaglia& Noonan, 1993).  It is suggested to 
organizations to organize workshops to further expand and develop these scenarios. Use 
the scenarios to challenge or test current strategies. Identify new robust strategies and risk, 
and setup monitoring units to identify signs & indicators for each scenario. In order to 
propose a set of strategies and recommendation, the project has combined key repeated 
opportunities and treats. Table 9 below lists combined opportunities and threats observed 
in the three hypothetical scenarios. 
TABLE 9: OPPORTUNITIES & THREATS SCENARIOS COMBINED 
Opportunities Threats 
Integrated global markets Disruptive technology 
New technologies Intense global competition 
New Products Substitute products 
Ageing population Increased due diligence and compliance 
standards 
Less bureaucracy Spreading prophylactic approaches 
Harmonized policies Price control 
New therapies and delivery systems  
Increased scope for use of generic drugs  
Positive attitude for soft medication (OTC 
drugs) 
 
Expanding health insurance coverage  
New institutional purchases  
New diagnosis and new social diseases  
Focus (Quality, Sustainability & 
Differentiation) 
 
Source: Authors interpretations 
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Figure 11 below is a schematic diagram that represents the opportunities and threats of the 
three scenarios. The threats list highlighted in the center of the diagram represents the 
common threats of each scenario. 
FIGURE 11: OPPORTUNITIES AND THREATS THEMATIC DIAGRAM 
 
Source: Authors interpretations 
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8.1 RECOMMENDATIONS 
1. Revisit your generic strategies 
Low cost or differentiation? In line to EU generic drugs industry circa 2030, our scenarios 
have identified intense foreign competition as we head towards globalization. Porter 
ƐƵŐŐĞƐƚƐƚŚĂƚĂĨŝƌŵ ?ƐĐŽŵƉĞƚŝƚŝǀĞƐƚƌĞŶŐƚŚƵůƚŝŵĂƚĞůǇĨĂůůƐ ŝŶƚŽŽŶĞŽĨƚǁŽĐĂƚĞŐŽƌŝĞƐ ?ĐŽƐƚ
advantage or differentiation. If these strengths are applied in either a narrow or a broad 
scope, we get three generic strategies, cost leadership, differentiation, and focus. These 
strategies can also be used to influence the industry forces as shown in Table 10below: 
TABLE 10: GENERIC STRATEGIES AND INDUSTRY FORCES 
Industry Force Generic Strategies 
Cost leadership Differentiation Focus 
Entry Barriers Ability to cut prices 
and achieve 
economies of scale 
can deter potential 
entrants 
Customer loyalty to 
brand can discourage 
potential entrants 
Focusing develops 
competencies that 
act as entry barriers 
Buyer Power Ability to offer low 
prices to powerful 
buyers 
Large buyers have 
less power to 
negotiate because of 
few close 
alternatives 
Large buyers have 
less power to 
negotiate because of 
few close 
alternatives 
Supplier Power Better insulated 
from powerful 
suppliers 
Ability to transfer 
price i.e. supplier 
prices to customers 
Suppliers have 
influence because of 
low volumes, but a 
differentiation-
focused firm is better 
able to pass on 
supplier price 
increases 
Threat of 
Substitutes 
Use low prices to 
defend against 
substitutes 
Differentiating 
attributes reduce 
threat of substitutes 
Specialized products 
& core competencies 
protect against 
substitutes 
Rivalry Able to compete on 
price 
Brand loyalty to fend 
against rivals 
Rivals cannot meet 
differentiation 
focused customer 
needs 
^ŽƵƌĐĞ PƵƚŚŽƌƐ/ŶƚĞƌƉƌĞƚĂƚŝŽŶƐŽĨWŽƌƚĞƌ ?Ɛ'ĞŶĞƌŝĐ^ƚƌĂƚĞŐǇ 
 
There are significant advantages and disadvantages to the three types of strategies. Cost 
leadership strategies are upstream strategies. In the event of a price war, industries who 
focus on cost leadership can maintain profitability while the competition suffers losses. Even 
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without a price war, as the industry reaches maturity, firm who can maintain cost leadership 
will remain profitable for long periods. However, cost leadership positions root from 
internal strengths which requires continuous capital investment for new production 
technologies and assets, skilled resources in designing efficient manufacturing, high level of 
expertise in manufacturing and efficient distribution channels, thus; cost leaders are not 
innovation focused. Whereas, differentiation strategies offer unique attributes to products 
and services that are perceived as valuable to customers and differentiated from 
competitors. They specialize in downstream strategies with strengths in leading research 
and development, skilled and creative product development teams, strong sales and 
marketing teams, reputation for quality and innovation.  In summary, it is assumed that cost 
leaders cannot innovate and that differentiators have strong brand equity to retain 
customer. However, as we head towards global competition, such assumptions can be 
futile. Global competitors might not select polar strategies, but choose mixed strategies, 
where they focus on achieving cost leadership and innovation. Therefore we suggest EU 
generic drugs players to revisit traditional strategic thinking and not focus explicitly on polar 
strategies.  
2. The key ingredient 
What is your ingredient? In all our scenarios we have identified the infiltration of counterfeit 
drugs into the EU generic drugs market. Scenario 2 & 3 explicitly highlights the growing 
percentages of counterfeit drugs where as it is implicit in scenario 1 as the problems were 
solved using strict regulatory measures. In light of such a potential threat, our scenarios 
predict that irrespective of the economic environment, counterfeit drugs will be a serious 
ĐŽŶĐĞƌŶ ĂŶĚ ŐŽǀĞƌŶŵĞŶƚ ?Ɛ ĂŶĚ ?Žƌ E'K ?Ɛ ǁŝůů ƚĂŬĞ ƐƚƌŝĐƚ ĂĐƚŝŽŶƐ ƚŽ ĐƵƌď ƚŚĞŝƌ ŝŶĨŝůƚƌĂƚŝŽŶ ?
These strict actions can lead to significant transaction costs as supply chains are scrutinized 
by either private or public bodies. Additionally, counterfeit drugs might instigate negative 
publicity to generic drugs; especially those manufacturers that are cost focused (low quality) 
or internationally sourced. It might even lead to tighter non-tariff trade barriers and/or a 
complete boycott of Non-EU produced generic drugs being purchased by institution. These 
threats however could represent opportunities for generic players in the EU. Players can use 
distinctive strategies such as local manufacturing, marketing, brand building, etc to improve 
authenticity/quality perceptions and create new customer value propositions. 
3. ǯenny wise with research 
Penny wise with research? Technological changes, adaptations and breakthroughs in the 
next 20 years can create and/or destroy industries. Possibly the greatest threat to the 
generic drugs industry is technological changes i.e. biotechnology, genomics, delivery 
systems, etc. New products/developments by pharmaceuticals are strong substitutes to 
generic drugs with approximately 20 years of protection. In the event of a revolutionary 
technology change as described in scenarios 1 & 3, we can predict high levels of competition 
in generic drugs industry fighting over a share in a contracting market. In this case we 
suggest generic drugs players to allocate resources that aim to research and identify the 
technology changes and their implications. This practice will reduce the surprise element 
and generic players can hedge risks by diversifying their product portfolio with unrelated 
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product mixes. We also remind generic players to incentivize innovation as generic drugs 
can have patents on formulation if not the active ingredient.  
4. Stakeholder Management 
Are my stakeholders happy? Stakeholder management is about managing the expectation of 
multiple actors or constituents who have a stake (not necessarily financial) in the company. 
Effective interaction with key stakeholder or groups could be a critical competency for the 
future success in the generics drug industry. In our scenarios we have highlighted several 
ƐƚĂŬĞŚŽůĚĞƌƐ ? ŝ ?Ğ ? >ĂďŽƌ ƵŶŝŽŶƐ ? E'K ?Ɛ ? h ĐŽŵŵŝƐƐŝŽŶƐ ? ŵĞŵďĞƌ ƐƚĂƚĞƐ ?etc. and their 
growing influence over the generic drugs industry. The challenge presented here is to 
understand their relationship with the commercial model of the generic drugs player and 
formulate plans and strategies to capitalize upon. The EU represents great potential for 
stakeholder management techniques as careful management can strengthen barriers of 
entry, provide a competitive edge, etc. We therefore recommend generic players to allocate 
explicit resources in marketing, sales, and research and development that will review and 
critically evaluate stakeholder landscape, including existing stakeholder knowledge, 
relationships and plans. 
5. Give in to the green 
Go Green! Our scenarios 1 & 2 have envisioned worlds where there is focus on 
ĞŶǀŝƌŽŶŵĞŶƚĂůůǇ ĨƌŝĞŶĚůǇ  ‘ŐƌĞĞŶ ? ƉƌĂĐƚŝĐĞƐ ? tĞ ďĞůŝĞǀĞ ƚŚĂƚ ŝŶ ĨƵƚƵƌĞ ƚŚĞƌĞ ǁŝůů ďĞ ƚŝŐŚƚĞƌ
environmental regulations and organizations that have already invested in green practices 
will sustain a competitive advantage. It is suggested to generic players that they focus on 
sustainability concepts not just on business process improvements but those that have 
related environment friendly implication. Sustainability is a continuous improvement 
practice; we recommend techniques such as carbon monitoring (i.e. supply chain), green 
building (i.e. manufacturing facility, head office quarters), drug recycling, ethical sourcing, as 
key differentiating elements that will not only defend from environment regulations but also 
increase stakeholder value proposition. 
6. Strategic Location 
Can location matter? We recommend EU generics players to investigate the possibility of 
sourcing manufacturing from EU countries rather than foreign countries. There are two 
distinct rationalities behind this recommendation. Firstly, sourcing manufacturing from EU 
member states (established members, new members, or potential members) can prove cost 
efficient in the long-run. For example, evaluate the possibility of Turkey housing the generic 
players manufacturing facility. In the short-run logic might dictate that this is not a cost 
efficient option because Turkey lacks the infrastructure or resources to achieve economies 
of scale. However in the long-ƌƵŶǁŚĞŶdƵƌŬĞǇ ?Ɛ ŝŶĨƌĂƐƚƌƵĐƚƵƌĞĚĞǀĞůŽƉƐ ? ŝƚŵŝŐŚƚƉƌŽǀŝĚĞ
strategic location advantages. These advantages could have huge transaction cost savings 
(i.e. reduce the rising international logistics costs, free trade, protectionist stance from 
foreign trade, etc.) and provide a competitive advantage against international generic drugs 
exporters. 
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The second advantage is the opportunity to exercise corporate social responsibility. As part 
of the EU mission of developing and supporting EU member states economies, life styles, 
etc. such a move will provide generic player the opportunity to support and develop the 
chosen member states economy. This move will help generic players reposition their 
customer value propositions and also strengthen stakeholder value propositions.  
7. Face the enemy 
Confront or partner? In all our scenarios we have discussed the inevitable global 
competition, and advocate that organizations who do not achieve significant economies of 
scale will find sustainability difficult. Even if there are artificial entry barriers by protectionist 
stance of the government, military strategies, buying the competition, etc. it will still 
eventually be subjected to foreign competition. In our supplemented report, we have 
discussed the Indian and Chinese generic industry and the potential it has to becoming 
global generic drugs leaders due to the various economies of scale and resources. In light of 
this potential we recommend EU generic players to form strategic alliances with players 
from India and China explicitly for organizational learning. By alliances either by mergers & 
acquisitions or joint ventures, generic drugs players from the EU will develop capabilities to 
achieve economies of scale and strengthen their ability to compete globally. 
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1. FACTOR RESEARCH 
1.1 POLITICAL FACTORS 
1. EU Expansion & Integration 
/ŶDĂǇ ? ? ? ?ƚŚĞhĞǆƉĂŶĚĞĚŝŶĂ ‘ďŝŐďĂŶŐ ?ĨĂƐŚŝŽŶĨƌŽŵƚŚĞŽƌŝŐŝŶĂů ? ?ŵĞŵďĞƌƐƚĂƚĞƐƚŽ
25 states, and in 2007, two more countries (Bulgaria and Romania) joined the EU. Over the 
next few years there are expectations for accession into the EU amongst several nations in 
Eastern Europe. Unlike the 'big bang' expansion of 2004, membership from henceforth will 
likely occur in piecemeal fashion. Croatia will more than likely be the first of many countries 
that will join the EU, followed by others waiting patiently in the pipeline namely Bosnia and 
Herzegovina, Serbia, Montenegro, Macedonia, Kosovo and Albania. Turkey has been in 
vigorous negotiations for entry into the EU for many years and there has been talk of 
accession by the year 2015. Although Ukraine is not a candidate country yet, the Ukrainian 
government has initiated processes to negotiate a multitude of free trade agreements with 
the EU. 
Having stated the above, there are issues that may delay or even block accession efforts e.g. 
euro zone sovereign debt woes and rampant corruption within many Eastern European 
ŶĂƚŝŽŶƐ ?KǀĞƌƚŚĞƉĂƐƚĨĞǁǇĞĂƌƐ ?ƚŚĞƌĞŚĂƐďĞĞŶĂƌŝƐĞŝŶƵƌŽƐŬĞƉƚŝĐŝƐŵ ?ĂŶĚ “ǁŚŝůĞƉƌŽ-
European political elites have steadily moved ahead with European integration, citizens 
ĂƉƉĞĂƌŝŶĐƌĞĂƐŝŶŐůǇǁĂƌǇŽĨƚŚĞƉƌŽũĞĐƚ ? ?ĞsƌŝĞƐ ?EĚ ? ?dŚĞĚŝǀĞƌŐĞŶĐĞŝŶŽƉŝŶŝŽŶƐďĞƚǁĞĞŶ
the political elite and the general public was visibly manifested through recent voting 
referendums in France, Ireland, and the Netherlands. These referendums resulted in votes 
against the expansion of EU powers thus making the vision of seamless integration within 
the EU increasingly difficult to attain. Politicians have swayed over this development 
ƚŽǁĂƌĚƐ ƚŚĞ ĚŝƌĞĐƚŝŽŶ ŽĨ ƚŚĞ ǀŽƚŝŶŐ ƉƵďůŝĐ ? ĂŶĚ  “ĂƐ Ă ƌĞƐƵůƚ ? ĐŽŶƚĞƐƚĂƚŝŽŶ ŽǀĞƌ ƵƌŽƉĞĂŶ
ŝŶƚĞŐƌĂƚŝŽŶĂƉƉĞĂƌƐƚŽŚĂǀĞƚƌĂŶƐĨŽƌŵĞĚĨƌŽŵĂ “ƐůĞĞƉŝŶŐŐŝĂŶƚ ?ŝŶĚŽŵĞƐƚŝĐƉŽůŝƚŝĐƐŝŶƚŽĂ
reality (van der Eijk and Franklin 2004). Interviewee Jonathan Farrington was of the opinion 
that EU expansion is likely to slow down over the coming decades and that of the current 
candidate countries, Turkey will be the most likely to gain accession into the EU.  
2. EU Regulatory Framework 
The European Union conducted and completed a review of EU pharmaceutical legislation 
(Directive 2001/83/EC and Regulation 2309/93) and there was a policy consensus 
formulated between the European commission, the European parliament, and the European 
council in March, 2004. The law ĂĚŽƉƚĞĚ  “ĐŽŶƚĂŝŶƐ Ă ŶƵŵďĞƌ ŽĨ ŝŵƉŽƌƚĂŶƚ
advances towards making lower-priced generic medicines more readily available to 
ƵƌŽƉĞĂŶƉĂƚŝĞŶƚƐĂŶĚŚĞĂůƚŚĐĂƌĞƐǇƐƚĞŵƐ ? ?ƵƌŽƉĞĂŶ'ĞŶĞƌŝĐƐDĞĚŝĐŝŶĞƐƐŽĐŝĂƚŝŽŶ ? ?dŚŝƐ
law, which came into effect in November, 2005 also addressed the market protection needs 
of originator pharmaceutical companies (that initially developed and patented drugs) so as 
to protect their research and development investments for new treatments. Additionally, a 
 “ďŽůĂƌ ĞǆĞŵƉƚŝŽŶ ? ƉŽůŝĐǇ ǁĂƐ ŝŶstituted to allow generic manufacturers to prepare 
production and regulatory procedures in advance such that generics could be available for 
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sale immediately upon the expiration of patents. The whole idea behind this regulatory 
framework was to have a uniform policy (vis-à-vis the active promotion of generics) across 
the EU to replace the fragmented approach that existed before e.g. health insurance 
organizations in the UK, Germany, the Netherlands and Denmark heavily promoted generics 
to lower health care expenditures, while similar organizations in countries like Spain, 
Greece, Italy and France did not.  
With regard to policy, fragmentation still exists amongst EU member states on the rights of 
ƉŚĂƌŵĂĐŝƐƚƐ ƚŽ ŽǀĞƌƌŝĚĞ ĚŽĐƚŽƌƐ ? ƉƌĞƐĐƌŝƉƚŝŽŶƐ ŽĨ ďƌĂŶĚĞĚ ĚƌƵŐs by dispensing generics 
instead (without first consulting the prescribing doctor or the patient). There are several 
reasons as to why generic substitution is disallowed in certain countries: liability issues in 
the event of adverse effects on patients, the notion that economic issues may override 
patient needs, and the view that this practice is a price control measure which can hamper 
free competition in the marketplace. Additionally, pharmaceutical companies in the EU have 
attempted to limit the bolar prŽǀŝƐŝŽŶ ďǇ ĐƌĞĂƚŝŶŐ ƉĂƚĞŶƚ ůŝŶŬĂŐĞƐ ?  “WĂƚĞŶƚ ůŝŶŬĂŐĞ ŝƐ ƚŚĞ
practice of linking market approval  ?  or the pricing and reimbursement status  ?  for 
ŐĞŶĞƌŝĐ ŵĞĚŝĐŝŶĞƐ ƚŽ ƚŚĞ ƉĂƚĞŶƚ ƐƚĂƚƵƐ ŽĨ ƚŚĞ ŽƌŝŐŝŶĂƚŽƌ ƌĞĨĞƌĞŶĐĞ ƉƌŽĚƵĐƚ ?  ?ƵƌŽƉĞĂŶ
Generics Medicine Association). Fragmentation could also be perpetuated as a result of 
member states having the freedom to make decisions e.g. on whether certain drugs can be 
approved for substitution by generics. There is no separate organization within the EU (as 
there is in the US) that specializes in, and has the authority to approve generics.   
3. EU Monetary Policy 
 “dŚĞ ŵŽƚŝǀĂƚŝŽŶ ĨŽƌ ĞƐƚĂďůŝƐŚŝŶŐ ƚŚĞ ƵƌŽƉĞĂŶDŽŶĞƚĂƌǇhŶŝŽŶ  ?Dh ?ǁĂƐƉĂƌƚůǇƉŽůŝƚŝĐĂů
ĂŶĚ ƉĂƌƚůǇ ĞĐŽŶŽŵŝĐ ŝŶ ŶĂƚƵƌĞ ?  ?,ĂŵĂĚĂ Ğƚ ? Ăů ? ?  ? ? ? ? ? Ɖ ?  ? ? ? ? ĐŽŶŽŵŝĐ ĐŽŶƐŝĚĞƌations 
included: facilitation of trade, elimination of currency exchange costs/uncertainties, pursuit 
of strong economic growth rates and lowering unemployment rates. The key political 
objective was to promote integration in Europe in order to avoid future conflicts.  
The Maastricht Treaty (1992) set out a timetable for economic and monetary convergence 
in three successive stages. The third stage of the timetable led to the establishment of a 
single monetary policy that would be overseen by the European Central Bank (ECB). 
Additionally, at this stage, the euro became the common currency of eleven member states 
(with Greece joining later in 2001). At present, there are sixteen countries within the EU that 
use the euro as their currency, and all the countries which joined the EU in 2004 and 2007 
are required at some point to join the euro-ǌŽŶĞ ?  ,ŽǁĞǀĞƌ ?  “ŚƵŐĞ ďƵĚŐĞƚ ĚĞĨŝĐŝƚƐ ĂŶĚ
bigger public debt piles accrued during the global recession mean most candidates will not 
meet the Maastricht criteria for four or fŝǀĞŵŽƌĞǇĞĂƌƐ ?  ?ZĞƵƚĞƌƐ ?  ? ? ? ? ? ?KĨƚŚĞĐĂŶĚŝĚĂƚĞ
countries, only Estonia is ready at present, with its 2011 euro bid expected to get a go ahead 
from the EU on May 12.   
There are however several factors which candidate countries are pondering as they 
contemplate the decision as to when to join the euro-zone. These include the current debt 
crisis in Greece, a spike in bond yields in southern European states, and arguments across 
the euro-zone bloc on whether budget offenders deserve aid. Additionally, countries are 
apprehensive about being tied in to policies delivered to them from Brussels, and there is 
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concern about surrendering their own interest rates and currency flexibility. Moreover, 
 “ŝŶƚĞŶƐŝĨǇŝŶŐƐƉĞĐƵůĂƚŝŽŶŽǀĞƌǁŚĞƚŚĞƌƚŚĞĞƵƌŽǌŽŶĞĐĂŶŝƚƐĞůĨŚŽůĚ together as its weakest 
members struggle has fuelled resistance among policymakers to admitting another country 
capable of a Greece-ƐƚǇůĞ ĨŝƐĐĂů ŵĞůƚĚŽǁŶ ?  ?ZĞƵƚĞƌƐ ?  ? ? ? ? ? ?,ĂǀŝŶŐ ƐĂŝĚ ƚŚŝ ?Ă ƌĞĐĞŶƚƉŽůů
shows that economists see most candidates (the Czech Republic, Poland, Hungary, Romania, 
Bulgaria and Latvia) joining by 2015. In conclusion, the benefits of a common currency 
within the EU will not be fully realized until all EU members join the euro-zone and 
economic fundamentals within all nations that are part of the bloc are consistently sound. 
4. EU Fiscal Policy 
 “dŚĞƐƵƐƚĂŝŶĂďŝůŝƚǇŽĨƉƵďůŝĐĨŝŶĂŶĐĞƐŝƐĂŬĞǇƉŽůŝĐǇŝƐƐƵĞĨŽƌƚŚĞƵƌŽƉĞĂŶhŶŝŽŶ ? ?ĨŽŶƐŽ ?
2009, p.731). The Eurozone Stability and Growth Pact (SGP) adopted in 1997 consisted of 
fiscal monitoring by the European Commission and the Council of Ministers. Member states 
unable to comply with the following criteria would face possible sanctions after multiple 
warnings: an annual budget deficit of no higher than 3% of GDP and a national debt lower 
than 60% of GDP. The aim was to ensure that inflationary pressures on the European 
economy would be held in check, and that member states would have a tight grip on their 
fiscal budgets. It is important to note that fiscal discipline within EU member states has 
important implications with regard to monetary policy within EMU (European Monetary 
Union) member states. A lack of coordination between fiscal and monetary policies within 
the EU is currently a key issue that regulators have to address (Ardy, 2010, p. 3). The 
European Central Bank (ECB) is responsible for monetary policy, but what is currently 
ƵŶĐůĞĂƌŝƐǁŚŽŝƐƌĞƐƉŽŶƐŝďůĞĨŽƌƚŚĞŽǀĞƌĂůůĨŝƐĐĂůƉŽůŝĐǇŽĨƚŚĞh ? “ƵƌƌĞŶƚĚĞǀĞůŽƉŵĞŶƚƐŝŶ
Greece make clear that the rules of the European Stability and Growth Pact (SGP) were 
ŶĞŝƚŚĞƌ ƐƚƌŝĐƚ ĞŶŽƵŐŚ ŶŽƌ ĞŶĨŽƌĐĞĚ ƐƚƌŝĐƚůǇ ĞŶŽƵŐŚ ? ?ŽĨŝŶŐĞƌ ?  ? ? ? ? ? Ɖ ? ? ? ? dŚĞ ƵƌŽƉĞĂŶ
Stabilization Mechanism (ESM) adopted on May 9
th
 2010, together with supporting 
measures of the ECB, were significant steps towards solving the current fiscal crisis within 
ƚŚĞƵƌŽǌŽŶĞ ?,ŽǁĞǀĞƌ ?ƚŚĞƐĞƐƚĞƉƐŚĂǀĞůĞĚƚŽ “ĂĚĞĐůŝŶĞŽĨƌĞƉƵƚĂƚŝŽŶŝŶƚŚĞĐĂƐĞŽĨƚŚĞ
ĂŶĚĂǁĞĂŬĞŶŝŶŐŽĨ ŝŶĐĞŶƚŝǀĞƐĨŽƌ ĨŝƐĐĂůĐŽŶƐŽůŝĚĂƚŝŽŶ ?  ?ŽĨŝŶŐĞƌ ?  ? ? ? ? ?Ɖ ? ? ? ?KǀĞƌƚŚĞ
coming years, it remains to be seen if EU regulators can collectively take a more stricter and 
proactive stance on Eurozone member states fiscal matters, and if fiscal deficits can be 
significantly reduced so as to ensure low and stable inflation rates over the long-term.      
5. EU Preferential Trade AŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? 
 “WƌĞĨĞƌĞŶƚŝĂůƚƌĂĚĞĂŐƌĞĞŵĞŶƚƐ ?WdƐ ?ĐŽŵƉƌŝƐĞĂǀĂƌŝĞƚǇŽĨƵŶŝůĂƚĞƌĂů ?ďŝůĂƚĞƌĂů ?Žƌregional 
arrangements which favor member parties over non-members by extending tariff and other 
ŶŽŶƚĂƌŝĨĨƉƌĞĨĞƌĞŶĐĞƐ ? ?ŚĞĂƌŶ ? ? ? ? ? ?Ɖ ? ? ? ?/ŶƚŚĞƉŽƐƚ-war period, the EU has been central 
ƚŽƚŚĞƉƌŽůŝĨĞƌĂƚŝŽŶŽĨWd ?Ɛ ?ƚŚĞhŝƚƐĞůĨ ŝƐƚŚĞǁŽƌůĚ ?Ɛ ůĂƌŐĞƐƚƉƌĞĨĞƌĞŶƚŝĂůĂŐƌĞĞŵĞŶƚ ?ƚ
present, the EU has most-favored-nation (MFN) trading status with ten countries: Australia, 
Canada, Taiwan, Hong Kong, China, Japan, Republic of Korea, New Zealand, Singapore, and 
ƚŚĞ hŶŝƚĞĚ ^ƚĂƚĞƐ ? dŚĞƐĞ ƚĞŶ ƐƚĂƚĞƐ ĂĐĐŽƵŶƚĞĚ ĨŽƌ  ? ? ? ?A? ŽĨ ƚŚĞ h ?Ɛ ƚŽƚĂů ŵĞƌĐŚĂŶĚŝƐĞ
imports in 2009, up from 40.4% in 2008 (Ahearn, 2010).  
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dŚĞh ?ƐWdƐŚĂǀĞƵŶƚŝůŶŽǁďĞĞŶ “ŵĂŝŶůǇĐŚĂƌĂĐƚĞƌŝǌĞĚďǇdifferentiation, flexibility, and 
relatively modest ambition in terms of market-ŽƉĞŶŝŶŐ ?  ?ŚĞĂƌŶ ? ? ? ? ? ?Ɖ ? ? ? ? ?dŚĞĐŽŶƚĞŶƚ
of agreements has varied based on numerous factors: level of economic development of 
partners, importance vis-à-vis security concerns, sectors that constitute competitive 
challenges. With regard to pharmaceuticals, future trade agreements will likely contain 
clauses that will protect intellectual property rights e.g. in an EU-India trade agreement (not 
yet finalized), transnational compĂŶŝĞƐ ĨƌŽŵ ƚŚĞ h ǁŽƵůĚ ƉƌŽŵŽƚĞ  “ĚĂƚĂ ĞǆĐůƵƐŝǀŝƚǇ
ƉƌŽƚĞĐƚŝŽŶ ?ǁŚŝĐŚǁŽƵůĚŐŝǀĞƚŚĞŵĞǆĐůƵƐŝǀĞƌŝŐŚƚƐŽǀĞƌƚŚĞŝƌƚĞƐƚĚĂƚĂĨŽƌĂƉĞƌŝŽĚŽĨ ?-10 
years (Paulus, 2009, p. 7). This scenario would create delays in competition from Indian 
generic drug manufacturers seeking to develop cheaper versions of patent protected drugs 
for domestic sale. On the other hand, exports to the EU of drugs whose patents have 
already expired will likely increase as a result of an EU-India free trade pact.    
6. EU Patent Protection 
  “WĂƚĞŶƚƐ ƉƌŽǀŝĚĞ ƚŚĞ ƉĂƚĞŶƚ ŽǁŶĞƌ ǁŝƚŚ ƚŚĞ ůĞŐĂů ŵĞĂŶƐ ƚŽ ƉƌĞǀĞŶƚ ŽƚŚĞƌƐ ĨƌŽŵ ŵĂŬŝŶŐ ?
using, or selling the new invention for a limited period of time, subject to a number of 
ĞǆĐĞƉƚŝŽŶƐ ?  ?ǁǁǁ ?ƵƌŽƉĂ ?Ƶ ? ? dŚĞ tŽƌůĚ dƌĂĚĞ KƌŐĂŶŝǌĂƚŝŽ  dZ/W^ ĂŐƌĞĞŵĞŶƚ  ?dƌĂĚĞ-
Related Aspects of Intellectual Property Rights) identifies the protection period as twenty 
years, and over this period, inventions can be protected whether they are a product or a 
process. The TRIPS Agreement makes provision for limited exceptions to patent rights: the 
research exception (researchers are allowed to use a patented invention to advance science 
ĂŶĚ ĨĂĐŝůŝƚĂƚĞ ƚĞĐŚŶŽůŽŐǇ ƚƌĂŶƐĨĞƌ ? ĂŶĚ ƚŚĞ  “WŽůĂƌ ƉƌŽǀŝƐ ŽŶ ?  ?ƚŽ ƐƉĞĞĚ ƵƉ ƚŚĞ ƉƌŽĐĞƐƐ ŽĨ
marketing a generic drug). Additionally, the TRIPS agreement offers flexibility vis-à-vis 
compulsory licensing and parallel imports in an effort towards striking a balance between 
promoting access to existing drugs and promoting R & D for new drug development. In 
ƐƵŵŵĂƌǇ ? ƚŚĞ ĂŐƌĞĞŵĞŶƚ  “ĂŝŵƐ ƚŽ ĞŶƐƵƌĞ ƚŚĂƚ ĂĚĞƋƵĂƚe rules on the protection of 
ŝŶƚĞůůĞĐƚƵĂů ƉƌŽƉĞƌƚǇ ĂƌĞ ĂƉƉůŝĞĚ ŝŶ Ăůů  ?tdK ? ŵĞŵďĞƌĐŽƵŶƚƌŝĞƐ ?  ?ǁǁǁ ?ƵƌŽƉĂ ?Ƶ ? ?  /Ŷ
ĐŽŵƉĂƌŝƐŽŶƚŽƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ ?ƚŚĞhŚĂƐƌĞĐĞŶƚůǇďĞĞŶŵƵĐŚŵŽƌĞĂĐƚŝǀĞŝŶ “ĂĚĚƌĞƐƐŝŶŐ
the consequences of what they perceive as imperfect intellectual property (IP) laws, thus 
ƌĞƐŚĂƉŝŶŐƚŚĞƐƵďƐƚĂŶƚŝǀĞƐƚĂŶĚĂƌĚƐĨŽƌ/WƉƌŽƚĞĐƚŝŽŶ ? ?ǌĂƉƌĂĐŬĂ ? ? ? ? ? ?Ɖ ?ŝǆ ? ?dŚĞŐŽĂůŽĨ
the EU vis-à-vis IP protection policies is to stimulate innovation and to increase competition 
so as to spur economic growth. Even though member states of the EU have IP protection 
regulatory power, this power has been significantly eroded by EU competition law; laws of 
member states may be and have been challenged by EU regulators. Interviewee Angela 
Farrell is of the opinion that there should be harmonization across the EU with regard to 
Patent protection as most requirements across the region are standardized and are not 
significantly different. Within the EU pharmaceutical sector, the case of AstraZeneca shed 
some light on the stance that regulators will be taking against dominant pharma companies. 
The ruling against Astra Zeneca ŝŶĚŝĐĂƚĞĚ  “ƚŚĂƚ Ă ĚŽŵŝŶĂŶƚ ĐŽŵƉĂŶǇ ŵƵƐƚ ƌĞĨƌĂŝŶ ĨƌŽŵ
ĞǆƉůŽŝƚŝŶŐ ƵŶĐĞƌƚĂŝŶƚŝĞƐ ŝŶ ĂƉƉůŝĐĂďůĞ ůĂǁƐ ƚŽ ƉƌĞƐĞƌǀĞ ŝƚƐ ĞǆĐůƵƐŝǀĞ ƌŝŐŚƚƐ ? ĂŶĚ ƚŚĂƚ
 “ĂĐƋƵŝƐŝtion and enforcement of IP rights will be subjected to greater antitrust scrutiny in 
ƚŚĞh ? ?ǌĂƉƌĂĐŬĂ ? ? ? ? ? ?Ɖ ?ǆŝ ? ? 
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7. EU Price Regulations 
There is an important distinction to make with regard to price regulation in pharmaceutical 
markets: products that need a prescription to be sold, and products that do not (Barros, 
2010). For pharmaceutical products that do not need a prescription (over the counter), the 
patient may decide which product to purchase based on prices. For products that need a 
prescription, the physician is the crucial decision maker, and regulators can provide 
incentives to physicians to prescribe lower cost products. Additionally, a distinction can be 
made with regard to pharmaceutical products under patent protection and those whose 
patents have expired. In the latter case, price regulation systems can utilize competition 
from generics as a way to bring prices down.  It is often the case that for over the counter 
products price regulation does not exist. The strongest form of intervention in the case of 
prescribed products is governments setting the prices/imposing price caps. There are also 
indirect price controls such as rate-of-return regulations, and where competition between 
branded drugs and generics exists, reference pricing systems exist in numerous countries 
(Barros, 2010). There are also some countries which regulate prices in cases where 
competition exists between generics and branded drugs. In countries with complete health 
insurance coverage, pharmaceutical companies set the highest possible prices because no 
additional demand is created even though price competition exists. In Europe, several 
countries have opted for international referencing rules whereby the price of a 
pharmaceutical product is determined by the price in a set of reference countries. With 
regard to the entry of generics into a market, the existence of price regulations in a 
particular country poses as a hindrance to the entry of generics into the country.  In 
summary, countries in Europe use two main mechanisms for price regulation: purely 
administrative measures (such as direct price controls) and market-based interventions 
(such as reference pricing). Recent trends in Europe are more towards market-based 
interventions, but there are still countries that utilize administrative measures e.g. on May 
3
rd
 2010, Greece imposed a weighted average of 21.5% price reductions on a total of 12,500 
medicines (2,500 originator branded products and 10,000 generic products) in an effort to 
save 1.9 billion euros annually
1
.  On the issue of the future prospects of harmonization vis-à-
ǀŝƐƉƌŝĐĞƌĞŐƵůĂƚŝŽŶƐĂĐƌŽƐƐƚŚĞh ? ŝŶƚĞƌǀŝĞǁĞĞ ?ƐŶŐĞůĂ&ĂƌƌĞůů ?'ƌĞŐŽƌ^ŝĞďĞƌƚĂŶĚ,ŝůůĂƌǇ
Jones were extremely skeptical.    
8. EU Political Stability 
The recent global financial crisis as well as the debt crisis in Greece has exposed fractures 
vis-à-vis political stability within the European Union. Additionally, events within specific 
European countries have also shed light on increasing levels of apprehension about political 
unity within the EU e.g. In June 2009, a ruling by Germany's constitutional court on whether 
the European Union's Lisbon treaty was compatible with German law asserted 
unambiguously that the EU "remains an association of sovereign states" and that the 
European parliament "is not a body of representation of a sovereign European people" 
 ?ĂƌďĞƌ ?  ? ? ? ? ? ? ƵƌƌĞŶƚ ƚƌĞŶĚƐ ƐƚƌŽŶŐůǇ ŝŶĚŝĐĂƚĞ ƚŚĂƚ “ƵƌŽƉĞ ŝƐ ƵŶƌĂǀĞůŝŶŐ ŝŶ Ă ƚĂŶŐůĞ ŽĨ
                                                             
1Greece puts into effect draconian new drug pricing regulations, despite protests from industry 
(www.thepharmaletter.com).  
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ŶĂƚŝŽŶĂů ŝŶƚĞƌĞƐƚƐ ?  ?^ƚĞƉŚĞŶƐ ?  ? ? ? ? ? ? ǀĞŶ ƚŚŽƵŐŚ ĨƌĂĐƚƵƌĞƐ ĂƌĞ ĨŽƌŵŝŶŐ ǁŝƚŚŝŶ ƚŚĞ ƵŶŝŽŶ ?
there are many issues which call for member states within the EU to act together. These 
include the aforementioned financial and monetary crises, as well as issues such as global 
warming, terrorism, uncontrolled migration, a newly assertive Russia, the emergence of 
ecoŶŽŵŝĐƉŽǁĞƌŚŽƵƐĞƐŝŶƐŝĂ ?ŶĂŵĞůǇŚŝŶĂĂŶĚ/ŶĚŝĂ ? ?ƚŚĞǁĂƌŝŶĨŐŚĂŶŝƐƚĂŶ ?ĂŶĚ/ƌĂŶ ?Ɛ
nuclear long-term ambitions. Many experts are pointing towards a lack of political 
leadership within the EU as a key problem area. Politicians within EU member states are 
trending more towards sacrificing long-term European strategic gains for short-term 
national tactical gains as they try to shelter their anxious voters from the insecurities that 
are becoming evident as a consequence of a borderless Europe. With regard to unity within 
ƚŚĞh ? “ƚŚĞƌŝƐŬŝƐŶŽƚƐŽŵƵĐŚŽĨĂŐƌĞĂƚƌƵƉƚƵƌĞ- though if Greece defaults the immediate 
ƐŚŽĐŬƐ ǁŝůů ďĞ ƉƌŽĨŽƵŶĚ ?  ?^ƚĞƉŚĞŶƐ ?  ? ? ? ? ? ? WŽůŝƚŝĐĂů ƐƚĂďŝůŝƚǇ ǁŝƚŚŝŶ ƚŚĞ h ŝƐ ŝŶƚƌŝŶƐŝĐĂůůǇ
linked to how united member states can be heading into the future. The more fractured the 
union becomes, the greater the risk of long-term instability within the region will be 
9. EU War & Conflicts 
dŚĞ ƵƌŽƉĞĂŶ hŶŝŽŶ  ?h ? ĐůĂŝŵƐ ĨŽƌ ŝƚƐĞůĨ ƚŚĞ ƐƚĂƚƵƐŽĨ Ă  ‘ǁŽƌůĚ ƉůĂǇĞƌ ?2 and the explicit 
stated goal of the EU ŝƐƚŽ “ĂĐƚĂƐĂĨŽƌĐĞĨŽƌƐƚĂďŝůŝƚǇ ?ĐŽŽƉĞƌĂƚŝŽŶĂŶĚƵŶĚĞƌƐƚĂŶĚŝŶŐŝŶƚŚĞ
ǁŝĚĞƌ ǁŽƌůĚ ?  ?ǁǁǁ ?ƵƌŽƉĂ ?Ƶ ? ? /Ŷ  ? ? ? ? ? ĞĨĨŽƌƚƐ ƚŽ ĂƚƚĂŝŶ ŵŽƌĞ ƵŶŝƚǇ ǁĞƌĞ ĨŽƌŵĂůŝƐĞĚ
through the Common Foreign and Security policy (CFSP) in the treaty of Maastricht. As a 
result of later conflicts in the Balkans and in Africa, the EU created a European Security and 
ĞĨĞŶƐĞWŽůŝĐǇ ?^W ?ƵŶĚĞƌǁŚŝĐŚ “ŵŝůŝƚĂƌǇŽƌƉŽůŝĐĞĨŽƌĐĞƐĐĂŶďĞƐĞŶƚƚŽĂƌĞĂƐŽĨĐƌŝƐŝƐƚŽ
carry out humanitarian operations, peacekeeping, crisis management and even 
ƉĞĂĐĞŵĂŬŝŶŐ ?  ?ǁǁǁ ?ƵƌŽƉĂ ?Ƶ ? ? /ƚ ŝƐ ŝŵƉŽƌƚĂŶƚƚŽŶŽƚĞŚĞƌĞ ƚŚĂƚ ƚŚĞhĚŽĞƐŶŽƚŚĂǀĞĂ
ŵŝůŝƚĂƌǇĨŽƌĐĞŽĨŝƚƐŽǁŶ ?ďƵƚŝŶƐƚĞĂĚƌĞůŝĞƐŽŶŵĞŵďĞƌƐƚĂƚĞƐ ?ŵŝůŝƚĂƌǇƵŶŝƚƐĂƐƉĂƌƚŽĨhEŽƌ
NATO forces. Diplomacy is seen as a key approach by the EU, and military intervention is 
seen as more of a peace-keeping initiative so as to address the root cause/s of current or 
potential future conflicts. The EU as an entity is currently involved in numerous global 
diplomatic efforts e.g. the situation in Iraq; the Israel-Palestine conflict; the nuclear 
ambitions of Iran; tensions between North and South Korea, missions in the Balkans etc. 
Having said this, when it comes to foreign policy  W especially security-related aspects, the 
ĂƚƚĂŝŶŵĞŶƚŽĨƚŚĞh ?ƐŐŽĂůƐĂŶĚŽďũĞĐƚŝǀĞƐĚepends on unanimous agreement between all 
27 member states. Member states have greatly differing conceptions of what security 
ŵĞĂŶƐ ? ĂŶĚ ŵĂŶǇ ĐŽŶƐƚŝƚƵƚŝŽŶĂů ƚŚĞŽƌŝƐƚƐ ŚĂǀĞ ĂĐŬŶŽǁůĞĚŐĞĚ ƚŚĂƚ  “ĂŶ ƵŶƵƐƵĂů ĚĞŐƌĞĞ
ŽĨ QŝŶĚĞƉĞŶĚĞŶĐĞĂŶĚƐĞĐƌĞĐǇŽĨĞǆĞĐƵƚŝǀĞĂĐƚŝŽŶ in foreign and military affairs was allowed 
ŝŶ ƚŚĞ ŶĂŵĞ ŽĨ ƚŚĞ ŶĂƚŝŽŶĂů ŝŶƚĞƌĞƐƚ ?  ?DĞŶŽŶ ?  ? ? ? ? ? Ɖ   ? ? ? ? dŚĞƌĞ ŝƐ ĨƌĞĞĚŽŵ ĂŵŽŶŐ
member states to choose from a variety of instruments and arenas to achieve their national 
security objectives; states can act on their own authority e.g. the UK in Iraq, via NATO e.g. 
the Kosovo intervention, via the EU using NATO e.g. the EU mission in Macedonia, or using 
the EU alone e.g. in the Democratic Republic of Congo (Menon, 2010, p. 81). Critics of the 
approaches the EU has taken towards conflict resolution in numerous cases have pointed 
                                                             
2European Commission, A World-Player - ǯȋ
Commission,2004). 
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out that because of a merry-go round in foreign policy the EU is not taken credibly as a 
player in global conflict management scenarios
3
.  
10. EU Market Intervention/s 
Currently in the EU, wiƚŚƌĞŐĂƌĚƚŽŐŽǀĞƌŶŵĞŶƚŝŶƚĞƌǀĞŶƚŝŽŶŝŶƚŽƚŚĞĨƌĞĞŵĂƌŬĞƚ ? “ƚŚĞŐƌĞĂƚ
majority of countries have some form of intervention, be it price controls, profit limits, 
ƌĞŝŵďƵƌƐĞŵĞŶƚ ůĞǀĞůƐ ƚŽ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐŽŶƐƵŵƉƚŝŽŶ ? ĞƚĐ ? ?  ?ĂƌƌŽƐ ?  ? ? ? ? ? Ɖ ? ? ? ? dŚĞ ŵĂŝŶ
objective of interventions is cost containment, because health care expenditures have been 
growing faster than GDP in most European countries. Intervention strategies have been 
focused on the demand as well as supply side of the market, and some measures have been 
ĂŝŵĞĚĂƚƌĞĚƵĐŝŶŐƚŚĞƉŚĂƌŵĂĐĞƵƚŝĐĂůƐŝŶĚƵƐƚƌǇŵĂƌŬĞƚƉŽǁĞƌ ? “ĞŵĂŶĚ-side interventions 
ĂƌĞ ĂŝŵĞĚ Ăƚ ƉĂƚŝĞŶƚƐ ĂŶĚ ƉŚǇƐŝĐŝĂŶƐ ? ǁŚŝůĞ ŽŶ ƚŚĞ ƐƵƉƉůǇ ƐŝĚĞ ?  “ƉƌŝĐĞ ĐŽŶƚƌŽůƐ ? ƉƌŽĨŝƚ
controls, and different layers of administrative authorizations for reimbursement of 
ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĞǆƉĞŶĚŝƚƵƌĞƐ ďǇ ƉĂƚŝĞŶƚƐ ŚĂǀĞ ďĞĞŶ ĞǆƉĞƌŝŵĞŶƚĞĚ ǁŝƚŚ ?  ?ĂƌƌŽƐ ?  ? ? ? ? ? Ɖ ?
8). Profit control as an intervention mechanism is used only in the UK, while margins are 
administratively set for retailers (pharmacies) and wholesalers in Denmark and Portugal. 
Reference pricing (as a mechanism of intervention in the free market) is quite common, and 
this occurs at both internal (within a country) and external levels (based on prices outside 
the country). Prescription practices are non-mandatory (i.e. not forced upon member states 
by EU regulators), and therefore these practices vary between member states and 
consequently affect levels of generics uptake. There is also the aspect of insurance coverage 
whereby third-party payers (insurance companies, sickness funds, and national health 
services) that are directly managed by governments affect the market significantly. The 
existence of insurance coverage leads to overconsumption and therefore overspending 
within the system (Barros, 2010). The trends that have been gaining momentum within the 
EU in recent years include: more market interventions by governments on the demand-side, 
cost-sharing (where patients pay a certain percentage of the bill), and external reference 
pricing. Additionally, policy makers within the EU have adopted numerous measures aimed 
at promoting generics as a way to increase competition within the marketplace.    
11. EU Tax Policy 
The European Commission's tax policy strategy has been explained in a Communication of 
23 May 2001 on "Tax policy in the European Union - Priorities for the years ahead" 
(Europa.eu). In this Communication, the commission explicitly states that there is no need 
ĨŽƌĂŶĂĐƌŽƐƐƚŚĞďŽĂƌĚŚĂƌŵŽŶŝǌĂƚŝŽŶŽĨŵĞŵďĞƌƐƚĂƚĞƐ ?ƚĂǆƐǇƐƚĞŵƐ ?dŚĞƌĞĨŽƌĞ ?ŵĞŵďĞƌ
states can freely choose the tax systems that they consider most appropriate based on their 
own preferences. The EU will only act (vis-à-vis tax policy) in cases where action/s by 
member states are unable to provide for effective solutions, and the general view is that 
better co-ordination of national policies can solve most tax-related problems. The goal of 
the EU is to focus on the elimination of tax obstacles related to all forms of cross-border 
economic activities as well as the eradication of harmful tax competition practices by 
member states. Additionally, the EU is determined to ensure that tax policies support wider 
EU policy goals stated in agreements such as the Lisbon Growth and Jobs strategy as well as 
                                                             
3 Gaza war shines spotlight on EU foreign policy (euobserver.com). 
Page 87 of 143 
objectives stated in agreements on the environment and energy.  With regard to company 
tax policy, multinational firms are presently filing separate accounts in each country that 
they operate in and operating on the principle of separate accounting, and this, in the view 
of the Commission, is extremely inefficient. Additionally, this practice leads to profit shifting 
to low-tax jurisdictions thereby creating disputes amongst governments and firms on the 
appropriate transfer prices for intra-company transactions (Bettendorf et. al., 2009). The 
Commission believes ƚŚĂƚ “ƚŚĞŽŶůǇƐǇƐƚĞŵĂƚŝĐǁĂǇƚŽĂĚĚƌĞƐƐƚŚĞƵŶĚĞƌůǇŝŶŐƚĂǆŽďƐƚĂĐůĞƐ
which exist for companies operating in more than one Member State in the Internal Market 
is to provide companies with a consolidated corporate tax base for their EU-ǁŝĚĞĂĐƚŝǀŝƚŝĞƐ ?
and presently, a Common Consolidated Corporate Tax Base Working Group (CCCTB WG) has 
been set up by the Commission to achieve this objective (Europa.eu).  
12. EU Trade Barriers and Tariffs 
The European Union Council Regulation (EC) No 1110/1999 of 10 May 1999 states that 
 “ĚƵƚǇ-free treatment should be given to designated pharmaceutical active ingredients 
bearing an international non-ƉƌŽƉƌŝĞƚĂƌǇŶĂŵĞ  ?/EE ?ĨƌŽŵƚŚĞtŽƌůĚ,ĞĂůƚŚKƌŐĂŶŝǌĂƚŝŽŶ ?
ĂŶĚ ƚŚĂƚ  “ĂĚĚŝƚŝŽŶĂů /EEƐ ĂŶĚ ƉƌŽĚƵĐƚƐ ƵƐĞĚ ĨŽƌ ƉƌŽĚƵĐƚŝŽŶ ĂŶĚ ŵĂŶƵĨĂĐƚƵƌĞ of finished 
pharmaceutical products should be granted duty-ĨƌĞĞ ƚƌĞĂƚŵĞŶƚ ?  ?ƵƌŽƉĂ ?ĞƵ ? ?,ŽǁĞǀĞƌ ?Ă
case study that was conducted on non-ƚĂƌŝĨĨďĂƌƌŝĞƌƐ ?Ed ?Ɛ ?ƚŚĂƚĂĨĨĞĐƚĞĚ/ŶĚŝĂ ?ƐĞǆƉŽƌƚƐŽĨ
pharmaceuticals to the EU concluded that, in general, Indian exporters faced numerous 
Ed ?Ɛ ƌĞůĂƚĞĚ ƚŽ  ?ŝ ? ƉĂĐŬĂŐŝŶŐ ĂŶĚ ůĂďĞůŝŶŐ ƌĞŐƵůĂƚŝŽŶƐ ?ŝŝ ? ƐƚĂŶĚĂƌĚƐ ?  ?ŝŝŝ ? ƵŶŝĨŽƌŵŝƚǇ
requirements, (iv) labor standards, (v) documentation and related procedures and (vi) 
company and product registration
4
. It is usually the case that when tariffs are eliminated by 
countries, wide-ƌĂŶŐŝŶŐ Ed ?Ɛ ĂƌĞ ŝŶƚƌŽĚƵĐĞĚ ĂƐ Ă ŵĞĂŶƐ ŽĨ ƉƌŽƚĞĐƚŝŶŐ ĚŽŵĞƐƚŝĐ
manufacturers. NTBs have mushroomed from a mere 389 in 1995 to 1,895 in 2009 (Dhar, 
 ? ? ? ? ?ĂŶĚĂĚĚŝƚŝŽŶĂůůǇ ?Ed ?ƐĂƌĞĂůƐŽĐƌĞĞƉŝŶŐŝŶƚŽWƌĞĨĞƌĞŶƚŝĂůdƌĂĚĞŐƌĞĞŵĞŶƚƐ ?Wd ?Ɛ ? ?
If the European Union wants to promote free trade and competition within the EU then 
non-tariff barriers will have to be eliminated.  
 
1.2 ECONOMIC FACTORS 
1. EU Economic Growth Rate 
As a result of the recent global financial crisis, GDP rates started to contract within EU states 
around the second quarter of 2008, leading to five consecutive quarters of contractions; the 
recession experienced within the EU was the deepest, longest and most broad-based in the 
history of the EU
5
.  Percentage rates of GDP contraction ranged from -2¼% in France and  
-5% in Germany and Italy to around -7½% in Slovenia and Ireland. Outside the euro area, 
where contraction rates were more severe than within the euro area, Denmark, Sweden 
and the UK registered contraction rates of around -4½%. The contraction rates were mainly 
                                                             
4ǯ Ȃ India Today (May 1st, 2010). 
5 European Economic Forecast Ȃ Autumn 2009 (European Commission Economic and Financial Affairs). 
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as a result of losses in trade and investment that came about as a result of the global 
financial crisis. Additionally, other factors of significant importance vis-à-vis the fall in GDP 
growth rates were: the collapse in fixed capital formation and strong stock liquidation. With 
regard to private consumption spending, the impact was not that significant  W in fact, 
because spending rates did not decline by much, this may have in fact served as a stabilizing 
factor. Increases in public spending and the forceful policy responses to the financial crisis 
by governments also played a big role in stabilizing GDP rates. External demand for EU 
products and services from high growth rate economies outside the EU (such as in India and 
China) also helped contraction rates from increasing even further. At present, the EU is 
going through a transition phase, and going into the future, uncertainty remains high. 
/ŶƚĞƌǀŝĞǁĞĞ ?Ɛ 'ƌĞŐŽƌ ^ŝĞďĞƌƚ ĂŶĚ :ŽŶĂƚhan Farrington were of the opinion that economic 
growth over the foreseeable future will remain flat. As economies outside the EU recover 
from the global financial crisis, and exports from EU member states to these economies 
continue to increase, GDP growth rates within the EU should start to rebound. The most 
crucial factor with regard to GDP rates going into the future will be whether governments 
within EU member states can get their deficits and debts under control i.e. all member 
states will need to robustly and effectively address the issue of sustainability of public 
finances. Other factors of significant importance include: private domestic spending rates 
within EU member states, the adverse effects of ageing populations, levels of 
unemployment, and rising oil and other commodity prices. There is also the issue of 
divergences within economies across all EU states; all member state economies will need to 
work collectively towards eradicating persistent divergences in competitiveness positions. 
This scenario will be ongoing into the long-term as new member states are allowed 
accession into the EU, and the domestic as well as external environment becomes 
increasingly competitive.  
2. EU Unemployment 
Eurostat estimates that 23.062 million men and women in the EU, of whom 15.771 million 
were in the euro area (EA-16), were unemployed in June 2010. The euro area 
unemployment rate (seasonally-adjusted) was 10.0%, and among EU member states, the 
lowest unemployment rates were recorded in Austria (3.9%) and in the Netherlands (4.4%), 
and the highest rates were in Spain and Latvia (20.0%), and Estonia (19.0%). The Youth 
(under 25s) unemployment rate was 19.6% in the euro area and 20.3% in the EU. It is 
important to note that unemployment levels move in a cyclical way (related to business 
cycles) and that factors such as labor market policies as well as changes in demographics 
have an impact on these rates over longer periods of time. Long-term unemployment is one 
of the major concerns of policymakers  W there are short-term financial and social effects, 
and over longer periods, high levels of unemployment can negatively affect social cohesion 
as well as economic growth rates. Additionally, social tensions related to high levels of 
unemployment can lead to increased protectionist measures by governments. There can 
also be increased pressure vis-à-vis government spending on social benefits and reduced tax 
revenues, and these aspects can significantly impact government budget and debt levels. 
 “tŝƚŚŝŶƚŚĞĐŽŶƚĞǆƚŽĨƚŚĞƵƌŽƉĞan employment strategy, there are a number of measures 
that are designed to help encourage people to remain in work or find a new job, including: 
the promotion of a lifecycle approach to work, encouraging lifelong learning, improving 
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support to those seekiŶŐ Ă ũŽď ? ĂƐ ǁĞůů ĂƐ ĞŶƐƵƌŝŶŐ ĞƋƵĂů ŽƉƉŽƌƚƵŶŝƚŝĞƐ ?  ?ƵƌŽƉĞĂŶ
Commission). Reducing volatility in unemployment rates has also been a key aim of 
policymakers and currently, the highest levels of volatility have been registered by regions 
on the EU periphery, while lower levels of variability are generally located in the central 
areas of the Union (Ezcurra, 2010, p.13). In order to achieve this aim, policy-makers often 
ĂƚƚĞŵƉƚ ƚŽĂƚƚƌĂĐƚŶĞǁ ŝŶĚƵƐƚƌŝĞƐ ƚŚĂƚǁŝůůĚŝǀĞƌƐŝĨǇ ƚŚĞŝƌƌĞŐŝŽŶ ?ƐĞĐŽŶŽŵŝĐďĂƐĞ  ?ĂůĚǁŝŶ
and Brown, 2004).  
3. EU Outsourcing/Offshoring 
In this era of global competition, firms have been facing increasing cost pressures, and this 
has in turn led to increased outsourcing. There are primarily two motives for outsourcing 
according to Alajaasko (2009), and these are reduction of labor costs and access to new 
markets. A recent survey conducted by Eurostat (the statistical office of the European 
Communities) presented some important findings on the topic of outsourcing by European 
firms (Neureiter, 2010). The period of the survey was 2001-2006, and numerous firms (from 
various sectors) in twelve European states (one non-EU) participated on a voluntary basis. 
Of the firms surveyed, about 16% reported to be engaged in international sourcing; 
countries where outsourcing was most predominant included Ireland, the United Kingdom, 
Denmark, Finland and Slovenia. Most of the international sourcing took place intra- EU, and 
the manufacturing sector was most impacted. In fact, overall employment in the 
manufacturiŶŐƐĞĐƚŽƌƐŽĨƚŚĞƵƌŽƉĞĂŶĐŽƵŶƚƌŝĞƐĐŽǀĞƌĞĚ ŝŶƚŚĞƵƌŽƐƚĂƚƐƵƌǀĞǇ  “ĚĞĐůŝŶĞĚ
ďǇ  ? ? ? ? ĨƌŽŵ  ? ? ? ? ? ? ? ? ? ƚŽ  ? ? ? ? ? ? ? ? ? ?  ?EĞƵƌĞŝƚĞƌ ?  ? ? ? ? ? ? ŵŽŶŐ ďƵƐŝŶĞƐƐ ƐƵƉƉŽƌƚ
functions, distribution and logistics as well as marketing and (after) sales were most 
commonly outsourced. High skill jobs were outsourced by firms only in instances where 
close proximity was not an important aspect with regard to service provision (Blinder 2007). 
Additionally, job losses within the high-skill category were predominant in sectors and 
countries where most firms rated market access as the most important motive for 
international sourcing. So will firms within the EU continue to outsource in the patterns 
identified above? Numerous factors such as high unemployment rates, ageing populations, 
increased competition etc. may affect outsourcing decisions in the future. At present, EU 
regulators have not drafted any comprehensive legislation on outsourcing practices 
amongst member states, but as the factors identified above continue to have a negative 
impact on member state economies, there may be a need to do so. With regard to the 
generics industry, there are clear manufacturing cost advantages in countries like India. At 
ƉƌĞƐĞŶƚ ? /ŶĚŝĂŚĂƐ  “ƚŚĞŚŝŐŚĞƐƚŶƵŵďĞƌŽĨƉŚĂƌŵĂĐĞƵƚŝĐĂůŵĂŶƵĨĂĐƚƵƌŝŶŐƉůĂŶts outside of 
ƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐĂƉƉƌŽǀĞĚďǇƚŚĞĨŽŽĚĂŶĚĚƌƵŐĂĚŵŝŶŝƐƚƌĂƚŝŽŶ ? ?ĂƐŝĂ-manufacturing.com).  
4. EU Infrastructure Quality 
Currently, the EU member states contain 5 million km of paved roads of which 61,600 km 
are motorways; there are 215,400 km of rail lines, of which 107,400 km are electrified; 
navigable inland waterways traverse 41,400 km (European Commission  W Mobility and 
Transport). The long-term goal of the EU is to establish a single multi-modal network that 
integrates land, sea, and air transport networks throughout the EU region. This goal was one 
key element of the Lisbon strategy for competitiveness and employment in Europe. Growth 
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in traffic within the EU, which is expected to double by the year 2020, will require a trans-
European transport network (the initiative has been named TEN-T) as described previously, 
and this network will require an investment to the tune of 500 billion Euros (from 2007-
2020). Funding will be obtained through the implementation of community financial 
instruments and by loans from the European investment bank. At present, there is growing 
ĐŽŶĐĞƌŶƚŚĂƚ “ƚŚĞƉƌŽĐĞƐƐŝƐŶŽƚŐŽŝŶŐĨĂƐƚĞŶŽƵŐŚĂŶd that the ambitious targets will not be 
ƌĞĂĐŚĞĚ ?  ?ƵƌŽĂĐƚŝǀĞ ?ĐŽŵ ? ? Ɛ Ă ƌĞƐƵůƚ ŽĨ ƚŚĞ ƌĞĐĞŶƚ ĞĐŽŶŽŵŝĐ ĚŽǁŶƚƵƌŶ ? ŵĂŶǇ ĐŽƵŶƚƌŝĞƐ
are keeping a tight grip on their wallets, and once again, political will is popping up as a key 
hurdle towards progress on initiatives such as TEN-T. The Kok report, which was presented 
ŝŶ  ? ? ? ? ? ŝĚĞŶƚŝĨŝĞĚ ƚŚĞ ŵĂŝŶ ƌĞĂƐŽŶƐ ĨŽƌ ƐůŽǁ ƉƌŽŐƌĞƐƐ ŽŶ ƚŚĞ >ŝƐďŽŶ ƐƚƌĂƚĞŐǇ ĂƐ  “ĂŶ
overloaded agenda, poor co-ŽƌĚŝŶĂƚŝŽŶĂŶĚĐŽŶĨůŝĐƚŝŶŐƉƌŝŽƌŝƚŝĞƐ ? ?ƵƌŽĂĐƚŝǀĞ ?ĐŽŵ ? ?
5. EU Business Cycles 
Several studies have been conducted on the effects of business cycle volatility vis-à-vis 
effects on long term economic growth rates. In a pre-budget report titled Stability and 
Steady Growth for Britain ? ƚŚĞ ƌŝƚŝƐŚ ŐŽǀĞƌŶŵĞŶƚ ŝƐ ĐůĞĂƌ ŝŶ ŝƚƐ ďĞůŝĞĨ ƚŚĂƚ  “ƚŚĞ ƐŚĂrp 
volatility in output, inflation and interest rates seen in the UK over the past thirty years 
damaged Britain's long-ƚĞƌŵ ŐƌŽǁƚŚ ƉŽƚĞŶƚŝĂů ?  ?,D dƌĞĂƐƵƌǇ ?  ? ? ? ? ? ? /Ŷ Ă ĐŽŵƉƌĞŚĞŶƐŝǀĞ
study covering the period 1961 to 1997, and using data from 24 OECD economies, a 
conclusion was reached that economic growth is damaged by business cycle volatility 
(Kneller & Young, 2001). Other studies have shown that strong links exist between the 
business cycles in the US and in the euro area (Agresti & Mojon, 2001). Within the EU, there 
ĂƌĞ ƉĞƌƐŝƐƚĞŶƚ ĚŝĨĨĞƌĞŶĐĞƐ ŝŶ ůĞǀĞůƐ ŽĨ ĞĐŽŶŽŵŝĐ ĂĐƚŝǀŝƚǇ ďĞƚǁĞĞŶ  ‘ĐŽƌĞ ? ĂŶĚ  ‘ƉĞƌŝƉŚĞƌǇ ?
member states (Giannone et. al., 2008). It is important to note here that Canova, Ciccarelli, 
and Ortega (2008) found no European cycle prior to the mid-80s, while an EU cycle emerges 
in the 1990s that is common to EMU (European Monetary Union) and non-EMU members. 
Since business cycles have hardly changed since the beginning of the EMU, the benefits of a 
common currency vis-à-vis business cycles and long-term growth rates of EMU economies 
ŚĂǀĞŶŽƚďĞĞŶƌĞĂůŝǌĞĚ ?/ŶƚŚĞĂĨŽƌĞŵĞŶƚŝŽŶĞĚ ‘ĐŽƌĞ ?ĐŽŶŽŵŝĞƐ ?ƚŚĞƌĞŵĂǇďĞůĞƐƐǀŽůĂƚŝůŝƚǇ
since levels of GDP per capita and growth rates are highly synchronized, but as a whole, the 
EU has to achieve this same level of synchronicity amongst all 27 member states to achieve 
business cycle stability, and consequently positive long term economic growth trends 
(Giannone et. al., 2008). As more nations are in the pipeline to join the EU over the coming 
years, the challenge within the EU will be to reduce business cycle volatility throughout the 
h  ?ĂŵŽŶŐƐƚ ƚŚĞ  ‘ĐŽƌĞ ?  ‘ƉĞƌŝƉŚĞƌǇ ? ĂƐ ǁĞůů ĂƐ ŶĞǁ ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ƚŽ ĞŶƐƵƌĞ ůŽŶŐ ƚĞƌŵ
benefits with regard to stability and growth.  
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6. EU Disposable and Discretionary Income 
 
Figure 1: Disposable income of private households per inhabitant Source: European 
Commission  W Eurostat  
Figure 1 above contains data collected by Eurostat from 23 EU member states over the 
period 2001-2006. Disposable income is measured in purchasing power consumption 
standards or PPCSs, and the bars on the graphs that represent each country have a 
comparison of PPCSs between Capital regions and National averages. The lowest figure for 
disposable income PPCSs is 3,610 per inhabitant in NE Romania while the highest is 25,403 
in the UK around inner London. Of the 30 regions with the highest levels of disposable 
income PPCSs per inhabitant, 11 are in Germany, 9 in the UK, 4 in Austria, 3 in Italy, and 1 
each in Belgium, France and Spain. The bottom thirty regions include 13 Polish and 7 
Romanian regions, 4 regions in Hungary, 2 in Slovakia, 1 in Greece. It is quite clear to see 
that there are significant variations in levels of disposable income between the original 15 
EU member states and states that gained membership after 2004. On average, disposable 
income in the EU in 2006 amounted to 87.2% of primary income, and this figure was 87.0% 
in 2001, therefore, little change has occurred over the five year period of the survey. This 
signifies that over the five-year period, the scale of state intervention and other transfers 
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hardly changed (Eurostat.ec). However, a measureable trend towards a narrowing of the 
spread in regional values did occur over the five-year period: the difference between the 
highest and lowest values fell from a factor of 8.5 to 7.0 while for primary income the 
difference between regions went up from a factor of 10.4 to 11.0. The challenge for EU 
policymakers would be to reduce disparities in disposable income over all the regions 
surveyed over the coming years.   
7. EU Exchange Rates 
The main goals of the European Union in establishing the EMU was to eliminate exchange 
rate risks, reduce transaction costs and to create exchange rate stability within the region. 
Ten years after the establishment of the monetary union the effort has been successful, 
however, there are some major challenges that lay ahead which if not properly addressed 
may in fact threaten the very existence of the euro-ǌŽŶĞ ?&ŝƌƐƚŽĨĨ ? “ĂĐŽŶƐƚŝƚƵƚŝŽŶĂůƉƌŽďůĞŵ
looms on the horizon as the countries of Central and Eastern Europe qualify for membership 
ŝŶƚŚĞƵƌŽƉĞĂŶŵŽŶĞƚĂƌǇƵŶŝŽŶ ?  ?<ĞŶĞŶ ? ? ? ? ? ?Ɖ ? ? ? ?KŶůǇƚŚƌĞĞƐŵĂůůĐŽƵŶƚƌŝĞƐ  ?^ůŽǀĞŶŝĂ ?
Cyprus, Malta) have qualified for membership into the EMU, and there are other much 
larger countries waŝƚŝŶŐ ŝŶ ƚŚĞ ǁŝŶŐƐ  ?ĐƵƌƌĞŶƚ ĂŶĚ ĨƵƚƵƌĞ h ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ?  “tŝƚŚ ƚŚĞ
ĂĚĚŝƚŝŽŶ ŽĨ ƚŚĞƐĞ ĂŶĚ ŽƚŚĞƌ h ĐŽƵŶƚƌŝĞƐ ? ƚŚĞ  ?Ɛ 'ŽǀĞƌŶŝŶŐ ŽƵŶĐŝů ǁŝůů ďĞĐŽŵĞ
unmanageably large, and the plan adopted by the ECB for rotating membership is, in my 
view, unsatisfactory ?  ?<ĞŶĞŶ ?  ? ? ? ? ? Ɖ ? ? ? ? ĚĚŝƚŝŽŶĂůůǇ ? ďĂŶŬŝŶŐ ĂŶĚ ĨŝŶĂŶĐŝ ů ƐǇƐƚĞŵƐ ŝŶ
Central and Eastern European countries are much more exposed to the consequences of 
mounting flights of capital and currency attacks (Gros, 2010). Furthermore, situations like 
the huge appreciation of the euro in 2006 and 2007 impaired the external competitiveness 
of some euro-area countries such as Spain and Italy, and situations like these in the future 
will call for swift intervention by the ECB to reduce the negative economic impact on certain 
member states economies (Kenen, 2010). Over the long-term, fiscal responsibility and 
discipline, as well as more economic flexibility and political unity are factors that could 
threaten the survival of the euro zone. As we head into the future, there is a likelihood that 
EU member states may revert to their old currencies due to the problems/challenges 
already mentioned. In this scenario, the prospects of achieving numerous objectives within 
the EU (e.g. long-term economic growth across the region) could be severely jeopardized.   
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8. EU Inflation Rates 
 
Table 1: Inflation Rates EU. Source: Commissions (2009). Source Eurostat 
As is evident from the above table 1, inflation rates within the Euro area have been quite 
stable over the period 2005-2010  W with the exception of the period of the global financial 
crisis. In 2008 there was a fear of stagflation (falling economic growth and rising inflation) 
followed by a deflationary period in 2009. The main reasons as to why inflation went up 
drastically from 2007 to 2008 were increases in food and energy prices. The fall in 2009 was 
mainly due to a fall in energy prices as well as downward pressure on producer prices. 
Stability in inflation rates is a key objective for EU policymakers, but since there are 
numerous disparities in economic conditions within the region, the goal of stabilizing 
inflation across the EU becomes ever more challenging. Within CEE (Central and Eastern 
European) member states recently granted EU accession, inflation became a problem to 
reckon with immediately after these states abandoned their centrally planned and largely 
fixed price systems (upon joining the EU), and in fact, inflation has remained a problem to 
the present day (Staehr, 2008). The CEE states that are now a part of the EU have had higher 
ŝŶĨůĂƚŝŽŶƌĂƚĞƐƚŚĂŶƚŚĞ “ŽƌŝŐŝŶĂů ?hŵĞŵďĞƌƐƚĂƚĞƐ ?ĂŶĚƚŚŝƐƐĐĞŶĂƌŝŽŝƐůŝŬĞůǇƚŽŶĞŐĂƚŝǀĞůǇ
affect these countries international competitiveness. In addition to the factors driving 
inflation already identified previously, the higher inflation in the new member countries is 
partly resulting from the catch-up process as capital deepening and high productivity growth 
ŝŶƚŚĞƚƌĂĚĞĚƐĞĐƚŽƌĚƌŝǀĞƵƉŝŶĨůĂƚŝŽŶ ?  ?^ƚĂĞŚƌ ? ? ? ? ? Ɖ ? ? ? ? ?ƐƵŶĐĞƌƚĂŝŶƚǇƉĞƌƐŝƐƚƐ ŝŶŶĞǁ
member states, and as these countries continue to experience higher economic growth 
rates as they play catch-up, inflation could creep up within the EU wide region over the 
coming years. Additionally, energy and food prices are likely to increase in the future as 
global demand rises, and this scenario could also lead to higher inflation rates.     
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9. EU Interest Rates 
Interest rates, set in the euro zone by the European Central Bank, have an enormous effect 
on economic growth rates as well as inflation. When the Euro zone was initially formed, 
 “DŝůƚŽŶ &ƌŝĞĚŵĂŶ ƉƌĞĚŝĐƚĞĚ ƚŚĂƚ ƚŚĞ ŶĞǁ ĞŶƚŝƚǇ ǁŽƵůĚ ĐŽůůĂƉƐĞ ǁŚĞŶ ĨĂĐĞĚ ǁŝƚŚ ĂŶ
economic crisis pitting the interests of one group of countries, against those of another 
ŐƌŽƵƉ ?  ?ŽǇĚ ?  ? ? ? ? ? Ɖ ? ? ? ? &ƌŝĞĚŵĂŶ ?Ɛ ĐŽŶƚĞŶƚŝŽŶ ǁĂƐƚŚĂƚ ǁŚĞŶ ĚŝĨĨicult decisions were 
necessary, policymakers would have to support initiatives favoring larger economies over 
smaller ones. This prediction by Friedman would come true as immediately after the 
formation of the euro zone, the ECB lowered interest rates to make the German and French 
economies (which were slumping at the time) more competitive. This led to severe effects 
on markets in smaller countries like Greece and Spain which were already experiencing high 
rates of inflation at the time; the sudden availability of cheap credit (due to the low interest 
rates) ushered in a wave of spending, and this in turn led to higher inflation and a rapid 
increase in prices and wages.  
 
Figure 2: Long-term Interest Rates in European Countries (2007). Source: Eurostat 
As is evident from the Figure 2, long-term interest rates still vary in the EU across countries, 
ǁŝƚŚ ůŽǁĞƌ ƌĂƚĞƐ ŝŶ ƚŚĞ  “ĐŽƌĞ ? ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ĂŶĚ ŚŝŐĞƌ ƌĂƚĞƐ ŝŶ  “ƉĞƌŝƉŚĞƌǇ ? ƐƚĂƚĞƐ ůŝŬĞ
Romania, Hungary, Estonia, Poland and Latvia. If the EU wants to avert severe effects on 
markets such as described in the case of Greece above, then, interest rates will have to be 
ƐƚƌĞĂŵůŝŶĞĚĂĐƌŽƐƐƚŚĞƌĞŐŝŽŶ ? “>ŽŶŐ-term interest rates are one of the convergence criteria 
indicators for Economic and monetary union, according to Article 121 of the Treaty 
establishing the European Community; Article 4 of the Protocol on the convergence criteria 
annexed to the Treaty states that a Member State has to have an average nominal long-
term interest rate that does not exceed by more than two percentage points that of the 
ƚŚƌĞĞďĞƐƚƉĞƌĨŽƌŵŝŶŐDĞŵďĞƌ^ƚĂƚĞƐŝŶƚĞƌŵƐŽĨƉƌŝĐĞƐƚĂďŝůŝƚǇ ? ?ƵƌŽƉĂ ?ĞƵ ? ? 
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10. Financial Markets 
The financial markets are the pivotal function of a modern economy. By aiming towards an 
increased level of integration, there will be a more efficient allocation of economic 
resources and long term economic performance (European Commission, 2005). It has 
ƚŚĞƌĞĨŽƌĞ ďĞĞŶ ƚŚĞ h ?Ɛ ƉŽůŝĐǇ ƚŽ ĐŽŵƉůĞƚĞ Ă ƐŝŶŐůĞŵĂƌŬĞƚ ŝŶ ĨŝŶĂŶĐŝĂů ƐĞƌǀŝĐĞƐ  ?ďĞŝŶŐ Ă
crucial part of the Lisbon Economic Process
6 ?ĨŽƌĂĚĚƌĞƐƐŝŶŐh ?ƐŐůŽďĂůĐŽŵƉĞƚŝƚŝǀĞŶĞƐƐ ? 
Since the economic crash and subsequent global crisis there have been calls for closer 
monitoring of the financial system and better EU coordination. With the perceived failure of 
the Lisbon Strategy outlined in 2000 (Wyplosz, 2010), many parties have urged a relook at 
the model particularly with the current global economic crisis afflicting the EU. Since the 
collapse of the US investment bank Lehman Brothers in September 2008, there has been no 
shortage of politicians rushing to prescribe what is to be done differently in the financial 
sector in the future (Dullien & Herr, 2010).  
The financial crisis has made it clear that the financial markets are in clear need of reforms 
and far more effective regulations are necessary to govern the future growth of the financial 
markets in the EU. While the topic has now refocused on the Eurozone crisis, the financial 
market regulation at both national and EU level has been experiencing a great deal of 
changes. Strength and confidence in financial markets will need to be re-established as 
pointed out by the Director General (2010). 
The European Commission has presented several draft directives that are undergoing 
evaluation by the decision making bodies around Europe. Unlike the US, the EU has had 
several attempts at harmonizing the financial markets (through the Lisbon Process) albeit 
these efforts have not entirely been successful. While all the financial institutions in Europe 
are very closely linked to each other, there has been a lack of a uniform basic regulation for 
financial supervision as national governments tend to pursue that which is in the best 
interest of their own countries rather than the region as a whole. This therefore allowed 
institutions from neighboring countries to enter into risky transactions in those markets 
with tight supervision but greater access of capital. The European Commission is now letting 
several directives to be considered for legislative purposes. 
1. Higher capital requirements for banks. 
2. Establishment of a European ratings agency that independently evaluates securities 
of issuers. 
3. New rules for Derivatives Trading and Securitization. 
4. Creation of a European System for Financial Supervision (with a Risk Board being set 
up alongside) that issues mandatory instructions to national supervisory authorities. 
                                                             
6The Plan was to an action and development plan for the EU between 2000 and 2010.Its aim was to make the EU "the most 
competitive and dynamic knowledge-based economy in the world capable of sustainable economic growth with more and better 
jobs and greater social cohesion," by 2010.It was set out by the European Council in Lisbon in March 2000 (EUROPA, 2000) 
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This however will be a challenge to the EU as such measures would potentially affect  the 
sovereignty of individual national governments to pursue national policies, something which 
several European nations are not willing to give up as seen in the Greek crisis. Such 
directives are not expected to be introduced by end 2010 with expectations gathering that 
ƚŚĞƐĞ ĚŝƌĞĐƚŝǀĞƐ ƚŚĞŵƐĞůǀĞƐ ǁŝůů ďĞ  ‘ǁĂƚĞƌĞĚ ĚŽǁŶ ? ĨƌŽŵ ƚŚĞŝƌŽƌŝŐŝŶĂů ĨŽƌŵ ŵĂŬŝng them 
 ‘ƚŽŽƚŚůĞƐƐ ?ǀŝƐ-a-vis enforcement purposes (Dullien & Herr, 2010). 
11. Savings Rate 
Savings rate are higher amongst several EU nations as compared to US households in 
general (Harvey, 2004). There has been a decline in recent years as per researcher Tina 
Aridas (2010) from the Global Finance Magazine. Ms. ƌŝĚĂƐŚĂƐƐƚĂƚĞĚƚŚĂƚďĞƚǁĞĞŶ ‘ ? ? ? ?
ĂŶĚ ? ? ? ? ?ƚŚĞƵƌŽƉĞĂŶhŶŝŽŶ ?ƐŚŽƵƐĞŚŽůĚƐĂǀŝŶŐƌĂƚĞǁĂƐůŽǁĞƌƚŚĂŶŝŶƚŚĞĞƵƌŽĂƌĞĂ ?ĚƵĞ
mainly to the low saving rates in the UK and the Baltic countries. The US saving rate was low 
compared with both the EU and the euro area. With the passing of the worst effects of the 
global crisis from 2008, EU households are again faced with the euro confidence crisis that 
ĐŽŶƐƚƌĂŝŶƐ ƚŚĞ ƌĞŐŝŽŶ ?Ɛ ĂďŝůŝƚǇ ƚŽ ƌĞĐŽǀĞƌ ĨĂƐƚĞƌ ƚŚĂŶŽƚher regions (as it struggles with 
unemployment, high deficits and generally bearish economic prospects outlook) (IMF, 
2010). As of July 2010, figure 3 below highlights the EU household savings rate, which is still 
declining as many households face decreasing real disposable incomes. 
 
Figure 3: Household saving rates in Euro area and EU 27 member states. Source Eurostat 
 
The general household will now need to brace itself for further cuts in income as major EU 
member nations embarks on tough public spending cuts (Traynor, 2010). Recovery in 
European economies is expected to be gradual and uneven as most of the savings gain from 
budget cuts is utilized for loan repayments for past debts incurred. 
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1.3 SOCIAL 
1. Demographics 
Based on the latest 2008 projections done by the Commission of the European Communities 
 ? ‘hZ->y ? ? ? ƚŚĞ h ŝƐ ĨĂĐŝŶŐ ƵŶƉƌĞĐĞĚĞŶƚĞĚ ĐŚĂŶŐĞƐ ŝŶ ƚŚĞƌ ŐŝŽŶƐ ƉŽƉƵůĂƚŝŽŶƐ ? dŚŝƐ
development would represent numerous challenges for member state governments as they 
would have to review and adapt existing policies. Demographic ageing, i.e. the increase in 
the proportion of older people, is above all the result of significant economic, social and 
medical progress giving EU citizens the opportunity to live a long life in comfort and security 
which is not withŽƵƚƉƌĞĐĞĚĞŶƚŝŶƚŚĞƌĞŐŝŽŶ ?ƐŚŝƐƚŽƌǇ ?hZ-LEX, 2006). This has become one 
of the main challenges for the EU as the following demographic trends observed throughout 
the member countries with various magnitudes.  
Fertility rate: Fertility rate at the last estimates for 2008 by EUR-LEX stands at just over 1.5 
children with a growth forecast of 1.57 by 2030 (2009, p.21). In all EU countries, the fertility 
rate would likely remain below the natural replacement rate of 2.1 births per woman which 
is the rate needed in order for each generation to replace itself. A period of slow growth, 
and in most cases actual decline in the population of working age people within the region 
ǁŝůů ĐŽŶƐƚƌĂŝŶƚ ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ĂďŝůŝƚŝĞƐ ƚŽ ŐƌŽǁ ĨƌŽŵǁŝƚŚŝŶ  ?ĚƵĞ ƚŽ ŚƵŵĂŶ ĐĂƉŝƚĂů
constraint). A fact illustrated below (Figure 4); despite entry of further new members, the 
rate remains below average required for repopulation. 
 
Figure 4 PhĐŝƚŝǌĞŶƐ ?ĨĞƌƚŝůŝƚǇƌĂƚĞ ? ? ? ?ƚŽ ? ? ? ? 
Mortality rate: The life expectancy has been rising steadily since the 20
th
 Century, with an 
increase of two and a half years per decade. As compared to countries around the world, EU 
citizens hold the record of highest life expectancy (EUR-LEX, 2008). It is undeniable that the 
proportion of EU citizens above the average age of 65 will climb further in time as seen in 
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Graph 6. The EU projects that life expectancy for males would increase by 8.5 years over the 
projection period, from 76 yrs originally in 2008 to 84.5 yrs by 2060 (EUR-LEX, 2009). For 
females, life expectancy at birth would increase by 6.9 years, from 82.1yrs in 2008 to 89yrsin 
2060, marking a narrowing life expectancy gap between both genders. Most of these 
increases in life expectancy will come from recent EU member states (Estonia, Poland, 
Hungary, Slovakia etc). Children in the EU today will face a high chance of living to their 80s 
or 90s in the long-term especially if they are from Western Europe with mid-high socio-
economic status.  
 
Figure 5: Proportion of population aged 65 and over. Source Eurostat 
Net Migration: Migration already plays a predominant role in population growth today. In 
many Member States, the size of net migration determines whether the population still 
grows or has entered a stage of decline (EUR-LEX, 2009). Annual net inflows to the EU are 
assumed to total 59 million people, of which the bulk (46.2 million) would be concentrated 
in the euro area. The trend according to the EUR-LEX study, assumes that this will 
decelerate over the projection period, falling from about 1,680,000 people in 2008 
(equivalent to 0.33% of the EU population) to 980,000 by 2020 and thereafter to some 
800,000 people by 2060 (0.16% of the EU population). Interviews conducted by our project 
team concur with the importance of migration noting that there will be a continual need for 
foreign talent to drive further economic growth in the EU. It is therefore only a matter of 
time for the EU to work towards a harmonized migration policy for its member states. 
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Figure 6: Total acquisitions of citizenship in the EU-27. Source Eurostat 
 
Figure 7: Total acquisitions of citizenship in the EU-27, relative change on previous year. 
Source Eurostat. 
In recent years, Moroccans and Turks represent the largest migrant group with the highest 
number of citizenship recorded in France, Italy and Spain. There has been a slight decline in 
the acquisition of EU citizenship since 2007 with the numbers slightly below 700,000 or 2 % 
in 2008 alone. Researchers have however pointed to the decline as being primarily due to 
the current economic climate and the tightening of immigration rules. This will not be a 
hindrance as making full use of the global labor supply through net migration will be 
increasingly important.  
2. Education 
Education and training have an important place in the Lisbon strategy for jobs and growth 
(European Commission, 2009). EUR-LEX studies expect that the ratio of children and young 
people to the working-age population will shrink over the coming decade. Nonetheless, 
education and training systems in the EU are generally improving. The EU benchmark on 
mathematics, science and technology graduates was already reached before 2005 (refer 
graph 9). New growth has been registered in maths, science and technology graduates 
whose numbers were more than the original target set. However, owing to the trends in 
birth rates, this is likely to become unsustainable unless the birth rate increases or foreign 
skills are imported into the EU.  
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Likewise, benchmarks on early school leaving, completion of upper secondary education and 
lifelong learning were the opposite, with literacy rates amongst young children on the 
decline. The respective countries will now need more effective national policies to address 
this trend of decline. 
 
&ŝŐƵƌĞ ? PEƵŵďĞƌŽĨŐƌĂĚƵĂƚĞƐŝŶDĂƚŚĞŵĂƚŝĐƐ ?^ĐŝĞŶĐĞĂŶĚdĞĐŚŶŽůŽŐǇ ? ‘D^d ? ?ŝŶƚŚĞh ?
Source Eurostat 
3. Entrepreneurial Spirit 
The Commission defines "Entrepreneurship" as 'the mind-set and process [needed] to 
create and develop economic activity by blending risk-taking, creativity and/or innovation 
with sound management, within a new or an existing organization' (EurActiv.Com, 2004). 
^D ?ƐĂƌĞĐŽŶƐŝĚĞƌĞĚƚŚĞďĂĐŬďŽŶĞŽĨƚŚĞƵƌŽƉĞĂŶĞĐŽŶŽŵǇ ?ƉƌŽǀŝĚŝŶŐũŽďƐĨŽƌŵŝůůŝŽŶƐŽĨ
ƵƌŽƉĞĂŶ ĐŝƚŝǌĞŶƐ ĂŶĚ ^D ?Ɛ Ăre also the basis for economic innovation. Back in 2004, 
ĐŽŶĚŝƚŝŽŶƐĨŽƌ^D ?ƐĂŶĚƐƚĂƌƚ-up companies were not as favorable in the EU as they were in 
the US making entrepreneurial initiative and risk-taking less developed in the EU. EU citizens 
are almost evenly divided in their preference for being self-employed or having employee 
status with many still preferring the comfort of being a salaried employee (European 
Commission, 2009). In general results showed that from 2007 to 2009, EU citizens views on 
entrepreneurs are mixed with almost all countries more likely to agree that entrepreneurs 
ĂƌĞŽŶůǇĐŽŶĐĞƌŶĞĚǁŝƚŚƉƌŽĨŝƚŽƌƚŚĂƚƚŚĞǇĞǆƉůŽŝƚŽƚŚĞƌƉĞŽƉůĞ ?ƐǁŽƌŬƚŽƚŚĞŝƌŽǁŶďĞŶĞĨŝƚ ?
The EU population in general prefers to either save money, or use it to buy a house, or to 
repay their mortgages, rather than embarking on risk taking ventures that threaten their 
way of life.  
The high level of migrants to particularly wealthy EU Member States will however serve to 
showcase their entrepreneurial spirit in these economies. As many arrive with the intention 
ŽĨŵĂŬŝŶŐĂďĞƚƚĞƌůŝĨĞĨŽƌƚŚĞŵƐĞůǀĞƐĂŶĚƚŚĞŝƌĨĂŵŝůŝĞƐ ?ĂŶĚǁŝƚŚƚŚĞŵĂũŽƌŝƚǇŽĨƚŚĞ^D ?Ɛ
coming mainly from this group of people, there will certainly be no lack entrepreneurial 
spirit in the EU in the near future. 
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4. Lifestyle changes 
Recent evidence shows that in industrialized countries people do not only enjoy longer life 
expectancy rates, but they are also experiencing better health conditions in old age due to 
both healthier lifestyles and more effective pharmaceuticals allowing people with chronic 
diseases to control the adverse effects of illness (European Commission, 2009). The 
ĐŽŶƚŝŶƵŝŶŐŝŵƉƌŽǀĞŵĞŶƚŽĨƚŚĞƉŽƉƵůĂƚŝŽŶƐ ?ŚĞĂůƚŚǇĂŐĞŝŶŐŝŶƚŚĞhƌĞĨůĞĐƚƐƚŚĞĚĞƐŝƌĞĨŽƌ
sustainable lifestyles, and a healthy environment amongst the people moving forward. With 
the Maastrich Treaty, the explicit mentioning of public health as an area of competence of 
the EU reinforces the expectation that having a sustainable, healthy lifestyle will be the way 
forward for the EU. Clearly, pharmaceutical drugs (patent or otherwise) will continue to 
provide a vital service to the EU population. 
Changing household and family trends need to be taken into account as the number of low- 
ŝŶĐŽŵĞ ?ƐŝŶŐůĞƉĂƌĞŶƚĨĂŵŝůŝĞƐ ?ŝŶĐƌĞĂƐĞƐ ?ƐĂresult of higher involvement of women in the 
work force, the economic crisis along with the spending cuts instituted at present is 
expected to create a more prudent, budget oriented household as the situation forces 
families to rein in their spending for essentials. Healthy lifestyles will become a more viable 
daily practice as a preventive measure against sickness as compared to incurring medical 
bills in the household due to illness. 
Preventive Healthcare: As stated in an interview with Ms. Angela Farrell (2010), preventive 
healthcare would become a normal trend as medical cost continues to increase. As with 
having more elderly people in the population in the EU at present, the prevalence of chronic 
and serious medical conditions remains on the rise. It is therefore no surprise that this 
becomes an area for further focus by the state governments that seek to control existing 
healthcare budgets (Hewitt Associates, 2010). Unlike the US healthcare system, EU states 
adopt a universal provision of heath care with at least, the basic aspects of heath care 
ƉƌŽǀŝĚĞĚĨƌĞĞƚŽ ŝƚƐĐŝƚŝǌĞŶƐ  ?WƌǌǇǁĂƌĂ ?  ? ? ? ? ? ?dŚĞƌĞĨŽƌĞƚŚĞt,KŚĂƐƉŽŝŶƚĞĚŽƵƚƚŚĂƚ  “ŝĨ
not successfully prevented and managed, they will become the most expensive problems 
ĨĂĐĞĚ ďǇ ŽƵƌ ŚĞĂůƚŚ ĐĂƌĞ ƐǇƐƚĞŵƐ ?  ?tHO, 2010). Because several diseases such as 
cardiovascular diseases, cancer, diabetes and chronic respiratory diseases - are linked by 
common preventable risk factors, healthcare authorities around the world (including the 
EU) have found it more cost-effective to put proactive preventive practices into action 
rather than continue with responsive-oriented healthcare systems. Amongst other 
measures, standard procedures by EU health authorities will involve providing information, 
education, programs and supporƚƚŽƚŚŽƐĞŝŶ ‘ƌŝƐŬ-ŐƌŽƵƉƐ ?ǁŝƚŚŝŶƚŚĞŐĞŶĞƌĂůƉŽƉƵůĂƚŝŽŶ ? 
5. Social Mobility 
ƐŝŵƉůĞŵĞĂŶŝŶŐŽŶƚŚĞƚĞƌŵ ‘ƐŽĐŝĂůŵŽďŝůŝƚǇ ?ƌĞĨĞƌƐƚŽƚŚĞĚĞŐƌĞĞƚŽǁŚŝĐŚĂŶŝŶĚŝǀŝĚƵĂůŽƌ
group's status is able to change in terms of position in the social hierarchy. Populations with 
the greatest access to education, and adopting a more tolerant if not more open attitude 
towards the society, will tend to experience a higher level of social improvement (Blanden 
et al, 2005). Historically, EU social mobility levels are mixed basĞĚ ŽŶ ůĂŶĚĞŶ ?Ɛ ƌĞƐĞĂƌĐŚ
study (2005) and Breen (2004) as countries like the UK and Ireland are seen as generally 
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more rigid with any mobility associated with parental income and educational attainment. 
Over the years since the formation of the EU, the mass migration of citizens with different 
social background has presented a difficult task in further upgrading mobility within 
societies. With the economic crisis, younger generations in EU member states will now 
struggle to scale upwards, especially with the loss of family income and limited government 
support, marking a risk that any cycle of poverty that an individual household will face is 
repeated. This is more so as essential costs such as health care become more costly towards 
households attempts toward improving living standards while at the same time aiming to 
scale towards a better way of life for themselves. 
1.4 TECHNOLOGY 
1. EĞǁWƌŽĚƵĐƚƐĂŶĚZĞƐĞĂƌĐŚ ?ĞǀĞůŽƉŵĞŶƚ ? ‘Z ? ? ?ǆƉĞŶĚŝƚƵƌĞ 
Increasingly, R&D spending by the pharmaceutical industry has been on a decline, forcing 
leading drug manufacturers to rely on existing lines of drugs for revenue generation 
(Kollewe, 2010). Based on a report by CMR International disclosed in The Guardian 
newspaper, the level of R&D spending had slipped by 0.3% in 2009 following a 6.6% drop in 
 ? ? ? ? ? ŵĂƌŬŝŶŐ ĂŶ ŝŶĐƌĞĂƐŝŶŐůǇ ĚŝĨĨŝĐƵůƚ ƉĞƌŝŽĚ ĂƐ ůĞĂĚŝŶŐ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐŽŵƉĂŶŝĞƐ ? ƐŚŽǁ
only 7% of sales originating from new drugs launched within the past 5 years. A decline in 
the success rates for new drugs to be introduced into the market is a major factor as the 
ŝŶĚƵƐƚƌǇ ĨĂĐĞƐ Ă  “ƉĂƚĞŶƚ ĐůŝĨĨ7 ? ĂŶĚ ƚŚŝƐ ŝƐ Ă ƐĐĞŶĂƌŝŽ ŝŶ ǁŚŝĐŚ ŐĞŶĞƌŝĐ ŵĂŶƵĨĂĐƚƵƌĞƌƐǁŝůů
increasingly benefit. In recognition of this, pharmaceutical groups have embarked on M&A 
routes with smaller firms, joint development with academic institutions/commercial 
competitors for new drugs while reducing cost incurring activities. Introduction of 
ďůŽĐŬďƵƐƚĞƌ ĚƌƵŐƐ  ?ƐƵĐŚ ĂƐ WĨŝǌĞƌ ?Ɛ >ŝƉŝƚŽƌ ? ŚĂƐ ďĞĞŶƐƚĂŐŶĂŶƚ ? ǁŝƚŚ ŐĞŶĞƌŝĐ ĚƌƵŐ ŵĂŬĞƌs 
from India and China crowding the pharmaceutical scene, making it tougher for the big 
pharmaceuticals companies to incur healthy margins that can finance R&D expenditures for 
future drug development.  
Genomics testing: Since the discovery of DNA and the associated study of it, this has been 
marked as one of the major breakthroughs in genetic testing (Amgen Scholars, 2009). 
Utilizing technological advances over the years, genomics testing allows for a more-accurate 
diagnosis of genetic diseases and therefore facilitates early treatment at an earlier stage. It 
also provides patients with both an understanding of possible risks for certain diseases and 
possible preventive measures long before the disease even forms within the body. 
Genomics testing in Europe however, suffers from a lack of widespread acceptance as 
compared to the US (Ramanathan, 2008) owing to the protection laws governing the genetic 
data obtained from such tests. The processing of genetic data in Europe has been subjected 
to stronger protection as provided in the Directive 95/46/EC and the national laws of the EU 
ŵĞŵďĞƌƐƚĂƚĞƐŝŵƉůĞŵĞŶƚŝŶŐŝƚ ?ZĂŵĂŶĂƚŚĂŶ ? ? ? ? ? ? ?,ŽǁĞǀĞƌ ?ĂƐhƌĞƐŝĚĞŶƚƐ ?ŚĞĂůƚŚĐĂƌĞ
costs grow, the development of an integrated knowledge base combining the insights of 
sciences, humanities and social sciences will be required to inform policy and to plan for the 
rational implementation of new healthcare services. EU health communities have 
                                                             
7 A term described when a firm or industry loses the monopoly granted by one or more patents. 
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recognized the benefits of genomics testing for healthcare prevention with the need for a 
strong integrated, interdisciplinary European link to manage the sheer volume and 
complexity of this emerging genomic knowledge (EUPHA, 2010). The EU has viewed 
genomics in a more positive manner as seen in one of its main theme for the Sixth 
Framework Program (that funds research work on genomic studies on diseases) to exploit 
this knowledge for human health as well as economic benefits (CORDIS, 2009). Genomics 
testing will continue to grow as more benefits are uncovered from researchers in the EU, 
with long term plans by the EC being provided towards nurturing such growth. 
There are multiple benefits of genomics for both pharmaceutical and generics makers as 
pointed out by Philips et al (2004). According to the research carried out, genomics is likely 
to proǀŝĚĞ Ă  “multitude of new drug targets, enable the development of drugs that avoid 
problematic genetic variants in drug-metabolizing enzymes, and increase the development 
of preventive interventions for patients identified as being at higher risk for future diseases ?
(Philips et al, 2004, p.428). Interviewee, Ms. Angela Farrell has pointed out the interest of 
many in the medical field to create more targeted forms of treatment. Genomics allows this 
as it allows drug therapies with greater efficiency and safety, which of course leads to higher 
prices due to the added value this can bring to patients. Genetic profiling in patients 
enrolled during the early testing phase for drugs will allow for shorter testing time this can 
increase approval chances amongst the health authorities. Drugs that previously were 
unsuccessful can be re-examined by targeting them to patients with specific genetic profiles 
ŝ ?Ğ ?  ‘ŶŝĐŚĞĚƌƵŐƐ ? ?'ĞŶĞƌŝĐĚƌƵŐŵĂŬĞƌƐǁŝůůĞǀĞŶƚƵĂůůǇďĞŶĞĨŝƚĂƐƐƵĐŚĂǀĞŶƵĞƐŽƉĞŶǁŝĚĞƌ
markets for patients upoŶ ĞǆƉŝƌǇ ŽĨ ƉĂƚĞŶƚƐ Žƌ ŝĨ ƉŽƐƐŝďůĞ ? ƐƉƵƌŶ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ  ‘ŶŝĐŚĞ
ĚƌƵŐƐ ?ƌĂƚŚĞƌƚŚĂŶƌĞůŝĂŶĐĞŽŶŽƌŝŐŝŶĂůĚƌƵŐŵĂŬĞƌƐ ? 
Drug delivery system: This is an area that has become increasingly popular within the 
pharmaceutical industry based on interviews with Ms Angela Farrell and Mr. Gregor Siebert. 
It is reported that at present, failure of drugs clinical trials are mainly due to the failure to 
deliver the compounds to the area of the body where it is needed most without going 
through some interaction with the entire human body (Cientifica,2007). It is therefore 
considered a very valuable and important development for any technology that enables 
direct delivery of drug compounds without triggering any or no side-effects on the patients. 
KŶĞŽĨƚŚĞh ?ƐĨŽĐƵƐĂƌĞĂƐ is currently nanotechnology-enabled drug delivery systems for 
patients. While there are delivery systems using laser, injection, sprays etc. nano particles 
are receiving particular attention owing to more development going on in this field. Drug 
development is a very costly affair for patent holders especially with the decline of new 
drugs being discovered each year. Many new biotech companies have become acquisition 
targets owing to keen interest towards this field.  
The future of nanotechnology is in a completely uncharted territory. It is almost impossible 
to predict everything that nanoscience will bring to the world considering that this is such a 
young science field today (Nanogloss, 2009). The field however is viewed as a revolutionary 
advancement but potentially controversial with its ability to bring materials to life. Religious 
and ethical issues aside, scientist are hoping that the further understanding of this 
technology would contribute towards improving the healthcare of populations globally in 
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the future. If successful, pharmaceutical companies should view this field as their next line 
of income as existing drug making expertise dries up. 
2. Biotechnology 
With 20% of new drugs launched from market each year derived from biotechnology (EFPIA, 
2009), the biotechnology field has long been a promising development for the medical and 
healthcare purposes. Areas such as pharmacogenomics, nanotechnology, stem cells and 
gene therapy are becoming part of a growing emphasis by medical professions. With a 
ǀŝƐŝŽŶƚŽŝŵƉƌŽǀŝŶŐĚĞƐŝŐŶĂŶĚƉƌŽĚƵĐƚŝŽŶŽĨĚƌƵŐƐǁŝƚŚŝŶĂŚƵŵĂŶ ?ƐŐĞŶĞƚŝĐŵĂŬĞƵƉ ?ƚŚŝƐ
field has become a new alternative for medicines, as previous reliance on conventional 
drugs (through use of chemical reactions) for treating illness have become scarce and 
increasingly difficult to produce. Using biomedicine, which creates drugs based on living 
molecules that are associated with specific genes and diseases, EU scientists under the JRC-
EU
8
 in 2007 have pointed out encouraging responses towards treatment of genetically 
inherited diseases such as hepatitis B, cancer and diabetes. JRC further pointed out that 
human medicine and healthcare are the most prominent fields for modern biotechnology 
with a high share of publications and patents targeted towards this sector (2007). 
dŚĞĚŝƌĞĐƚĂŶĚ ŝŶĚŝƌĞĐƚĞůĞŵĞŶƚƐŽĨZ ?ǁŽƌŬƐĨŽƌďŝŽƚĞĐŚŶŽůŽŐǇǁŽƵůĚĂĚĚƚŽǁĂƌĚƐh ?Ɛ
GVA
9
 and improving state of heath for EU citizens as part of tŚĞĐŽŶƚĞǆƚŽĨƚŚĞ ?ƐŽďũĞĐƚŝǀĞ
ŽĨ ŵĂŬŝŶŐ ƚŚĞ h  “ƚŚĞ ŵŽƐƚ ĐŽŵƉĞƚŝƚŝǀĞ ĂŶĚ ĚǇŶĂŵŝĐ ŬŶŽǁůĞĚŐĞ-based economy in the 
world, capable of sustainable economic growth with more and better jobs and greater social 
ĐŽŚĞƐŝŽŶ ? ?:Z-EU, 2007, p.5). Numerous researchers suggest that biotechnology can offer 
patients more and better healthcare choices. The biomedical healthcare industry is viewed 
ĂƐ ƚŚĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ŝŶĚƵƐƚƌǇ ?Ɛ ĞǆƚĞƌŶĂů Z ? ĐĞŶƚƌĞ ĂŶĚƐŽƵƌĐĞ ŽĨ ƉƌŽĚƵĐƚ ŝŶŶŽǀĂƚŝŽŶ
(EMCC, 2005). 
However, the strength of the biomedical healthcare industry differs widely between 
European countries. As of 2003, the UK is considered to have the most mature industry as 
compared to other EU states (EMCC, 2005) but this has narrowed as other EU states nurture 
their own industries.  
At this time, there has been a lack of attempts towards producing generic versions of 
biotechnology drugs. Many of these drugs are very expensive because they are so difficult to 
produce owing to complex molecules involved (Montgomery, 2009). Furthermore, 
regulatory guidelines are still lacking on existing bio-medicines due to the different 
arrangements governing both the US and EU member states (Manley, 2006). However as 
ĞǆƉĞƌƚŝƐĞ ĂŶĚ ĞǆƉĞƌŝĞŶĐĞ ĐŽŶƚŝŶƵĞ ƚŽ ŐƌŽǁ  ?ĞƐƉĞĐŝĂůůǇ ǁŝƚŚ ƚŚĞ ĐĂŵƉĂŝŐŶ ďǇ ' ?Ɛ
biosimilar drugs), it is only a matter of time before biotechnology becomes a huge part of 
patient healthcare in the EU and around the world. 
 
 
                                                             
8 Joint Research Centre Ȃ European Commission 
9 Gross Value Added 
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3. Incremental & Disruptive technologies 
To practitioners in the drug industry, incremental (or sustainable) technologies will come in 
form of mostly new drugs for an existing class with similar action mechanisms but these 
ĚƌƵŐƐ ǁŝůů  ‘ ? ? ?ĚŝĨĨĞƌ ŝŶ ĨĞĂƚƵƌĞƐ ƐƵĐŚ ĂƐ ? ƚŚĞƌĂƉĞƵƚŝĐ ƉƌŽĨŝůĞ ? ŵĞƚĂďŽůŝƐŵ ? ĂĚǀĞƌƐĞ 
ĞĨĨĞĐƚƐ ? ĚŽƐŝŶŐ ƐĐŚĞĚƵůĞƐ ? ĚĞůŝǀĞƌǇ ƐǇƐƚĞŵƐ ? ĨŽƌ ĞǆĂŵƉůĞ ?  ?'^< ?  ? ?08). Incremental 
technologies are in this sense, seen as innovation capacity, which is according to 
Wertheimer & ^ĂŶƚĞůůĂ ?  ‘ƚŚĞ ůŝĨĞďůŽŽĚŽĨ ƚŚĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ŝŶĚƵƐƚƌǇ ?  ? ? ? ? ? ? ? dŚĞ ĐƵƌƌĞŶƚ
issue surrounding this subject matter has largely pertained to criticism that the 
ĚĞǀĞůŽƉŵĞŶƚƐ ŽĨ  ‘ŵĞ-too10 ? ĚƌƵŐƐ ŚĂǀĞ ůĞĚ ƚŽ ƚŝŵĞ ǁĂƐƚŝŶŐ ? ďĞĞŶ Ă ĚƌĂŐ ŽĨ ĞǆŝƐƚŝŶŐ
resources, (R&D, money etc. ? ĂŶĚ ŚĂǀĞ ĂŝŵĞĚ ƚŽǁĂƌĚƐ  ‘ĨůĞĞĐŝŶŐ ƵŶƐƵƐƉĞĐƚŝŶŐ ĐŽŶƐƵŵĞƌƐ ?
(Wertheimer & Santella, 2009) particularly as the patented drugs life is ending. Generic 
manufacturers in the US and Europe have been particularly vocal towards this practice as it 
ĂůůĞŐĞƐ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐŽŵƉĂŶŝĞƐ ƵƐĞ ƚŚŝƐ ŵĞƚŚŽĚ ƚŽ ĞǆƚĞŶĚ ƉĂƚĞŶƚ ůŝĨĞ ƐƉĂŶ ?Ɛ ƚŚƌŽƵŐŚ
introduction of small changes that deprive generic manufacturers access to such drugs (and 
therefore an anti-competitive practice). It is therefore a contentious issue as both individual 
corporations such as GSK and its trade representative in the EU (the EFPIA) continue to 
debate this publicly, and with the European Commission. 
Other incremental technologies that serve to complement the medical drug industry arise 
from rapidly improving testing, diagnostic, and other technologies (Brill & Robbins, 2005) 
which allow better and more targeted drugs in the heath care sector thus ensuring the 
continued relevance of conventional medical drugs in the market. 
Disruptive Technology here is both a worry for patented and generic manufacturers as 
witnessed by the continued interest in biotechnology as the new alternative in medical 
ĚŝƐĐŽǀĞƌŝĞƐ ? tŝƚŚ ƚŚĞ ĐŽŶƚŝŶƵĞĚ ƐůŽǁ ƉƌŽŐƌĞƐƐ ŝŶ ƚŚĞ ĐƌĞĂƚŝŽŶ ŽĨ  ‘ďůŽĐŬďƵƐƚĞƌ ? ĚƌƵŐƐ ĨƌŽŵ
conventional pharmaceutical research, EU policy makers have continued to show further 
interest in biomedicine thru policy development initiatives such as funding (EFB, 2010). 
Pharmaceutical giants too, have gradually increased R&D spending in this field with many 
ĐŽŵƉĂŶŝĞƐ ĞŵďĂƌŬŝŶŐ ŽŶ D ? ĂĐƚŝǀŝƚŝĞƐ ǁŝƚŚ ĞǆŝƐƚŝŶŐ ďŝŽŵĞĚŝĐĂů ĐŽŵƉĂŶŝĞƐ  ?ŝ ?Ğ ? WĨŝǌĞƌ ?Ɛ
acquisition of Wyeth) besides growing internal resources to sustain their business. 
1.5 LEGAL 
1. Labor Laws 
The legal framework of the EU is vast and diverse due to the numerous countries within the 
union and hence only an overall review of selected laws and regulations is discussed in this 
report. It is however noted that European generic medicine companies face the problem of 
disharmonized implementation of new pharmaceutical legislation in member states (EGA
11
, 
2007) as well as cost constraints as a result of legislative requirements imposed by EU 
member states. 
                                                             
10 Drugs within the same chemical class as one or more others 
already on the market (Wertheimer &Santella, 2009) 
11 The European Generic Medicines Association  
Page 106 of 143 
ƵƌŽƉĞ ?Ɛůegal systems are largely founded on Roman Law and Germanic customary law and 
therefore these systems share a common linkage. Legal systems have been highly influential 
in shaping national codes and have given rise to legal frameworks that rely less on case law 
and 'precedent' cases occurring elsewhere for countries within the European continent 
(FedEE, 2010). The attraction for EU citizens pertains to the freedom of movement of labor. 
This is because every EU national is entitled to take up and pursue employment in the 
territory of another member state under the same conditions as the nationals of the host 
state (EU Treaty Art 1 and Regulation 1612/68). When first introduced, the movement was 
aimed at facilitating a competitive environment for member states to pursue economic 
growth as it provided labor mobility for EU businesses to move workers to any member 
state for the best optimal outcome, thus generating further growth for all member states.  
Since 1969 (Strauder v City of Ulm) a 'de facto' body of general human rights principles has 
been introduced by the European Court of Justice (ECJ) to avoid clashes with national 
constitutional rights when making their decisions (FedEE, 2010). This therefore mounts the 
complexity for any business as host states may impose conditions relating to linguistic 
competence where this is directly relevant to their employment (ECJ case reference C-
397/87).  
2. Health and safety regulations 
HS regulations play an important role in the medical drugs industry owing to the test type 
and chemical process used in production facilities. European Agency for Safety and Health at 
Work imposes directives on EU member states under Article 137 of the TEC
12
 which ranges 
from workplace and safety equipment, chemical agents exposure, physical hazards, and 
biological agents to sector specific provisions. These directives are updated regularly to 
reflect the current trends in the EU workplace. Pharmaceutical and generic manufacturers 
therefore face high costs in time and labor as they try to maintain compliance to the various 
health and safety codes introduced from time to time. This is not all negative however as 
the existence and monitoring of HS regulations ensures that medical drugs produced are at 
the highest quality for usage by patients anywhere. Generic manufacturers, unlike original 
medicine developers, do not share as much compliance concerns owing to the lesser 
amount of work activity required for rolling out their drugs as most (if not all) the main risk 
has been carried out by the patent holders instead. 
Nonetheless, HS regulations for patients are given equal weight by both pharma and generic 
players making such environment tough for the EU drug industry as it monitors all 
adherences to standards imposed by the EU governmental agencies. 
3. Consumer Protection 
ŽŶƐƵŵĞƌƉƌŽƚĞĐƚŝŽŶŝƐƉƌŽǀŝĚĞĚĨŽƌƵŶĚĞƌƚŚĞ ?ƐŽŶƐƵŵĞƌWŽůŝĐǇĨŽƌƚŚĞ ? ? ?ŵŝůůŝŽŶh
consumers. The Consumer Policy supports the aims laid out in Articles 153 and 95 of the 
Treaty establishing the European Community, which promote the interests, health and 
safety of European consumers. The policy stresses on market transparency, consumer 
                                                             
12Treaty on the Functioning of the European Union 
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protection, and consistency in operational objectives for all EU member states. This 
therefore puts both pharmaceutical and generic drug manufacturers on notice with regard 
to being transparent in their dealings, manufacturing methods, and using ingredients that 
comply with the highest level safety standards for EU patients. With the EU internal market 
ŚĂǀŝŶŐƚŚĞƉŽƚĞŶƚŝĂůƚŽďĞĐŽŵĞƚŚĞǁŽƌůĚ ?Ɛ ůĂƌŐĞƐt retail market (CEC13, 2009), the market 
has remained largely fragmented along national lines, forming 27 mini-markets
14
instead, 
therefore making it a challenge for EU consumers that engage in cross-border disputes as a 
result of consumer purchases outside their own home countries. The CEC report has quoted 
that despite the technological advancement (i.e. e-ĐŽŵŵĞƌĐĞ ?  “ďƵƐŝŶĞƐƐ ĂŶĚ ĐŽŶƐƵŵĞƌ
behavior lags far behind, restrained respectively by internal market obstacles and a lack of 
confidence in cross-border ƐŚŽƉƉŝŶŐ ? ? ? ? ? ? ?Ɖ ? ? ? ? 
Despite the still predominantly fragmented nature of retail markets around the EU, the 
 ?Ɛ ǀŝĞǁ ŝƐ ƚŚĂƚ ĐƌŽƐƐ ďŽƌĚĞƌ ƚƌĂĚĞ ůŝďĞƌĂůŝǌĂƚŝŽŶǁŽƵůĚ ďĞ ƚŚĞ ŬĞǇ ƚŽ ƵŶůŽĐŬŝŶŐ ƚŚĞ
potential of the EU retail market (CEC, 2009), and has therefore continued to push for 
further liberalization of various business sectors around the EU. It is therefore inevitable 
that EU markets will become gradually consolidated into one single market once consumer 
protection regulations are harmonized across all member states. As better informed and 
educated EU consumer numbers grow, the medical drug industry will be one of the growing 
focus for protection of patients across individual state borders once quality benchmarks are 
established in the healthcare sector for all EU states to comply. 
Counterfeit medicine: This problem was first addressed in 1985 (Pharmaceutical Technology 
Europe, 2010) in the World Health Organization (WHO) meeting with experts. With the 
explosion of e-commerce from the year 2000, the problem has increased substantially, with 
the magnitude difficult to access due to the variety of the information sources available 
(WHO, 2010). While the European Commission proposed several features to be present on 
the medicines (i.e. mass serialization, seals etc) (British Generics Association, 2010), 
counterfeit medicine remains a growing threat. Currently, counterfeiters have tended to 
focus on expensive patented drugs rather than generics, but as global acceptance of online 
purchasing increases, counterfeit drugs are increasingly being detected in the supply chain. 
This is an issue of major concern for generic manufacturers as any products discovered as 
counterfeit can easily harm patient confidence in generics. As over 50% of the medicines 
purchased online are found to be counterfeit (WHO, 2010), monitoring of counterfeit drugs 
particularly those purchased from online sources has become a necessity for the 
pharmaceutical industry. 
Patient Data Protection: Usage of online purchasing for medicines by patients on 
illegitimate sites has resulted in the risk of private and personal health information being 
disclosed publicly to unscrupulous operators (Berstein, 1999). The issue of spamming has 
become a major concern for most internet users as likewise for sick and vulnerable patients 
that choose to source cheaper medications i.e. generic drugs. Private health and financial 
information (i.e. credit card numbers) can be compromised to criminals and this confronts 
the pharmaceutical companies with bad publicity should anything negative occur. 
                                                             
13 Commission of the European Communities  
14As of date of the report published. 
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4. Benefits System 
Welfare benefits across EU Member states are largely generous with many offering free/ 
low cost medical care for citizens upon their reaching the legal retirement age. Continued 
development in the EU region resulted in many of the member states developing some of 
the best health care systems in the world (Eurostat, 2010) in an attempt to deal with the 
ageing demographics within the region. The provision of generous benefits is however 
facing challenges on several fronts. The current severe recession that is affecting the global 
economy and the recent Euro zone crisis has left many national treasuries under pressure 
due to the rising costs as well as depleting financial resources towards financing heath care. 
As many citizens of the EU grow older, the trend of declining birth rates which has lowered 
the number of younger people to replenish societies has resulted in many EU populations 
resorting to allowing foreign migrants into the region.  
Migration has been responsible for large increases in the EU population over the past few 
years (Eurostat, 2010) with many foreigners coming from non-EU member states. Generic 
drugs will gradually become the medicine of choice due to the lower costs of these drugs. 
Public spending has the potential to be restricted by many governments and there will be a 
trend towards encouraging EU citizens to consider private health care for the more 
 ‘ĞǆƉĞŶƐŝǀĞ ? ĚŝƐĞĂƐĞƐ ? dŚĞ ƐƚƌƵŐŐůĞ ƚŽǁĂƌĚƐ ƉƌŽǀŝĚŝŶŐĂ ĨŝŶĂŶĐŝĂůůǇ ƐƵƐƚĂŝŶĂďůĞ ŚĞĂůƚŚ ĐĂƌĞ
system in the EU will continue towards the near future and beyond. 
5. Anti-Trust Laws 
h ?ƐĂŶƚŝƚƌƵƐƚůĂǁƐƌĞƉƌĞƐĞŶƚĂŶŝŵƉŽƌƚĂŶƚƉĂƌƚŽĨƚŚĞŵĂƌŬĞƚŝŶƚĞŐƌĂƚŝŽŶĞĨĨŽƌƚƐďǇƚŚĞ
as the EC seeks to enhance a free market trading environment. Given that there are 
numerous national companies in all the member states, antitrust laws for the EU are 
particularly geared towards addressing this under Article 107 of the Treaty. This is 
particularly important with regard to both competition policy and the creation of the 
European single market and could be rendered ineffective when member states are free to 
support national companies as they see fit. 
With the pharmaceutical market being heavily regulated at national levels, this leaves less 
room for competition on prices and therefore market forces cannot realize their full effect 
here as they do in most other industry sectors within the EU (European Commission, 2010). 
Currently, the EC is focusing more on attempts by companies to delay or hamper the 
introduction of generic medicines or of new innovative drugs that may compete with 
products already on the market (European Commission, 2010). This issue has long been a 
concern raised by the European Generic Medicines Association in their arguments with the 
original pharmaceutical companies using intellectual property to maintain their grip on their 
patented drugs.  
Pharmaceutical companies who try to prolong patent protection for a product may breach 
EU competition rules which are enforced by the EC. The recent AstraZeneca case which 
ƌĞƐƵůƚĞĚ ŝŶ ƚŚĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐŽŵƉĂŶǇ ďĞŝŶŐ ĨŝŶĞĚ  ? ? ? ŵŝůůŝŽŶ ŝƐ ĂŶ ĞǆĂŵƉůĞ ŽĨ
commitment by the EU towards encouraging competition within the industry for both 
pharmaceutical and generic manufacturers. Both industries must take care in ensuring that 
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whatever business practices deemed anticompetitive (M&A, parallel trade, state aid) have 
to be approached carefully as the EU market gradually expands and grows over the decades 
to come.  
1.6 ENVIRONMENT 
1. Environmental legislation, Social Responsibility, Sustainability & Global Climate 
Change 
The EU has some of the highest environmental standards in the world, developed over 
decades to address a wide range of issues (EUROPA, 2010). As awareness on climate 
change, biodiversity and sustainable development increases amongst the EU population, it is 
therefore undeniable the effect it has on the pharmaceutical/generic drug industry. 
Companies with industrial biotechnology involvement (that produce pharmaceutical 
compounds) will face issues relating to genetic modification and its impact on patients 
thereby making it a serious issue to address as this field continues to grow for medical R&D.  
The European Parliament views the field of biotechnology to have vast potential in 
pharmaceutical innovation, in creating new cures and with less impact on the environment 
during manufacturing (Europarl
15
, 2004). It does acknowledge the concerns by some that 
having too much legislation governing biotechnology would only stifle innovation, 
competition, as well as reduce incentivĞƐƚŽǁĂƌĚƐ “ŽƌƉŚĂŶĚƌƵŐƐ ? ?ĨŽƌƌĂƌĞĚŝƐĞĂƐĞƐ ?ĂŶĚŝƚ
aims to provide policies that serve to encourage this area of development carefully. 
There will be continuous ethical questions that need to be addressed to the public as it 
involves the life and death of living organisms (Europarl, 2004), the very factors that have 
shaped the deepest religious, ethical and cultural heritage of humanity as enshrined in the 
EU Fundamental Rights Charter. Cross border cooperation in research on ethical usage of 
this technology would be the way forward towards reducing such skepticism. 
2. Waste Products 
Growing awareness of environmental impacts and the need to conduct tests to evaluate 
such effects are creating cost pressures for the pharmaceutical industry (EEA
16
, 2009). Our 
project teams discussion with Ms. Hilary Jones of Pfizer led to our knowledge that there is a  
need for drug manufacturers (generic or otherwise) to be well versed with the latest EU 
drug legislation and best practices adopted by surrounding countries (i.e. Sweden
17
) in order 
ƚŽĐŽŵƉĞƚĞŝŶƚŚĞhŵĂƌŬĞƚ ?hƐĞĚĂŶĚƵŶƵƐĞĚW/ ?Ɛ18 have a considerable implication for 
waste streams especially in wastewater and river sources making this a growing concern in 
the EU. Therefore, there has been an effort to control the level of chemicals used for 
ŝŶĚƵƐƚƌŝĂů ƉƌŽĚƵĐƚŝŽŶ  ?ĚƌƵŐƐ ŝŶĐůƵĚĞĚ ? ĂƐ ŽƵƚůŝŶĞĚ ŝŶ ƚŚĞ h ?Ɛ Z,19 Regulation, while 
ƉƌŽŵŽƚŝŶŐ ƚŚĞ ĐŽŶĐĞƉƚ ŽĨ  ‘'ƌĞĞŶ WŚĂƌŵĂĐǇ ?  ? ?  ? ? ? ?  ŝŶ ĂĚĚƌĞƐƐŝŶŐ ƚŚŝƐ ŝƐƐƵĞ ? ůů
                                                             
15 European Parliament 
16 European Environment Agency 
17 Sweden adopts a stringent policy towards the environmental disposal of medical drugs in the system.  
18 Active Pharmaceutical Ingredients 
19 Registration, Evaluation, Authorization and Restriction of Chemical Substances 
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interviewees agree concurrently that while the environmental factors are not high on their 
agenda, it is nevertheless a significant consideration factor when planning for business 
sustainability and competitiveness in the future.  
3. Non-Governmental Organizations (NGOs) 
The role of NGOs will become ever more crucial as the industry serves to maintain a social 
responsibility outlook with all stakeholders. Patient rights and other public interest groups 
can at times be barriers during the decision making process. Their involvement with the 
company through partnerships and continuous engagement can contribute towards the 
sustainability and effectiveness of projects while introducing innovative approaches and 
community participation (World Bank, 1995). This working partnership is gradually gaining 
acceptance in various sectors and governmental organizations and would be an important 
feature for businesses that is concerned about their continued business sustainability and 
their impact on the business landscape. This is especially so when working in a complex and 
diverse business environment such as the EU. Pharmaceutical and generic companies can 
use this chance to create innovative solutions toward new/existing drugs that serves to the 
best benefit of patients in the EU and the world as a whole. 
4. Packaging 
On Sanofi-AventŝƐǁĞďƐŝƚĞ ?ƚŚĞĐŽŵƉĂŶǇƐƚĂƚĞƐƚŚĂƚ ŝƚ  ‘ŵƵƐƚƉƌŽƚĞĐƚƚŚĞƉƌŽĚƵĐƚ ?ƐƉŚǇƐŝĐĂů
and chemical integrity in order to ensure pharmaceutical-ŐƌĂĚĞ ƋƵĂůŝƚǇ ĨŽƌ ƚŚĞ ƉƌŽĚƵĐƚ ?Ɛ
ĞŶƚŝƌĞ ůŝĨĞ ĐǇĐůĞ ?  ?^ĂŶŽĨŝ-Aventis, 2010). Present packaging methods by the producers (i.e. 
plastic bottles, glass, paper etc) to protect medicines are judged to be environmentally 
unfriendly owing to the use of plastic components which are difficult to dispose off in an 
environmentally safe way.  Hence, there are constraints owing to the limited capacity for 
suppliers to produce suitable, environmentally friendly packaging within the marketplace. 
Advances in the production of medicine have resulted in a need not only for enhanced 
protection against various environmental factors (moisture, heat, light, oxygen, mechanical 
forces) but also for packaging to play a more integral role in delivery e.g. stability and shelf 
life. As a result of strict EU legislation, drug packaging itself has undergone changes in 
response to these developments. Plastic components are gradually being reduced with 
biodegradable plastics used instead, while refillable packets are being introduced by 
pharmacists for recurring patients. 
Manufacturers are examining the use of prefillable inhalers and syringes for meeting the 
requirements while further discoveries are being made in new bioengineered medicines 
(Plastemart, 2008). Given that there is no other cost efficient solution with drug packaging 
at the moment for new storage methods, manufacturers will continue to rely on bottles and 
bags for patients to keep until a more cost effective delivery mechanism is found especially 
in the field of biotechnology.  
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1.1 QUALITATIVE QUESTIONNAIRE 
EU Macro-Environmental Scan Questionnaire 
1. With regard to intellectual patent laws, how can legislators enhance competition within 
the EU drugs market? 
2. Will countries within the EU trend more towards protectionism or open and free trade? 
3. What changes can you project vis-a-ǀŝƐ ƚŚĞ h ?Ɛ ƉŽůŝĐŝĞƐ ŽŶ ŽĨĨ ƐŚŽƌŝŶŐ ?  ?Ɛpecifically 
related to the pharmaceutical industry) 
4. tŝůů ƚŚĞ ƵƌŽƉĞĂŶ hŶŝŽŶ ƌĞƚĂŝŶ ƚŚĞ ƉŽůŝĐǇ ŽĨ  “ŶŽ ŶĞĞĚ ĨŽƌ ĂŶ ĂĐƌŽƐƐ ƚŚĞ ďŽĂƌĚ
ŚĂƌŵŽŶŝǌĂƚŝŽŶŽĨƚŚĞDĞŵďĞƌ^ƚĂƚĞƐ ?ƚĂǆƐǇƐƚĞŵƐ ? ? 
5. tŚĂƚ ĂƌĞ ǇŽƵƌ ĞǆƉĞĐƚĂƚŝŽŶƐ ǁŝƚŚ ƌĞŐĂƌĚ ƚŽ ƚŚĞ h ?Ɛ ĨƵƚƵƌĞ ĞǆƉĂŶƐŝŽŶ ?ŝŶƚĞŐƌĂtion 
policies?  
6. What actions and/or trends can you forecast with respect to monetary policy within the 
EU? How likely is the prospect of the Euro being the only currency within the EU? Will 
the Euro survive or will countries revert to their previous national currencies?  
7. How likely is the prospect of Fiscal policy integration within the EU?  
8. What changes can you project vis-a-ǀŝƐ ƚŚĞ h ?Ɛ ƉŽůŝĐŝĞƐ ŽŶ ŝŵƉŽƌƚ ůĂǁƐ ƚŽ ƐƵƉƉŽƌƚ Žƌ
hinder the flow of pharmaceutical products manufactured outside the EU? 
9. In March 2 ? ? ? ƚŚĞ ƵƌŽƉĞĂŶ ŽŵŵŝƐƐŝŽŶ ŵĂĚĞ Ă ĐŽŵŵŝƚŵĞŶƚ ƚŽ  “ƌĞŶ ǁ ƚŚĞ h
strategy to promote Corporate Social Responsibility as a key element in ensuring long 
ƚĞƌŵ ĞŵƉůŽǇĞĞ ĂŶĚ ĐŽŶƐƵŵĞƌ ƚƌƵƐƚ ? ? ,Žǁ ĐŽƵůĚ ƚŚŝƐ ĐŽŵŵŝƚŵĞŶƚ ƉŽƐƐŝďůǇ ĂĨĨĞĐƚ ƚŚĞ
pharmaceuticals/generics industry in the EU over the coming years?  
10. /ŶǁŚĂƚǁĂǇƐĚŽE'K ?ƐŝŶĨůƵĞŶĐĞƉŽůŝĐǇŽŶƉŚĂƌŵĂĐĞƵƚŝĐĂůƐǁŝƚŚŝŶƚŚĞƵƌŽƉĞĂŶhŶŝŽŶ ?
ŽE'K ?ƐŚĂǀĞĂƐƚĂŶĐĞ ?ƌŽůĞŽŶƚŚĞƐĂůĞĂŶĚƵƐĞŽĨŐĞŶĞƌŝĐƐǁŝƚŚŝŶƚŚĞh ? 
11. What role will the movement towards sustainability have on the 
pharmaceuticals/generics industry over the coming years?  
12. What is the likelihood of a unified legal framework within the European Union on a 
community patent system?  
13. What are the projected trends with regards to benefits policies within European Union 
member states? Will there likely be a unified policy on benefits across the EU? 
14. What changes are likely to occur over the coming ten-twenty years within the European 
ŽŵŵŝƐƐŝŽŶ ?Ɛ ĞŶǀŝƌŽŶŵĞŶƚĂů ůĞŐŝƐůĂƚŝŽŶ ƉŽůŝĐŝĞƐ ƚŚĂƚĐŽƵůĚ ƉŽƐƐŝďůǇ ĂĨĨĞĐƚ ƚŚĞ ƐĂůe of 
generics in the EU?  
15. What is the likelihood of the EU adopting a unified pricing regulation structure in the 
pharmaceutical industry?  
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16. What trends can you forecast vis-à-ǀŝƐƚŚĞh ?ƐĨĂǀŽƌĞĚƚƌĂĚŝŶŐƉĂƌƚŶĞƌƉŽůŝĐŝĞƐ ?tŝůůƚŚĞ
EU trend more towards free trade or protectionism? Which countries do you expect to 
be granted Most Favored Nation (MFN) status by the EU over the coming years? Will 
India be granted MFN status? If yes, when do you anticipate this to occur? How will EU 
trade policies affect the pharmaceuticals industry over the coming years/decades? 
17. What technological advancements (disruptive and/or incremental) are most likely to 
have a significant impact on the future of the generics drug industry? 
18. Over the coming years/decades, in which specific areas do you anticipate developments 
vis-à-vis pharmaceutical industry cost structures and value-chains?  
19. Are there any current or forecasted factors/indicators that are likely to have a significant 
impact on GDP growth rates within the EU?  
20. What are the ĞǆƉĞĐƚĂƚŝŽŶƐ ǁŝƚŚ ƌĞŐĂƌĚ ƚŽ h ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ĚŝƐĐƌĞƚŝŽŶĂƌǇ ŝŶĐŽŵĞ
patterns and what specific EU policies/actions (current or future) are likely to have an 
impact on these patterns? 
21. What are your projections regarding business cycle volatility within the EU over the 
coming years and what policies/actions can the EU central bank adopt to ensure 
business cycle stability? 
22. Can you project any significant changes in immigration policy within the EU - with regard 
to migration within member states and migration from non-EU countries? What is the 
prospect of a harmonized immigration policy within the EU? 
23. What are the current and projected future trends (ten-twenty years) with regard to the 
life-styles of citizens within the EU? How will these trends specifically affect healthcare 
practices?  
24. /ŶǁŚĂƚǁĂǇƐĚŽE'K ?ƐŝŶĨůƵĞŶĐĞƉŽůŝĐǇŽŶƉŚĂƌŵĂĐĞƵƚŝĐĂůƐǁŝƚŚŝŶƚŚĞƵƌŽƉĞĂŶhŶŝŽŶ ?
ŽE'K ?ƐŚĂǀĞĂƐƚĂŶĐĞ ?ƌŽůĞŽŶƚŚĞƐĂůĞĂŶĚƵƐĞŽĨŐĞŶĞƌŝĐƐǁŝƚŚŝŶƚŚĞh ? 
25. Will EU member state governments increase/decrease healthcare spending (as a 
proportion of overall budgets) over the coming years/decades?  
26. What changes do you project with regard to the private healthcare sector in the EU over 
the coming years/decades?  
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1.2 QUANTITATIVE QUESTIONNAIRE 
 
Policy on Price Regulations
Patent Laws
Taxation policy
Govt. interventions in the free 
market (Protectionism)
Favoured trading partners
Monetary & Fiscal Policy
Prescribing drugs
Dispensing drugs
Reimbursement for drugs
Pharmacovigilance
Packaging/Waste
Trade Restrictions
Tariffs
Outsourcing/off shoring
Inflation Rates
Healthcare Expenditure
Policies on Demographics (eg. 
Migration)
R&D spending
Labour Laws (e.g. minimum 
wage, retirement age etc)
Health and safety regulations
Consumer Protection
Benefits System
Anti-Trust Laws
Environmental Legislation
Social Responsibility
Sustainability
Policy
Please click on the drop box and select the projection of th
policy over the next 20 years in the EU. After selection 
please save the file on your desktop and e-mail it to 
lixazk@nottingham.ac.uk
Notes: The following 5 
options are to be selected 
by the respondents  
Fully National 
Predominantly 
National 
50/50 
Predominantly 
European 
Fully European 
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1. RESPONSES AND KEY POINTS FROM INTERVIEW CONDUCTED 
1.1 ANGELA FARRELL. INTERVIEW ON 2 AUGUST 2010 
Explains that revenue generation for most pharmaceutical companies are made through 
volume production of drugs. This is in line with an ageing customer base in the EU which is 
growing and therefore providing adequate supply of medicine is important by the respective 
EU government. 
Agrees that demographic age trend will increased throughout EU, therefore companies 
should be in the positions to meet healthcare need of such population through increased 
supply of pharmaceutical drugs. 
Consumer attitude towards prescription of generic / original brand is mixed throughout EU 
owing to the different policies adopted by the member states in healthcare prescription. 
In terms of new technology developments, she views that original growth driver for generic 
companies are increasingly complex due to the more sophisticated drug delivery system 
requirements. This will hold back generic drugs development growth as R&D cost for 
original is already high. 
However as result of the sophisticated environment today, the ability for patented 
pharmaceutical companies to introduce new drugs is also decreasing. A problem not evident 
for generic manufacturers as it does not spends so many resources as patent drugs makers 
especially for the established generic players. 
Different approaches to market was suggested (both patented and generic) such as 
effectiveness of drugs administered into patients, monitoring of drugs dispensed W 
expanding more effective use of original drugs (genomics used) to the selected population 
which responds more favourably to such drugs (also for enhancement of existing drug 
products). 
In terms of R&D area  W suggest more niche drugs development focus now rather than 
massive investments in the mass producing the drugs volume. However the industry cannot 
ƌĞůǇƚŽŽůŽŶŐŽŶƚŚŝƐƐƚƌĂƚĞŐǇ ?ĚŽĞƐŶ ?ƚƐĞĞZ ?ƚŽďĞŵŽƌĞĐŽŵƉůĞǆƚŚĂƚŐĞŶĞƌŝĐĐĂŶ ?ƚĐŽƉǇ
in this step. Generic players will continue to adapt as they always have over time.  
Developments for the drug industry are more incremental rather than disruptive type 
especially with the dearth of new products coming into the market at present.It is therefore 
ŝŶ ŚĞƌ ǀŝĞǁ ƚŚĂƚ ƚŚĞƌĞ ǁŽŶ ?ƚ ďĞ ĂŶǇ ŵĂũŽƌ ĐŚĂŶŐĞƐ ŝŶƚŚĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ŝŶĚƵƐƚƌǇ ƚŚĂƚ
makes generic manufacturers life tough to follow. 
In terms of a variety of delivery system: 
Explains that there is a trend towards preventive healthcare throughout most markets in the 
EU, new developments such as installation of monitoring system at home to regulate drug 
intake are being considered especially with the older and weak patients. 
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Points out that the people are becoming aware of use of genetic  technology  W marking a 
potential to generate new markets for pharmaceutical companies. She cautions however 
that there is an incline to take protective measures as compared to past to restrict certain 
aspects of this technology. 
Certain drugs dosage may be reduced as studies show its actual effectiveness on the 
patients administered. This will result in drugs becoming more tailored towards patients 
requirement in future in her view. 
Opinion on nanotechnology: agrees on its application for the drug delivery system will 
useful in treating illness. Government will become more committed to generics rather than 
reliance on new patented medicine as this source dries up. 
Manufacturing will more centralised in future as pressure of decreasing cost increases. Also 
raised the possibility of it moving toward larger, higher volume manufacturing sites 
elsewhere that might in non-EU region (India, China, Brazil etc).  
Difficulties pointed out with pharmaceutical industry situation in the EU: As EU healthcare 
system mostly cater with providing massive range of drugs (for different symptoms), 
wholesaling operations will be consolidated further (possibly between companies) to 
address the efficiency aspect of delivery throughout the EU. 
When further discussing, she explains that wholesalers here will want to consolidate in her 
opinion. This is because the margins are getting smaller as selling price drop but 
development cost aspect on the other hand, remains unchanged significantly. This is where 
generics benefit as making a new drug is seldom a priority for generics. Should this be 
unsuccessful, she sees that profit margins by pharmaceutical sector might be re-examined 
to address this.  
During interview, raised a question on the possibility of the middleman being removed from 
the supply chain. However, Ms Angela also pointed out the risk of supply security especially 
with counterfeit drugs circulation becoming an issue for the pharmaceutical sector. When 
pressed further, her view was that the current supply chain is process is viewed as not so 
important as compared to the price factor for original manufacturers. 
Tendering practice might be practiced by every EU member state government in future. But 
points out that this could be complicated due to the various stakeholders involved in the 
whole chain which has long relied on past practices. 
Not much progress on harmonisation of pricing as in reality, it has always relied on market 
force to determine pricing in each country.  
Agrees that there have always been parallel pricing issues afflicting medical drugs in the EU. 
This is because pricing for some drugs in demand tend to be more expensive in some states 
ŚĞŶĐĞĂ ‘ŐƌĞǇ ?ŵĂƌŬĞƚĞǆŝƐƚĨŽƌƚŚŽƐĞƚŚĂƚǁĂŶƚƐƐƵĐŚĚƌƵŐƐǁŚŝĐŚƉĞŽƉůĞǁŝůůďĞƚĞŵƉƚĞĚƚŽ
supply it even at risk. This problem cannot be solved easily owing to complexity in reality for 
uniform pricing. 
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She is also sceptical of harmonisation prospect (for pricing) as every EU member states has 
different agendas in many of such issues. This is because each country wants to obtain the 
best value for money for their citizens. Therefore, harmonisation may not necessary benefit 
EU member states with lower income levels compared to the stronger EU members and 
vice-verse. It is therefore in her opinion that unless there is a strong EU will to impose it on 
all members, this option is unlikely to happen. 
Patent laws: 
Explains that there has been attempts to extent patent life (changing / enhancing existing 
core patent drugs just before expire) as reported in media. 
The issue for thought was that this depends on how quick the generic drugs manufacturer 
exploit it upon expiry of the patent (main thing is to produce the necessary commercial 
quantity especially just before expiry possible to make a profit) 
On query by the team that whether this causes competition enhancement to be difficult?: 
Explains that extending patent life must also be matched with having more benefits for 
innovation for the patent drug manufacturers. 
For generic sector, this will be the other way around. 
How to encourage generic players more into the market? 
She is of the opinion that this is more on fine tuning the existing provision. But there is 
expected to have not many changes to enhance competition other than existing 
mechanism.  
Suggestion to allow substitution on certain category of drugs in order to encourage more 
competition but points that this strategy is tricky for such strategy. 
Sees a trend towards free trade in the EU but with limitations in some areas, one of which 
could be the pharmaceutical industry. 
Not optimistic on harmonised tax system for drug companies so long as pricing is not set 
especially. Also points out economic factors which also affect this step as each country has 
its own unique policies and factors towards managing their own economies. 
Points out that attitude of branded products vs generic for prescription in different EU 
states differs  W it is therefore a barrier for the business. 
Highlights from her experience that incentives for pricing will likely persuade how the 
popularity on drug usage. Therefore, generic drugs will always have a place in the market 
Regulatory approval issues has always been a problem for any pharmaceutical companies 
ďƵƚŽŶĐĞƚŚĂƚ ?ƐĐůĞĂƌĞĚ ?ŝƚ ?ƐƐŚŽƵůĚďĞĂƐƚƌĂŝŐŚƚĨŽƌǁĂ ĚŝŶŚĞƌŽƉŝŶŝŽŶ ? 
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A commercial incentive for pricing to push acceptances of any drugs is important for its 
success. Volume and pricing are the most important factors that any generic business would 
need to consider in whatever strategy it operates. 
On whether EU has the appetite for branded generic, explains that the company to look at 
promotional policy of respective governments to see business opportunities for the 
company. 
Notes for some drugs to succeed in the market, pressure from consumers on having familiar 
products can be a deciding factor in some drugs sales. 
When suggested by team on using refillable bottles, it could be 1 aspect for some generic 
business to promote but regulatory / health issues might be barrier in this sense. In her 
view, environmentalist issue on packaging is negligible compared with concerns of unused 
drugs disposed being a more pressing concern in the EU. 
Trend on counterfeiting will continue to rise however; her opinion is that there will always 
be technology developed eventually to check any uncontrollable rise in the EU. 
Pharmaceutical industry will need to be on guard on any new trends in counterfeit as well as 
detection method. 
At this moment, more information disclosure might be required on the packaging by EU 
governments in future. 
Regulatory compliance will increase, might impact generic drug pricing due to the cost 
compliance. 
She however feels that despite the attitude of some consumer markets in the EU, the 
consumer will still eventually go towards generic compared to the branded originals in these 
markets. 
Patent issue should be harmonised in her opinion as most requirements are standardised 
and are not significantly different. However, political constraints might upset such measures 
and therefore, more studies need to be considered on this. 
In terms of heath caƌĞƐǇƐƚĞŵ ?ĚŽĞƐŶ ?ƚƚŚŝŶŬ ƚŚĂƚ ŝƚŵŝŐŚƚďĞŚĂƌŵŽŶŝƐĞĚƐŽĞĂƐŝůǇĚƵĞƚŽ
different system practiced by each member states 
 
1.2 HILARY JONES. INTERVIEW ON 3 AUGUST 2010. 
On query pertaining to patent laws, she points out that the latest ruling by the EU will 
provide further clarification of patent laws. 
In her opinion, restriction of free trade is not possible due to EU- Rome Treaty which 
prohibits such practices amongst EU members 
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Therefore, she is confident that legislation on free trade will remain unchanged  W does not 
see any trend on protectionism in her opinion 
Query on risk of outside medical drugs being imported into the EU. She responds that this is 
not possible for import of drugs produced outside as there are simply so many stringent 
regulations to comply  W points out examples such as regulations on marketing, GMP, 
manufacturing, import laws as EU must provide valid marketing authorisation, parallel 
import licenses etc. It is therefore not possible of the risk. 
Highlights that the environment is getting stricter due to increase of outsourcing activities to 
3
rd
 world countries by drug companies. Outsourcing here is in the sense of obtaining the 
APIs for producing the relevant drugs. 
Directs attentions to the proposed EU legislation on counterfeit  W EU Ruling 2001/83 which 
will impose new laws on 3
rd
 party manufacturing sites on level of EU standards compliance. 
Points out that Sweden has a high standard on drugs impact on environment which has 
been closely followed by EU legislations for similar enactments. 
Also point out importance of REACH legislation  W although more to do with chemicals, some 
elements touch of pharmaceuticals  W example: legislation on manufacturing standards and 
impact on environment 
The current situation is that EU is now tightening regulations on the existing rules especially 
those that touches on impact of the pharmaceutical against the environment. 
Of the opinion that it is not possible for harmonised pricing of the medicines in the EU. 
 
1.3 GREGOR H. SIEBERT. INTERVIEW ON 3 AUGUST 2010. 
Has a negative impression on any developments pertaining to EU from political and 
healthcare policy as the region has too many differences. 
Only positive aspect in his view comes from technology development. Something which EU 
can work together he explains. 
His view on the significant technology impact will be new applications form for drugs to 
administer into patients. 
Delivery system, administering of medicine into the patients, packaging for elderly could be 
a potential areas for pharmaceutical companies to improve further. 
Biological developed drugs has positive impact for pharmaceutical but not for generic due to 
their lack of familiarity with such technology. 
In future sees development of drugs will be more value, cost-sharing between companies on 
manufacturing due to the high cost if developed individually. Further thinks that as part of 
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the ways of enhancing efficiency, cooperation will be more on costly development stage of 
drugs between all patented drug manufacturers. 
Not likely to adopt unified pricing regulation although EU is trying to do so. But many 
industry players hope to narrow the differences in time. 
Cost reducing is one of the ways looked by companies operating in the EU environment and 
is not surprising given the rising cost over the years for developing new drugs. 
Stability of the economy is still unknown in her personal opinion and expects it to be 
relatively flat in the future. 
Agrees that ageing group is of a concern and therefore migration policy will continue to 
change to accommodate foreign talent to enter EU. Therefore, thinks there might be a 
harmonised immigration policy for the EU in next 20 years. 
Lifestyle and differences between EU states will continue to narrow to similar trends and 
hence a higher chance of acceptance of EU members pertaining to the standard regulations 
over the years. 
There will be a focus on better delivery of drugs as it is one of the main developments in the 
pharmaceutical industry in recent times. 
Sees NGOs as having a strong influence on the industry and the government for example: 
HIV groups efforts in pushing for the rights of such patients in the EU healthcare in the past. 
There are many more such pressure groups that will continue to highlight their plights to 
authorities. Explains that this is something the industry has accepted and worked with over 
the years. 
 
1.4 JONATHAN FARRINGTON. INTERVIEW ON 11 AUGUST 2010 
View on free trade: it will continue to grow as EU governments struggle with rising budget 
deficit (concerns on finding ways to obtain cheaper cost) but will be balanced by the need to 
perform strategic assessment on liberalisation of certain sectors to protect jobs for their 
citizens. 
Opinion on EU Expansion: It will slow down with Turkey being the most next likely candidate 
to be considered for admission. This is because EU admission criteria is based on more 
political stability rather just concentrating on economic criteria. EU will not want developing 
country that are risk of adding instability to the economic union. Political factors will ensure 
that Turkey comes closer to EU circle even if it is not a full member. 
Tax regulations will not be uniformed owing to the differences in the system. 
Euro currency will not make any further progress than where it is currently in the future at 
this stage. While not likely, there is a possibility that countries might revert back to national 
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currencies especially for the bigger country that have centre right govt  W like Germany or 
France which will be likely to follow this due to public pressure.  
View that there will be some pressure to conform to a uniform fiscal policy but not likely to 
be 100% full compliance by the member states themselves. 
Healthcare policy is a member internal competence, not a EC competence consideration to 
be a member of the EU. This therefore cannot be a factor for harmonisation in this case. 
Govt will continue to squeeze cost structure of the drugs sold through EU member states. 
Generic will enjoy a competitive advantage in this as their cost structure is already low. 
Sees that there will be continued economic stagnation in the EU for the foreseeable future. 
In general, EU residents have less disposable income as a result of tax imposed. Wage will 
continue to be stagnant due to economic environment. Therefore, consumer spending will 
be tight with higher savings rate instead. 
In terms of business cyĐůĞƐ ?ƚŚĞƌĞǁŽŶ ?ƚďĞĂŶǇĞǆƚƌĞŵĞďŽŽŵ ?ďƵƐƚ ?ZĂƚŚĞƌ ?ŝƚǁŝůůďĞĂĨůĂƚ
or gradual decline in economy. This is something that ECB will not have much influence here 
as national government will need to play a heavier involvement in addressing the business 
cycle.  
Feels that there will be tightened migration policy especially with the economic conditions 
depreciation. ,Ğ ŝƐ ŽĨ ƚŚĞ ŽƉŝŶŝŽŶ ƚŚĂƚ ƚŚĞƌĞ ǁŽŶ ?ƚ ďĞ ĂŶǇ ĐŚĂŶĐĞ ŽĨ ŚĂƌŵŽŶŝƐĂƚŝŽŶ ŽĨ
migration policy. 
Healthcare issues: With the obesity on the rise, his personal opinion is that people will 
become unhealthier but this will be compensated with improving health care that leads to 
increase lifespan of the population. 
Opportunities in the horizon: Private health care biz will grow especially in developing 
country which are doing well. Drug companies should aim to establish business relationship 
with the competitors in this sector. 
 
1.5 JOHN RICHARDS. INTERVIEW ON 12 AUGUST 2010 
Query on biggest mistake in industry: Mergers and having larger R&D department would 
lead to more creativity. The reality is that this has not given the results expected. The type 
of research in the past conducted are not helping in creating new drugs nowadays. As stated 
ďǇŚŝŵ P “ƚŚĞƚǇƉĞŽĨƐĐŝĞŶĐĞƵƐĞĚŚĂƐƌƵŶŽƵƚŽĨƐƚĞĂŵ ? ?
Views that many companies have not had much in the pipeline hence the merger exercise as 
a result. 
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Explains that many companies are looking towards smaller start up companies especially 
biotech given the vast potential in this field. Spotting those with good ideas  W either buying 
technology, purchasing the company outright, creating partnership or strategic alliances. 
Query on where is the new treatments going to come from? 
Agrees that new treatments will come from the new types of sciences like biotech, stem 
cells etc. 
Suggested to us on the easiest ways to look at the scenario. Look at the 2 dimensions where 
it could be. i.e European Harmonisation, rich budgets for healthcare. 
For a company in the EU to succeed, he suggest that these are following factors to consider. 
- Market Size, healthcare legislation in each country, how to distribute products to the 
prescribers in the systems. Generics has to compete with existing branded products 
which may be performing satisfactory towards patients 
Likelihood of existing products going generic? 
Explains that attitude amongst patients has to change as well in order for generic products 
to ever get a foothold in the market. 
One of the ways would be for government to switch to more generic supply of medicine. 
That way, patients will be exposed to the availability of such drugs for their illness. 
Tailoring drugs to suit individual needs. Also adds that this could be a major trend in the 
future. Also suggest that delivery methods should be more creative in order to capture the 
market. There cannot be a single strategy as EU has a wide and diverse system of 
governance to consider. 
 
1.6 DR DAVID LIU. INTERVIEW ON 15 AUGUST 2010 
Discussion about generics and topic explanation conducted by the team.  
Opinion is that there is a cost pressure going on in the EU authorities with the rising deficits 
and healthcare. Therefore, generic manufacturers will benefit in the EU market by going on 
cost basis.  
Original patent drug manufacturers would require support to continue in the market when 
the patent expires. Two key support advantages that the companies would have is  W (i) Trust 
and (ii) quality. 
Pointed out that from his experience, with the opening of the market to generics, regulation 
enforcement tends to be poorer. Lax overview and quality control is of concern as a result of 
this. However, this problem occurs globally and is not restricted to the EU. 
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Counterfeit drugs are a concern in the pharmaceutical industry now. As pointed out, NHS 
suffers 15% faulty rate annually due to the presence of such drugs in the system. This is due 
to the pressure to source for the cheapest source as a result of cost cutting and recession 
afflicting the countries. In most cases many of the offenders are producers are from India, 
China  W countries which are still lax in the quality control and supervision.  
It is inevitable that drug companies look for opportunities to outsource their drugs 
production but there is a risk that such manufacturers might not comply with what is 
request if left to their device putting pharmaceutical companies reputation at risk. 
Suggestion in such situation: In order to sell drugs, company should ensure that the 
manufacturing value chain is supervised closely in the foreign factories it has, this way brand 
and quality is assured to customers.  
Another suggestion is that pharmaceutical companies do not stay with the low cost business 
model in order to compete with the generic manufacturers. Rather, perform targeting 
marketing by selling products to governments in the EU, institution in the EU and private 
hospitals in the EU. Leverage on the existing position it has rather than compete direct with 
generic. 
Suggested strategy for scenario development. Within EU, if product loses patent. It will be 
best to move out of the existing market and head towards higher level of manufacturing 
expertise. I.e move upmarket, target more high tech industrial innovation (i.e 
biotechnology) rather reliance on low cost labour. 
dŚĞ ƉƌŽďůĞŵ ǁŝƚŚ ůŽǁ ĐŽƐƚ ŝƐ ƚŚĞ ƋƵĂůŝƚǇ ŝƐƐƵĞ ďǇ ŐĞŶĞƌŝĐƐ ? dŚŝƐ ƌĞƉƌĞƐĞŶƚƐ ĂŶ  “ĐŚŝůůĞƐ
,ĞĞůƐ ?ĨŽƌƐƵĐŚŵĂŶƵĨĂĐƚƵƌĞƌƐĞƐƉĞĐŝĂůůǇǁŝƚŚŵĂŶǇŽƌŝŐŝŶĂƚŝŶŐĨƌŽŵĚĞǀĞůŽƉŝŶŐĐŽƵŶƚƌŝĞƐ ?
As elaborated further, company like Pfizer can consider making a branded generic brand of 
its product by leveraging on the reputation of its company reputation in the market. This 
could be used to counter-generic marketing which do not possess the same level of brand 
perception amongst the patients. To do that, the company must accept that is strategy 
entail high cost (if manufacturing is done in the EU) but must aim for cost efficiency. 
Otherwise, if manufactured overseas, the key worry is to ensure that there is controls are 
overseen by the original companies themselves. The key point here is to emphasize on 
brand leveraging and protecting its reputation in the market as part of the original 
ĐŽŵƉĂŶǇ ?ƐƉĂƚĞŶƚƉƌŽĚƵĐƚ P^ĞůůŽŶŐƵĂƌĂŶƚĞĞŽĨƚŚĞƉƌŽĚƵĐƚƋƵĂůŝƚǇ ? 
Another recommendation for consideration. Go strongly on evidence-based medicine in new 
markets such as China & India. A growing trend globally especially in Europe in order to gain 
acceptance in new markets. By going on medical based therapy, drug integrity is stronger.  
In NHS for example, this has been the criteria when evaluating potential drugs for purchase. 
When going to new markets with evidence based approach. Educating the public where it 
markets will enforce this strength especially against traditional medicine. 
Honesty is going to be the best weapon when approaching this evidence based strategy.  
Pharmaceutical companies are in general do not have a really good reputation. Promoting 
honesty and clarity in their messages will improve brand perception as well. 
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If the generic market proves to be too competitive, suggestion might also be to consider 
exiting it. Venture into new areas such as supplement market. Acknowledge that this is 
competitive but company might want to consider an industry that is still relevant to their 
core advantages. An example would be to serve the growing ageing population in many 
markets around the world. This is a mass market which can be profitable unlike niche drug 
development. However, he pointed out that niche drug has a higher area of potential to 
develop. This is important in creating a competitive advantage against other competitors 
and not just generic. Build on innovation to survive. 
How do we that? 
Link up with a global network of universities. Allow some form of profit sharing mechanism 
that encourage creativity and participatiŽŶƚŚĂƚŵĂŬĞƐƵƐĞŽĨƚŚĞƵŶŝǀĞƌƐŝƚǇ ?ƐĞǆƉĞƌƚŝƐĞĂŶĚ
ƌĞƐŽƵƌĐĞƐ ?dŚĂƚ ?ƐƚŚĞǁĂǇŽĨŵŽǀŝŶŐŝŶƚŽƚŚĞŶŝĐŚĞŵĂƌŬĞƚ ? 
Drop a pyramid structure which is a top down approach to all subsidiaries in a group. 
Develop a web / network of companies that operate under 1 organisation instead. 
We note his consistency on maintaining one point throughout the discussion 
IMPORTANT: Remember the ethical component when deciding the environment of the 
company (honest) 
Green marketing will be big in 20 years is acknowledged to be a major factor but drug 
manufacturers main concern would be in the area of ethics and honesty towards the public. 
He urged to look at weakness of competitors to capitalise on competitiveness when 
competing against generic players. For example, quality emphasis is an issue in India and 
China owing to lack of education, attitude of the population on its importance. Ethical 
marketing can be strongly emphasized especially if the company is to compete in such 
markets especially in developing countries. It is an arĞĂǁŚĞƌĞŐĞŶĞƌŝĐƉůĂǇĞƌƐĐĂŶ ?ƚĐŽŵƉĞƚĞ
as this involves the mindset of the population. 
Technology will improve substantially in the future but there will still be a need for a human 
interface when it comes to the making the right decision on drug prescription. There will 
also be growing number of lower level subordinates handed the responsibility of prescribing 
the drugs which were held by doctors previously. Not all is lost as the range of drugs 
available will continue to be restricted. Therefore we expect the control regulations to 
continue to play a role in healthcare sector.  
 
1.7 DR PETER SWANN. E-MAIL RESPONSE  
EU Macro-Environmental Scan Questionnaire 
 
1. With regard to intellectual patent laws, how can legislators enhance competition within 
the EU drugs market? 
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/ ?ŵ ŶŽƚ ƐƵƌĞ / ĨƵůůǇ ƵŶĚĞƌƐƚĂŶĚ ƚŚĞ ƋƵĞƐƚŝŽŶ ?  Ɛ ŝƚ ƐƚĂŶĚƐ ? ƉĂƚĞŶƚƐ ŐŝǀĞ  ?ĞĨĨĞĐƚŝǀĞůǇ ? Ă
monopoly for a restricted period of time and then there is open competition after that 
ƉĞƌŝŽĚ ĞǆƉŝƌĞƐ ?  / ĐĂŶ ?ƚ ƐĞĞ ĂŶǇ ůŝŬĞůŝŚŽŽĚ ŽĨ Ă ĨƵŶĚĂŵĞŶƚĂů ĐŚĂŶŐĞ ŝŶ this, though the 
optimum lifetime of a patent (in years) is always a subject of debate. 
 
2. Will countries within the EU trend more towards protectionism or open and free trade? 
 
For intra-EU trade, the answer must be a move towards the removal of any barriers to trade 
within the EU.  That project is largely complete for the old EU, but there is still some way to 
go for the new members of the EU.  For EU trade with the rest of the world, it depends on a 
balance of interests.  Some politicians in some countries may be lobbied for protectionism in 
some cases by small business and labor interests, but in the UK at least, the dominant 
influence on the British Government (big business) is generally in favor of free trade. 
 
3. What changes can you project vis-a-vis the h ?Ɛ ƉŽůŝĐŝĞƐ ŽŶ ŽĨĨ ƐŚŽƌŝŶŐ ?  ?ƐƉĞĐŝĨŝĐĂůůǇ
related to the pharmaceutical industry) 
 
/ ?ŵŶŽƚƐƵƌĞƚŚĂƚƚŚĞhƌĞĂůůǇŚĂƐĂƉŽůŝĐǇŽŶŽĨĨƐŚŽƌŝŶŐ ?KĨĨƐŚŽƌŝŶŐŝƐĂĐĐĞƉƚĞĚĂƐĂĨĂĐƚŽĨ
life, and the decision is left to business to make on the grounds of what makes business 
sense.  This does not deny that there are contrary interests (recall the US TV video we 
watched on resistance to offshoring in middle-American). 
 
4. tŝůů ƚŚĞ ƵƌŽƉĞĂŶ hŶŝŽŶ ƌĞƚĂŝŶ ƚŚĞ ƉŽůŝĐǇ ŽĨ  “ŶŽ ŶĞĞĚ ĨŽƌ ĂŶ ĂĐƌŽƐƐ ƚŚĞ ďŽĂƌĚ
harmonization of ƚŚĞDĞŵďĞƌ^ƚĂƚĞƐ ?ƚĂǆƐǇƐƚĞŵƐ ? ? 
 
Whether there is or is not a need, I see no prospect of this.  Certainly, it is inconceivable that 
the present UK government would cooperate with an across the board harmonization. 
 
5. What are your expectations with regard ƚŽ ƚŚĞ h ?Ɛ ĨƵƚƵƌĞ ĞǆƉĂŶƐŝŽŶ ?ŝŶƚĞŐƌĂƚŝŽŶ
policies?  
 
/ ?ŵƐŽƌƌǇ ?ďƵƚŵǇŽƉŝŶŝŽŶƐŽŶƚŚŝƐĂƌĞŶŽƚĐůĞĂƌĞŶŽƵŐŚƚŽŐŝǀĞǇŽƵĂŶǇƌĞůŝĂďůĞĂĚǀŝĐĞ ? 
 
6. What actions and/or trends can you forecast with respect to monetary policy within the 
EU? How likely is the prospect of the Euro being the only currency within the EU? Will 
the Euro survive or will countries revert to their previous national currencies?  
 
If a Labour government in the UK (1997-2010) resisted membership of the Euro, I think it 
inconceivable that a Conservative government will agree to membership of the Euro.  As to 
the survival of the Euro, I was amused that in the early days of the Euro, economists in 
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banks in the City of London confidently predicted that the Euro would be the weakest of 
currencies  W and yet for long periods it was stronger than the US Dollar or the GB Pound!  
Granted, the Euro is in a mess now, but I still believe it will survive  W though I suspect that 
the rules of membership will be mad a lot tougher. 
 
7. How likely is the prospect of Fiscal policy integration within the EU?  
 
No prospect of the UK agreeing to this. 
 
8. What changes can you project vis-a-ǀŝƐ ƚŚĞ h ?Ɛ ƉŽůŝĐŝĞƐ ŽŶ ŝŵƉŽƌƚ ůĂǁƐ ƚŽ ƐƵƉƉŽƌƚ Žƌ
hinder the flow of pharmaceutical products manufactured outside the EU? 
 
In general, I see a project to harmonize EU standards with general international standards, 
and that should in most cases lower barriers faced by countries outside the EU to exporting 
into the EU.  However, sometimes the standards are set very high  W which does act as a 
ďĂƌƌŝĞƌƚŽĞǆƉŽƌƚƐĨƌŽŵĚĞǀĞůŽƉŝŶŐĐŽƵŶƚƌŝĞƐ ?/ ?ŵŶŽƚƐƵƌĞŚŽǁƌĞůĞǀĂŶƚƚŚĂƚŝƐƚŽƉŚĂƌŵĂ ?
however. 
 
9. /Ŷ DĂƌĐŚ  ? ? ? ? ƚŚĞ ƵƌŽƉĞĂŶ ŽŵŵŝƐƐŝŽŶ ŵĂĚĞ Ă ĐŽŵŵŝƚŵĞŶƚ ƚŽ  “ƌĞŶĞǁ ƚŚĞ h
strategy to promote Corporate Social Responsibility as a key element in ensuring long 
ƚĞƌŵ ĞŵƉůŽǇĞĞ ĂŶĚ ĐŽŶƐƵŵĞƌ ƚƌƵƐƚ ? ? ,Žǁ ĐŽƵůĚ ƚŚŝƐ ĐŽŵŵŝƚŵĞŶƚ ƉŽƐƐŝďůǇ ĂĨĨĞĐƚ ƚŚĞ
pharmaceuticals/generics industry in the EU over the coming years?  
 
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚĞƐƉĞĐŝĨŝĐŝŵƉůŝĐĂƚŝŽŶƐŽĨƚŚŝƐĨŽƌWŚĂƌŵĂ ? 
 
10. /ŶǁŚĂƚǁĂǇƐĚŽE'K ?s influence policy on pharmaceuticals within the European Union? 
ŽE'K ?ƐŚĂǀĞĂƐƚĂŶĐĞ ?ƌŽůĞŽŶƚŚĞƐĂůĞĂŶĚƵƐĞŽĨŐĞŶĞƌŝĐƐǁŝƚŚŝŶƚŚĞh ? 
 
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚŝƐŝŶƚŚĞƐƉĞĐŝĨŝĐĐŽŶƚĞǆƚŽĨWŚĂƌŵĂ ? 
  
11. What role will the movement towards sustainability have on the 
pharmaceuticals/generics industry over the coming years?  
 
/ ĐĂŶ ?ƚ ĐŽŵŵĞŶƚ ŽŶ ƚŚŝƐ ŝŶ ƚŚĞ ƐƉĞĐŝĨŝĐ ĐŽŶƚĞǆƚ ŽĨ WŚĂƌŵĂ ?  DŽƌĞ ŐĞŶĞƌĂůůǇ ? ƐŽŵĞ
commentators see rapid innovation as the solution to issues of sustainability.  More 
controversially, perhaps, I see rapid innovation as one of the causes of problems with 
sustainability.  These two different perspectives suggest very different policies towards 
sustainability. 
 
12. What is the likelihood of a unified legal framework within the European Union on a 
community patent system?  
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There has been some progress in this direction already.  There is a European Patent Office, 
and many companies view patenting as a European and/or international activity, and not 
just a domestic issue. 
 
13. What are the projected trends with regards to benefits policies within European Union 
member states? Will there likely be a unified policy on benefits across the EU? 
 
Ǉ ďĞŶĞĨŝƚƐ ? ĚŽ ǇŽƵ ŵĞĂŶ ƵŶĞŵƉůŽǇŵĞŶƚ ďĞŶĞĨŝƚƐ ? ĚŝƐĂďŝůŝƚǇ ďĞŶĞĨŝƚƐ ? ĞƚĐ ?  /Ĩ ƐŽ ? / ĚŽŶ ?ƚ
expect to see great progress towards a unified policy in the next 5-10 years. 
 
14. What changes are likely to occur over the coming ten-twenty years within the European 
ŽŵŵŝƐƐŝŽŶ ?Ɛ ĞŶǀŝƌŽŶŵĞŶƚĂů ůĞŐŝƐůĂƚŝŽŶ ƉŽůŝĐŝĞƐ ƚŚĂƚĐŽƵůĚ ƉŽƐƐŝďůǇ ĂĨĨĞĐƚ ƚŚĞ ƐĂůĞ ŽĨ
generics in the EU?  
 
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚŝƐŝŶƚŚĞƐƉĞĐŝĨŝĐĐŽŶƚĞǆƚŽĨWŚĂƌŵĂ ? 
  
15. What is the likelihood of the EU adopting a unified pricing regulation structure in the 
pharmaceutical industry?  
16.  
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚŝƐŝŶƚŚĞƐƉĞĐŝĨŝĐĐŽŶƚĞǆƚŽĨWŚĂƌŵĂ ? 
  
17. What trends can you forecast vis-à-ǀŝƐƚŚĞh ?ƐĨĂǀŽƵƌĞĚƚƌĂĚŝŶŐƉĂƌƚŶĞƌƉŽůŝĐŝĞƐ ?tŝůů
the EU trend more towards free trade or protectionism? Which countries do you expect 
to be granted Most Favoured Nation (MFN) status by the EU over the coming years? Will 
India be granted MFN status? If yes, when do you anticipate this to occur? How will EU 
trade policies affect the pharmaceuticals industry over the coming years/decades? 
 
tŽǁ ?ƚŚĞƐĞƋƵĞƐƚŝŽŶƐĂƌĞďŝŐƋƵĞƐƚŝŽŶƐ ?/ƚŚŝŶŬ/ǁŝůůŚĂǀĞƚŽ ‘ƉĂƐƐ ?ŽŶƚŚĞƐĞ ? 
 
18. What technological advancements (disruptive and/or incremental) are most likely to 
have a significant impact on the future of the generics drug industry? 
 
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚŝƐŝŶƚŚĞƐƉĞĐŝĨŝĐĐŽŶƚĞǆƚŽĨWŚĂƌŵĂ ?/ƐŝŵƉůǇŬŶŽǁƚŽŽůŝƚƚůĞĂďŽƵƚƚŚĞ
technology. 
 
19. Over the coming years/decades, in which specific areas do you anticipate developments 
vis-à-vis pharmaceutical industry cost structures and value-chains?  
 
/ĐĂŶ ?ƚĐŽŵŵĞŶƚŽŶƚŚŝƐŝŶƚŚĞƐƉĞĐŝĨŝĐĐŽŶƚĞǆƚŽĨWŚĂƌŵĂ ?/ƐŝŵƉůǇŬŶŽǁƚŽŽůŝƚƚůĞĂďŽƵƚƚŚĞ
technology. 
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20. Are there any current or forecasted factors/indicators that are likely to have a significant 
impact on GDP growth rates within the EU?  
 
Yes, lots of them. 
 
21. tŚĂƚ ĂƌĞ ƚŚĞ ĞǆƉĞĐƚĂƚŝŽŶƐ ǁŝƚŚ ƌĞŐĂƌĚ ƚŽ h ŵĞŵďĞƌ ƐƚĂƚĞƐ ? ĚŝƐĐƌĞƚŝŽŶĂƌǇ ŝŶĐŽŵĞ
patterns and what specific EU policies/actions (current or future) are likely to have an 
impact on these patterns? 
 
Pass. 
 
22. What are your projections regarding business cycle volatility within the EU over the 
coming years and what policies/actions can the EU central bank adopt to ensure 
business cycle stability? 
 
Pass. 
 
23. Can you project any significant changes in immigration policy within the EU - with regard 
to migration within member states and migration from non-EU countries? What is the 
prospect of a harmonized immigration policy within the EU? 
 
Opinions differ on this.  I think it is likely that pressure from labor interests will grow for 
limits on migration from outside the EU.  But many business interests are in favor of such 
immigration (lower wage rates). 
 
24. What are the current and projected future trends (ten-twenty years) with regard to the 
life-styles of citizens within the EU? How will these trends specifically affect healthcare 
practices?  
 
Pass. 
 
25. /ŶǁŚĂƚǁĂǇƐĚŽE'K ?ƐŝŶĨůƵĞŶĐĞƉŽůŝĐǇŽŶƉŚĂƌŵĂĐĞƵƚŝĐĂůƐǁŝƚŚŝŶƚŚĞƵƌŽƉĞan Union? 
ŽE'K ?ƐŚĂǀĞĂƐƚĂŶĐĞ ?ƌŽůĞŽŶƚŚĞƐĂůĞĂŶĚƵƐĞŽĨŐĞŶĞƌŝĐƐǁŝƚŚŝŶƚŚĞh ? 
 
Same as question 10 above. 
 
26. Will EU member state governments increase/decrease healthcare spending (as a 
proportion of overall budgets) over the coming years/decades?  
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I doubt they will do this.  The demographic trends alone suggest otherwise  W growing life 
expectancy. 
 
27. What changes do you project with regard to the private healthcare sector in the EU over 
the coming years/decades?  
 
Pass. 
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A
T
S
SCENARIOS 1,2, & 3 SEGMENTED OPPORTUNITIES & THREATS
Opportunities
Integrated global 
markets
New Technologies
Affluent society
Less bureaucracy
Expanding EU
Expanded health 
insurance sector
Quality focus
Environmental focus
Differentiation focus
Opportunities
Long-term contracts
Lobbying
Secure large market 
share
Market knowledge
Govt. support
Cost leadership
Opportunities
Dual market
Multi strategies
Multi positioning
Environmental focus
Strong barriers to entry
Secure large market 
share
Threats
Disruptive technology
Intense global 
competition
Substitute products
Increased buyer power
Increased due diligence 
& compliance
Spreading prophylactic 
approaches
Price control
Threats
Increased buyer power
Threats
Counterfeit drugs
Parallel import
Transaction costs
Threats
Counterfeit drugs
Parallel import
Transaction costs
Increased buyer power
´Todo es Buenoµ
´1HLQnicht JXWµ
´Deux Union Européenneµ
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